Human antibodies to dendritic cells : generation, analysis and use in vaccination by Lekkerkerker, A.N.
  
 
 
 
 
 
 
 
 
 
HUMAN ANTIBODIES TO DENDRITIC CELLS 
GENERATION, ANALYSIS AND USE IN VACCINATION 
 
 HUMAN ANTIBODIES TO DENDRITIC CELLS 
GENERATION, ANALYSIS AND USE IN VACCINATION 
 
 
 
 
HUMANE ANTILICHAMEN TEGEN DENDRITISCHE CELLEN 
Ontwikkeling, analyse en gebruik in vaccinatie 
 
(met een samenvatting in het Nederlands) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROEFSCHRIFT 
 
 
 
 
ter verkrijging van de graad van doctor 
aan de Universiteit Utrecht 
op gezag van de Rector Magnificus, Prof. dr. W.H. Gispen, 
ingevolge het besluit van het College voor Promoties 
in het openbaar te verdedigen 
op vrijdag 31 mei 2002 des middags te 2.30 uur 
 
 
 
door 
 
 
Annemarie Nicolette Lekkerkerker 
 
geboren op 6 december 1972, te Asse, België 
 Promotoren  Prof. dr. T. Logtenberg 
  Prof. dr. H. Clevers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover: ‘Black Hollyhock with Blue Larkspur’ Georgia O’Keeffe 1929 
 
ISBN: 90-393-3038-7 
 
 
The studies described in this thesis were performed at the Department of Immunology, 
University Medical Center Utrecht, The Netherlands and were financially supported by 
Crucell N.V.. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When you take a flower in your hand and really look at it, it’s your world for the moment. 
 
Georgia O’Keeffe
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CONTENTS 
 
 
 
CHAPTER 1 
General introduction                9  
         
CHAPTER 2A  
Phage antibodies against human dendritic cell subpopulations by     33 
flow-cytometry based selection on freshly isolated cells 
 
CHAPTER 2B                                
Phage antibodies selected on dendritic cells in human tonsil      51  
 
CHAPTER 3 
Reactivity profiles of human IgG4 monoclonal antibodies on naturally    69 
occurring and cultured dendritic cell subsets 
 
CHAPTER 4 
Binding and crosslinking of huMab MatDC 64 prevents the in vitro    97 
differentiation of human monocytes into dendritic cells 
 
CHAPTER 5 
In vitro antibody-mediated delivery of melanoma tumor antigen MAGE-1  111 
to immature dendritic cells results in anti-tumor TH and CTL responses 
 
CHAPTER 6 
Lipid-tagged scFv fragments incorporated in tumor cells mediate    131  
receptor-dependent targeting to antigen presenting cells 
 
CHAPTER 7                                                                                                                                     
Summarizing discussion             145  
                                                                    
 
Nederlandse Samenvatting                       155 
 
 
Curriculum Vitae               157 
 
 
List of Publications              158 
 
 
Nawoord                159 
  
 
 
CHAPTER 1 
 
 
GENERAL INTRODUCTION 
 
 
 
 
  
GENERAL INTRODUCTION 
 
11 
INTRODUCTION 
 
The life cycle of dendritic cells 
Dendritic cells (DCs), first described in 1973 by Steinman and Cohn 1, are now widely 
recognized as professional antigen presenting cells (APCs) that play a pivotal role in 
directing the immune response. The ability of DCs to process and present a broad variety of 
antigens, to which an organism is exposed, is unmatched. 
The functioning of the immune system is based on two distinct types of responses, the 
innate and the adaptive immune response. The innate immune response, mediated by a 
variety of cell types including natural killer (NK) cells and macrophages, forms the first line 
of defense towards infections and is regarded as non-specific. The adaptive immune response 
depends on the activity of antigen-specific effector T and B cells and is notable for its 
exquisite specificity for the inciting antigen and the generation of memory for antigens. DCs 
are innate immune cells and acutely activated when a pathogen invades the body, but they 
also play a decisive and instructive role in the adaptive immune response that arises 2. Given 
that the induction of productive T cell responses depends upon activation of DCs, it follows 
that the DC serves as a pivotal interface bridging the innate and adaptive immune system. 
Generated in large numbers in the bone marrow every day, precursor DCs circulate in 
the blood stream and migrate into tissues, where they reside as sentinels in an immature state, 
the prototype being Langerhans cells in the epidermis. Immature DCs have a high phagocytic 
and endocytic capacity and constantly sample their environment for antigens at potential sites 
of pathogen entry. 
Upon encounter of an antigen and the exposure to ‘danger’ signals (pathogens, tissue 
damage and local inflammation) immature DCs migrate to the lymphoid organs (Fig. 1). 
During this migration, which is regulated by altered expression of chemokine receptors, DCs 
undergo the maturation process that is characterized by down-regulation of the capacity to 
capture antigen and up-regulation of antigen processing and presentation, and of expression 
of co-stimulatory molecules. In the secondary lymphoid organs, mature DCs present antigens 
captured in the periphery to resting or naive T cells, inducing an adaptive immune response. 
After delivery of their pathogen-related information, the DCs, no longer necessary for the 
acute response to antigen, presumably undergo apoptotic cell death and are eliminated. 
 
 
CHAPTER 1 
 
12 
BONE MARROW 
CIRCULATION 
T 
T 
T 
T 
B 
B 
B 
B 
T 
T 
CD34+ PROGENITORS 
DC PRECURSORS 
IMMATURE DC 
MATURE DC 
Antigen presentation 
Antigen capture/ 
processing 
T 
T 
MIGRATION/ 
MATURATION 
TISSUE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 The life cycle of DCs. DCs, originating from bone marrow-derived hematopoietic CD34+ progenitors, enter 
the circulation. Precursor DCs migrate into tissues all over the body, where they reside as immature DCs. Invading 
pathogens are captured by immature DCs, followed by antigen processing. The immature DCs mature and migrate to 
secondary lymphoid organs where they present antigens to T cells and initiate an immune response. The activated T 
cells migrate to the site of inflammation. B cells become activated after contact with T cells and DCs, migrate to 
various areas where they mature into plasma cells, secreting antibodies that can neutralize the invading pathogen. 
 
Identification of DCs 
DCs received their name on account of their distinctive cell shape 1. Morphological 
characteristics, however, are insufficient as a discriminatory factor to distinguish DCs from 
other cell types. The identification of DCs relies on a combination of morphological, 
phenotypical and functional criteria. This includes the presence and absence of combinations 
of cell surface markers and the capacity to take up, process and present antigens. The relative 
scarcity of molecules that are uniquely expressed by DCs has hampered unraveling the 
ontogeny and lineage relationships of different DC subsets. The search for novel molecules, 
not only using monoclonal antibodies but also by differential display technology, continues 
and has resulted in several new molecules that are DC-specific, such as the intracellular 
maturation marker DC-LAMP 3, the chemokine DC-CK1 4, and the C-type lectin DC-SIGN 
5
, or expressed relatively selectively by DCs, such as CMRF44 6, CMRF 56 7 and DC-
STAMP 8. 
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HETEROGENEITY OF DCS 
 
Generation of DCs 
Over the past few years, many different cell culture systems using various combinations 
of cytokines and diverse starting populations to generate DCs have been described. In 
general, DCs are generated in vitro from hematopoietic CD34+ progenitor cells or from 
peripheral blood monocytes. In cultures of CD34+ progenitor cells, two different myeloid 
pathways as well as a putative lymphoid pathway of DC differentiation have been identified 
depending on the cytokine environment 9-11. In the presence of GM-CSF and TNFα, the 
myeloid pathways lead to the generation of either Langerhans cells-like DCs or DCs with a 
dermal DC phenotype. The Langerhans cells-like DCs express CD1a, Birbeck granules and 
langerin, and DCs with a dermal DC phenotype are characterized by the expression of CD1a, 
CD68, CD2 and factor XIIIa 9. A CD34+CD45RA+CD10+ progenitor cell population derived 
from bone marrow has been described, that develops, in the presence of a mixture of 
cytokines, into T, B, NK cells and DCs, but not myeloid cells 11. In addition, a CD34+ 
CD45RA- progenitor has been shown to develop into a putative lymphoid, plasmacytoid DC 
in the presence of Fms-like tyrosine kinase receptor 3 ligand (Flt3L) 12. 
In cultures of monocytes stimulated with GM-CSF and IL-4, immature myeloid DCs are 
generated. These immature DCs are characterized by high antigen capture and processing 
capacity and the induction of CD1a 13;14. When cultured with M-CSF, the immature DCs 
differentiate to the macrophage phenotype, demonstrating the plasticity of these cells. 
Activation signals such as TNFα, LPS or CD40 ligand, induce the maturation of these 
immature DCs, indicated by the upregulation of adhesion and co-stimulatory molecules, the 
induction of CD83 expression and extremely efficient presentation of antigens. Once they 
have matured, DCs become resistant to modulation. 
In vivo, the choice of whether a monocyte becomes a DC or a macrophage may in part 
be influenced by the endothelium. In a culture system involving endothelial cells grown on a 
collagen matrix, a subset of monocytes that have reverse transmigrated, display a DC 
phenotype, while the monocyte-derived cells that remain in the subendothelial layer become 
macrophages 15. This model mimics the trafficking of DC precursors from blood to tissues 
through endothelium and the subsequent reverse transmigration mimics their movement from 
tissues to lymphatic vessels. Since this system is free of any exogenous cytokine, the 
relevance of monocytes as DC precursors is investigated in a more physiological context. 
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Additionally, CD2 expression by monocytes might be a property of DC precursors, as CD2+ 
monocytes acquire a DC phenotype when cultured in the absence of cytokines, while CD2- 
monocytes remain CD14+ and become macrophages under the same conditions 16. 
Overall, the exact physiological differentiation pathway that generates DCs in vivo 
remains to be established 17. However, a very recent study provides evidence for a DC-
committed precursor in the mouse, which has the capacity to generate all the different DC 
subsets as found in mouse lymphoid organs, pointing toward an independent, common DC 
differentiation pathway 18. 
 
Heterogeneity of DCs in vivo 
Morphologically and phenotypically distinct DC subsets may be identified at many 
different anatomical sites and within a single tissue 19. These differences probably may not 
only reflect different stages of maturation but also diverse origin of DC subsets. In humans, 
two subsets of DCs were originally identified in the peripheral blood based on the differential 
expression of CD11c 20. Both subsets have in common the expression of CD4, MHC class II 
molecules, and the absence of lineage-specific markers such as CD14 (monocytes), CD3 (T 
cells), CD19, CD20 (B cells), CD56 (NK cells) and CD66b (granulocytes). 
The CD11c- DCs express high levels of CD123 (interleukin (IL)-3Rα) 21 and display 
characteristic plasmacytoid morphology 22. A lymphoid origin has been proposed for these 
so-called plasmacytoid DCs. Plasmacytoid DCs express pre-T cell receptor α chain 
transcripts 23 and development of plasmacytoid DCs, T and B cells, but not myeloid DCs is 
blocked by ectopic expression of inhibitor of DNA binding (Id)2 and Id3 inhibiting 
transcriptional activation of many basic helix-loop-helix-transcription factors 24. When 
cultured with IL-3 or CD40L 22 or viruses 25;26, plasmacytoid DCs develop into mature DCs. 
Plasmacytoid DCs are identical to the natural type 1 interferon (IFN) producing cells that 
secrete high amounts of type 1 IFN (IFN α/β) in response to viruses 27. DCs with a 
plasmacytoid phenotype are localized around high endothelial venules and in T cell areas 
within lymphoid organs such as tonsil 22, spleen 28 and thymus 29;30. 
The CD11c+ DCs express myeloid markers and require GM-CSF for survival in culture 
and are thus thought to be of myeloid origin 31. CD11c+ DCs constitute a heterogeneous 
subset with a variable differentiation capacity. Under different culture conditions, CD11+ 
DCs develop in either CD1a+ DCs or CD14+ macrophages 20. More recently, it was suggest 
that a distinctive CD11c+ CD1a+ DC subset in blood represent Langerhans cell precursors 32. 
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Whether CD11c+ DCs in peripheral blood represent a reservoir that constitutively repopulates 
the pool of tissue DCs or are circulating while constantly sensing the endothelium followed 
by recruitment at inflammation sites is not known 33. 
A panel of four recently described antibodies (BDCA-1-4) might help to further 
characterize DC subsets in human peripheral blood 34. Using these antibodies, three 
phenotypically distinct subsets have been identified. BDCA-2 and BDCA-4 are uniquely 
expressed on plasmacytoid DCs, whereas BDCA-3 is only expressed on a small CD11c+ 
CD123- DC subset and, in addition, on monocytes. BDCA-1 was identified as CD1c and is 
expressed, in addition to B cells, on the CD11c+ CD123- DC subset. 
In vivo, interstitial DCs have an immature phenotype and are found in almost all organs. 
It is thought that these immature interstitial DCs are precursors of the mature interdigitating 
DCs found in the T cell areas of secondary lymphoid organs. Another view is that 
Langerhans cells, immature DCs found in skin and other epithelia 35 are the precursors of 
interdigitating cells, whereas interstitial DCs move into germinal centers as germinal center 
DCs (GCDCs) 19;36. The identification of distinct DC subsets at different anatomical 
localizations has lead to idea that distinct DC subsets may have different specialized 
functions 37. 
 
 
DCS AND THE ADAPTIVE IMMUNE RESPONSE 
 
Antigen uptake by DCs 
Three pathways of antigen uptake have been described in DCs: phagocytosis, 
macropinocytosis and receptor-mediated endocytosis. Receptors that mediate endocytosis 
include C-type lectins (DEC-205 38, mannose receptor 39, DC-SIGN 5), Fc receptors that 
allow uptake of antigen opsonised with antibody 40;41, and Toll-like receptors (TLR) that 
recognize microbial products 42. DCs also can very efficiently take up dying cells via CD36 
and αvβ5 integrins 43;44. The captured antigens enter the endocytic pathway of antigen 
presentation of DCs and are targeted to MHC class II compartments, followed by loading on 
MHC class II molecules. Subsequently, the MHC class II-peptide complexes are translocated 
to the cell surface. 
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Endogenous MHC class I pathway 
For a long time, it was thought that exogenous antigens could not access the antigen 
presentation pathway that loads peptides onto MHC class I molecules of APC. For MHC 
class I-peptide complexes to form, only peptides derived from newly synthesized, 
endogenous proteins in the cytoplasm, were thought to be processed via the proteasome and 
transported into the endoplasmic reticulum via transporters for antigen processing. However, 
it has been shown that DCs efficiently present exogenous proteins that have gained access to 
the cytosol and are therefore presented on MHC class I molecules, a phenomenon called 
cross-presentation 45-47. The nature of the antigen is critical for cross-presentation as soluble 
proteins are poorly presented, whereas antigens introduced via receptor-mediated endocytosis 
and phagocytosis are presented very efficiently. Heat shock proteins, released from dying 
cells, can chaperon peptides into the MHC class I pathway 48. 
 
T cell response 
Adaptive immunity is controlled by the generation of MHC-restricted effector T cells 
and the production of cytokines. T cells recognize peptides bound to MHC molecules by 
their T cell receptor (TCR). In addition, T cells express CD4 or CD8 coreceptors. CD8+ T 
cells detect MHC class I-peptide complexes and differentiate into cytotoxic T effector cells 
(CTL) that directly kill cells infected with intracellular pathogens such as viruses. CD4+ T 
cells detect MHC class II-peptide complexes and perform mainly helper functions for CTLs 
or B cells, and are thus called T helper (TH) cells. These differentiated T cells develop from a 
common pool of naive precursor T cells. In secondary lymphoid organs, DCs prime naive 
CD4+ T cells by displaying MHC class II-peptide complexes, which are recognized by the 
TCR (signal 1:antigen-specific stimulation), in combination with an interaction of co-
stimulatory molecules and their ligands on T cells (signal 2: co-stimulation). This physical 
DC-T cell interaction is referred to as the ‘immunological synapse’ 49. 
Activation of CD4+ T cells induces TH development and accordingly the recruitment of 
non-antigen specific effectors including NK cells, eosinophils and macrophages, resulting in 
diverse immune responses. The capacity of DCs to induce stimulatory T cells is dependent 
on the state of DC maturation. In the absence of inflammatory stimuli, immature, resting DCs 
are relatively poor stimulators of the proliferation of resting T cells and can presumably 
induce tolerance. 
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T helper 1 vs. T helper 2 
Immune responses to different pathogens are associated with different types of effector 
responses directed by polarization of TH cells into either a TH type 1 (TH1) response or a TH 
type 2 (TH2) response. The cytokines produced by these TH subsets have a definitive 
influence on the outcome of the cellular and humoral immune response. In general, TH1 cells 
secrete primarily IFNγ and promote cell-mediated immunity against intracellular pathogens. 
In contrast, extracellular pathogens induce the development of TH2 cells, producing IL-4, 
IL-5, IL-10 and IL-13, which are instrumental for B cell activation in a humoral immune 
response. Evidence has accumulated that in addition to providing signal 1 and signal 2, DCs 
produce cytokines,such as IL-12, IL-18, IL-4 or IL-10, in response to different stimulating 
tissue or pathogen-related factors, which are able to polarize the emerging T cell response 
(signal 3: polarization) 50.  
 
DC -B cell interactions 
DCs can also directly activate naïve and memory B cells. DCs express BAFF, a member 
of the TNF superfamily, which plays an important role as co-stimulator of B cell 
proliferation and function 51. CD40-stimulated DCs also secrete IL-12 and other factors that, 
together with IL-2, may signal naive B cells during initiation of the immune response. 
GCDCs present in the germinal center induce differentiation into plasma cells secreting high 
levels of IgM in the presence of IL-2 52. DCs can also produce factors that can specifically 
regulate naive and memory B cell migration 53 of relevance within secondary lymphoid 
organs. 
 
 
FUNCTIONAL HETEROGENEITY OF DC SUBSETS 
Functionally, DCs represent a heterogeneous cell population. DCs exist in different 
maturational states, and exhibit functional and phenotypic differences. Functional 
heterogeneity is reflected by the observation that distinct DC subsets polarize TH cell 
responses, i.e. elicit IFNγ producing TH1 cells or IL-4 producing TH2 cells. In humans, 
mature monocyte-derived DCs, termed DC1, were shown to generate a TH1 response by 
producing the TH1-polarizing cytokine IL-12 and induce a strong CTL response 54. 
Especially CD40 ligand induced mature monocyte-derived DCs produce high levels of IL-12 
55
. Immature monocyte-derived DCs induce IL-10 producing regulatory T cells 56;57. The 
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proposed human DC2 lineage comprises the plasmacytoid DCs, which induce a strict TH2 
response by a deficiency in IL-12-producing capacity 54, although that this was not observed 
in another study 25. 
The observation that murine Peyers patch CD11c+ DCs elicit TH2 responses whereas 
CD11c+ DC from spleen induce TH1 responses 58 indicate that DC subsets isolated from 
discrete tissue microenvironments differently affect TH responses.  Immature DCs are also 
susceptible to pathogen-derived products or pathogen-induced nonspecific tissue factors that 
modulate the capacity of immature DCs to polarize naïve T cells into TH1 or TH2 cells 50;59. 
Prostaglandin E2, IL-10 or glucocorticoids induce a TH2-inducing DC subtype while the 
addition of IFNγ during DC maturation results in high IL-12 producing DCs that promote a 
TH1 response 50;60;61. Thus, functional specialization of DCs can be related to maturation 
stage and subset. Functional plasticity of DC subsets is demonstrated by tissue derived-
factors and pathogen-related molecules that modulate DC responses and thus signal 3. 
 
 
DCS IN INNATE IMMUNITY 
 
The Toll-like receptors 
In addition to their role in adaptive responses, DCs play a critical role in innate 
immunity. Many of the ‘danger’ signals that influence surveillance DC activity are mediated 
via or modified by the innate immune system. These signals may come from molecules such 
as LPS, IFN α and γ, and IL-1β and directly from invading pathogens.  
Viruses and bacteria are identified by DCs by the presence of pathogen-associated 
molecular patterns (PAMPs) that trigger pattern recognition receptors (PPRs) expressed on 
DCs. Toll-like receptors represent a newly recognized family of vertebrate PPRs. To date, ten 
TLRs (TLRs 1-10) have been reported 42. Signaling through TLRs strongly activates DCs to 
upregulate co-stimulatory molecules CD80 and CD86 and to produce cytokines 62. The 
involvement of TLRs in maturation provides an attractive mechanism by which DCs link 
innate to adaptive immunity. 
Each TLR appears to recognize a distinct microbial product: human TLR2 recognizes an 
array of molecules including bacterial lipoproteins 42, whereas TLR4 recognizes 
lipopolysaccharide (LPS) 63;64, TLR5 recognizes bacterial flagellin 65, and DNA containing 
unmethylated CpG motifs, which are found in greater abundance in microbial DNA than in 
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mammalian DNA signal trough TLR9 66. In addition, extension of the repertoire of 
recognition modules may be achieved by TLR heterodimerization, for example TLR2 is able 
to form functional pairs with TLR1 or TLR6 67. 
Plasmacytoid DCs strongly express TLR7 and 9, whereas CD11c+ blood DCs 
preferentially express TLR 1, 2 and 3 68. In addition, monocytes express TLR 1,2, 4, 5 and 8. 
Since distinct DC subsets express distinct sets of TLRs, they may recognize different 
microbial products, in turn produce different sets of chemokines involved in trafficking of 
DCs, and cytokines, leading to polarization of the immune response. This suggests a limited 
plasticity in DC function. 
 
DCs and NK cells 
NK cells and NK T cells are effector cells of the innate immune system that are able to 
kill a variety of cells spontaneously, including tumor and virus-infected cells and produce 
important cytokines, particularly IFNγ. DCs can activate NK and NK T cells, by direct cell-
cell interactions or indirectly e.g. by the production of IFNα or IL-12. This leads to enhanced 
anti-viral and anti-tumor activity of these cells 69;70. In turn, NK cells are capable of 
enhancing DC maturation 71. 
 
 
 
DCS IN CANCER IMMUNOTHERAPY 
 
Cancer vaccines 
Anti-tumor vaccination has a defined goal: to induce the specific recognition of tumor-
associated antigens (TAAs) by cells of the immune system with the aim of selectively 
eliminating tumor cells. DCs have acquired a central role in vaccination approaches for the 
treatment of cancer because DCs are uniquely potent in inducing a CTL response against 
exogenous antigens. In addition, DCs are capable of generating and maintaining 
immunological memory 72. Encouraging results in initial vaccination studies using DCs 
presenting tumor antigens and the identification of a growing number of tumor antigens have 
accelerated the development of DC-based vaccine approaches to human cancer 73-76. The 
development of protocols to generate sufficient numbers of human DC ex vivo from either 
hematopoietic CD34+ progenitor cells or peripheral blood monocytes for clinical application 
have led to an increase in clinical vaccination trials using DCs ex vivo loaded with tumor 
antigens. 
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The capacity of DCs to engage both arms of the human T cell response is crucial in light 
of evidence that resistance to experimental tumors is enhanced when both CTLs and TH cells 
are generated 77-79. Results of clinical trials suggest that DC-based vaccines are safe and well 
tolerated. Encouraging clinical data are demonstrated, at least for some tumors, confirming 
the promise of DC-based immunotherapy80-82. 
 
Different strategies to delivers antigens to DC 
Different strategies are employed to get a TAA delivered to DCs so that an effective 
immune response is elicited (Table 1). Ex vivo loading of MHC class I molecules on DCs 
with peptides derived from known tumor-associated antigens (TAA) such as MAGE-1 83 and 
MAGE-3 84 or Melan-A/MART 75;85;86 has been most commonly used. Because of MHC 
restriction, this approach is limited to patients that express a defined specific HLA haplotype. 
Moreover, using MHC class I restricted peptides ignores the role of MHC class II restricted 
TH cells in initiation and sustaining an immune response 78. Foremost, immunization with 
defined tumor antigens is limited to cancers where effective TAA have been identified. In 
addition, the use of vaccines consisting of single TAA bears the risk of leading to the 
generation of antigen-loss escape mutants. 
Using unfractionated tumor material or tumor lysates to pulse DCs ex vivo, tumor types 
for which no TAA have been identified can be treated. The presence of multiple tumor 
antigens in this approach results in a broad variety of epitopes presented via both the MHC 
class I and II pathways, minimizing the risk of escape mutants. The disadvantage of this 
approach lies in the availability of sufficient amounts of tumor tissue from patients. 
Moreover, the complete lack of control on the nature of the antigens that are being present by 
the DCs may cause induction of undesired autoimmune responses directed against self 
antigens 87. Another appraoch to improve the diversity of tumor-derived peptides presented 
by DCs, is the uptake of dead or dying tumor cells by DCs, which also leads to cross-
presentation 45. However pulsing of apoptotic bodies may require necrotic material for 
optimal antigen presentation 88. 
Ex vivo transfection of DCs with tumor RNA also appears to lead to the presentation of a 
wide array of tumor peptides 89. DCs can be transduced with RNA coding for a specific TAA 
or the entire RNA extracted from tumor cells. The RNA can be used directly of after 
amplification from small amount of starting material from a few tumor cells in a biopsy. In 
this RNA approach, the lack of control over the nature of antigens that are being presented by 
the DC forms a possible limitation. 
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Naked plasmid DNA has been used extensively in the development of tumor vaccines 
90;91
. A further possibility is the expression of genes encoding a TAA in DCs by means of 
appropriate viral vectors. Among the viral vectors, retroviral, adenoviral, and vaccinia 
vectors have been widely used to transduce either monocyte-derived or CD34+-cell derived 
DCs. The advantage of using 
retroviral vectors is that retroviral 
transduced DCs should be able to 
constitutively express and process 
TAA to produce a long-term 
antigen presentation in vivo 92. 
However, their low efficiency of 
transduction limits the clinical use 
of retroviruses. In contrast, 
adenoviral vectors transduce 
monocyte-derived or CD34+-cell 
derived DCs with a high efficiency but the preexisting natural immunity against adenoviral 
vectors may pose a major hurdle 93.Yet another strategy to deliver antigens to DCs exploits 
the ex vivo somatic fusion of tumor cells and DCs. These heterohybrids have already been 
explored to vaccinate cancer patients in clinical trials and have shown some promising 
therapeutic effect 94;95. 
Another strategy to involves the usage of exosomes. Exosomes are small vesicles either 
released from tumor cells and presented by DCs 96 or released by DCs that have processed 
tumor cells 97 and contain MHC class I and II products, co-stimulatory molecules and other 
cell-derived products. Exosomes can potentially be developed into a standard form of TAA 
for in vivo or ex vivo loading and stimulation of DCs. 
 
Source of DCs 
The majority of clinical studies to date have been carried out with ex vivo generated 
monocyte-derived DCs 91. Purified peripheral blood monocytes are cultured with GM-CSF 
and IL-4 that require additional maturation stimuli such as TNFα or monocyte-conditioned 
medium to increase their stimulatory capacity 98;99. Alternatively, DCs can be generated form 
purified CD34+ progenitor cells using appropriate cytokine combinations. Sources of CD34+ 
cells include bone marrow, cord blood, and G-CSF mobilized peripheral blood. Although the 
Table 1 Delivery of antigens into DCs in DC-based vaccines 
Defined TAA 
   Synthetic or eluted peptides 
   Transfection with cDNA or RNA encoding TAA 
   Viral vectors 
Whole tumor vaccine 
   Tumor lysates 
   Dying cells 
   Tumor RNA 
   DC-tumor cell fusions 
   Exosomes 
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high antigen capture and processing capacity of immature DCs makes them suitable for 
uptake of exogenous antigens such as RNA, proteins or dead tumor cells, recent reports 
demonstrate that immature DC can induce tolerance to antigen used for vaccination 56;57;100. 
However, other reports show that in murine models, mature monocyte-derived DCs were 
unable to elicit an anti-tumor response while immature monocyte-derived DCs elicit 
therapeutic effects 101;102. Perhaps mature DCs have lost migrating capacity necessary to 
reach the appropriate secondary lymphoid organs. In general it is unclear to what extent DCs 
ex vivo cultured and loaded with TAA are able to migrate to relevant lymphoid organs in 
humans. Parameters to define effective versus ineffective antigen presenting cells for use in 
clinical trials and appropriate co-stimulatory and activation molecules to expose DCs in order 
to optimize DC function in vivo are addressed in current studies 103. Also the route of 
administration may effect the quality of the response 104. Several parameters, such as the dose 
of DCs, the route and the frequency of injection are also examined in ongoing clinical trials 
to optimize immune responses in order to maximize clinical efficacy against cancer 105. 
 
The future of DC-based cancer vaccines 
Cellular vaccines, such as the DC-based approach, are expensive, time consuming, and 
complex, and may not be simply implemented as a standard treatment of cancer patients. A 
perhaps more realistic strategy may be the induction of large numbers of DCs through the use 
of growth factors in vivo. For example, the administration of Flt3L in humans results in a 
reversible accumulation of functionally active DCs. Both the CD11c+ and CD11c- DC 
subsets are expanded: the increase in circulating CD11c+ DCs adds up to a mean of 48-fold, 
and in CD11c- DCs to a mean of 13-fold 106;107.  
Direct in vivo targeting of TAA to receptors expressed on DCs may abolish the need for 
the tedious generation and loading of DCs ex vivo 108. Antigen targeting using monoclonal 
antibodies may provide an elegant way for receptor-mediated targeted delivery of antigens to 
DCs 109;110. Early studies, using an anti-MHC class II monoclonal antibody in a rat model, 
has validated this idea 111;112. Targeting to a monocytic cell line by means of a fusion protein 
consisting of a antibody directed against FcγRI (CD64) and the prostate specific antigen 
PSA, results in the induction of presentation of PSA antigens on MHC class I molecules in 
vitro 113. 
In a murine model, selective delivery of antigens was achieved in vivo by means of a 
fusion protein between an antibody against the DEC-205 (CD205), an endocytic receptor, 
GENERAL INTRODUCTION 
 
23 
and HEL peptide resulting in presentation on MHC class II molecules 100. However, in this 
study tolerance was induced due to lack of addition stimuli to mature DCs. In addition, 
adjuvants such as CpG oligonucleotides may be valuable for in vivo maturation of DCs, 
while they also prolong the survival of DCs 114;115. Targeting direct to DCs in vivo by means 
of an antibody as vector could result in presentation of antigens on both MHC class I and II 
molecules leading to a broad immune response involving both TH cells and CTLs. The 
specificity of the antibody permits selective targeting of the desired DC subset. 
 
 
SCOPE OF THIS THESIS 
 
The goal of the research described in this thesis was to identify human antibodies that 
bind to DCs and to explore whether these antibodies could be used to further delineate DC 
subsets and to evaluate their potential as targeting vehicles for the in vivo delivery of tumor 
antigens to DC. Human antibodies do not appear to be immunogenic, making human 
antibodies the most desirable antibody format for clinical application. DCs play a pivotal role 
in the induction of immune responses, explaining why they have received much attention in 
the design of new cancer vaccination strategies. Current DC-based vaccine approaches 
mostly rely on the ex vivo generation of DCs from precursor cells, which are subsequently 
loaded with tumor antigens and re-infused into patients to evoke an anti-tumor response. An 
alternative approach is provided by human antibodies as vectors for in vivo targeted delivery 
of tumor antigens to DCs. 
In the search for suitable cell surface molecules expressed by DCs in peripheral blood 
and tonsil, we employed a phage antibody display approach to generate phage antibodies 
binding to cell surface molecules 116;117. We performed selections using a phage antibody 
display library in combination with flow cytometry on freshly isolated DCs found in human 
peripheral blood (Chapter 2A) and human tonsil (Chapter 2B). We obtained several phage 
antibodies with desirable characteristics, recognizing both DCs and their precursors the 
monocytes, which have been used as tools in further delineation of DC subsets. 
These phage antibodies were converted to fully human monoclonal antibodies (huMabs) 
of the IgG4 isotype. Furthermore, different DC subsets have been described based on 
phenotype, function and anatomical localization. The diversity of DC subsets and their 
potential role in polarization of the immune response, prompted us to determine in detail the 
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reactivity patterns of our huMabs on in vivo DC subsets found at different anatomical 
localizations and in vitro generated DCs  (Chapter 3). 
In light of the potential application of our huMabs as tools to target antigens to DCs, we 
analyzed whether engagement of the molecules recognized by the huMabs exerted functional 
effects (Chapter 4). 
In a first step toward in vivo targeting of DCs in cancer immunotherapy, we explored 
whether antibody-mediated targeting of tumor antigens to DCs using a huMab as vector 
could provide a novel antigen delivery strategy. This strategy involves the construction of an 
eukaryotic expression vector encoding a huMab, genetically fused to a tumor antigen. We 
established proof of principle of this approach in an in vitro setting (Chapter 5). 
In a cell-based approach to cancer vaccination, we explored whether these lipid-tagged 
scFvs incorporated in tumor cells could induce receptor-mediated endocytosis by monocytes 
(Chapter 6). Therefore, the phage antibodies were converted to lipid-tagged scFv antibody 
fragments. 
At the end of this thesis, a summarizing discussion is provided in which our findings are 
discussed and the main perspectives for future studies emanating from the research described 
in this thesis are presented (Chapter 7). 
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ABSTRACT 
 In one application of phage display technology, large libraries of antibody fragments 
displayed on phage particles are used to select antibodies that bind to molecules expressed on 
the surface of eukaryotic cells. The advantage of this method is that antibodies can be 
selected against antigens in their native configuration, without the need to purify or express 
the antigen as a recombinant protein. Moreover, this approach may be used to search for 
novel membrane molecules expressed by subpopulations of cells that are difficult to address 
by conventional methods, e.g. small numbers of cells present in heterogeneous mixtures. It 
has been shown that the isolation of cell-bound phages is compatible with 
immunofluorescence staining and flow cytometric identification and sorting of cells based on 
multiparameter analysis. Here, we have employed a semi-synthetic phage display library of 
human single chain Fv antibody fragments in combination with flow cytometry to isolate 
antibodies against rare populations of precursor and mature dendritic cells present in human 
peripheral blood. Dendritic cells are a phenotypically heterogeneous population of 
professional antigen presenting cells of bone marrow origin with complex and only partly 
understood developmental relationships and functions. We have isolated phage antibodies 
against subpopulations of blood DCs and analyzed the distribution of the target antigens. The 
results show that these phage antibodies are useful tools to further dissect relationships and 
function of DCs in healthy and diseased tissues. 
 
          
INTRODUCTION 
Dendritic cells (DCs) are professional antigen presenting cells that play a central role in 
the initiation of the immune response. DCs are well equipped to take up antigens from their 
environment, to process antigens that have entered the endocytic pathway and to present 
them as immunostimulatory peptides to T lymphocytes in the context of major 
histocompatibility (MHC) antigens. In addition to their role in stimulating primary T cells, 
DCs also have a direct effect on the growth and immunoglobulin secretion of B lymphocytes 1. 
 DCs are derived from bone marrow stem cells and are found in small numbers in most 
lymphoid and non-lymphoid tissues 2. There appear to be several developmental pathways 
that lead to the generation of DCs 3. To this date, no cell surface markers that exclusively 
identify DC subpopulations or lineages have been found. The identification of DCs relies on 
a combination of morphological, phenotypic and functional criteria, including the presence 
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and absence of combinations of cell surface markers and the capacity to take up, process and 
present antigens.  
 In the bone marrow, the small subset of CD34+ hematopoietic progenitor cells contains 
the progenitors for at least two discrete DC populations: the epidermal Langerhans cells and 
the dermal or interstitial type DCs 4;5. In blood, the minute numbers of cells with DC 
characteristics belong to at least two different phenotypically and functionally distinct 
subpopulations. One population is defined as CD33dimCD14-CD16- 6;7, and is also referred to 
as the CD11c- DC population that lacks lineage-specific markers (Lin-) 8 and the Lin-HLA-
DR+ cells that express high levels of the interleukin-3α receptor 9. The CD33dimCD14-CD16- 
DCs represents a precursor population that efficiently takes up and processes antigens yet it 
fails to efficiently present peptides to T cells. The blood CD33dimCD14-CD16- DCs 
phenotypically resemble a recently described DC precursor population in T cell areas of 
lymphoid tissues 10. The second blood DC population has been defined as CD33+CD14-
CD16-, whereas DC populations with similar characteristics have been identified as Lin-
CD11c+. This population also expresses the CMRF44 marker 11;12, yet lacks CD83 13. The 
CD33+CD14-CD16- cells are considered more mature as they have an increased accessory 
function compared to the CD33dimCD14-CD16- DC precursors 7. A phenotypically similar 
population has been found in germinal centers of lymphoid tissue 14. 
 Recent studies have shown that large numbers of cells with DC-like properties can be 
generated in vitro from CD34+ bone marrow and cord blood cells and blood monocytes by 
stimulation with cytokines such as granulocyte-macrophage colony stimulating factor (GM-
CSF), interleukin (IL) 4, and tumor necrosis factor α (TNF-α) 15-17. Most of our current 
understanding of the developmental relationships between DC subpopulations has been based 
on results obtained with these culture systems 3; the relevance for in vivo DC relationships 
and differentiation pathways largely remains to be established.  
 Monoclonal antibodies represent an important tool in delineating developmental 
relationships between cells and in unraveling functional properties of cell surface molecules. 
In search for unique surface markers expressed by DCs in peripheral blood and other tissues, 
we have employed a phage antibody display approach to generate recombinant antibody 
fragments binding to cell surface molecules. We have previously shown that semi-synthetic 
libraries of recombinant human single chain (sc) Fv antibodies expressed on phage particles, 
in combination with flow cytometry may be used to isolate phage antibodies against 
subpopulations of cells present in heterogeneous mixtures 18;19. This selection procedure is 
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rapid and independent of the immunogenicity of the target antigen, a limitation associated 
with conventional hybridoma technology. Monoclonal phage antibodies (MoPhabs) isolated 
by this method are directed against antigens in their native configuration, unaltered by 
purification or antigen immobilization procedures that may introduce neo-epitopes. This 
approach was shown to be applicable to very rare populations of cells such as hematopoietic 
stem cells that occur in the bone marrow mononuclear cell fraction at a frequency of 1/104-
1/105 cells 20. Here, we have applied this procedure to isolate MoPhabs binding to blood 
CD33dimCD14-CD16- precursor DCs and CD33+CD14-CD16-  mature DCs. We demonstrate 
that these MoPhabs can be used as a tool to investigate lineage and subpopulation 
relationships between DCs in different lymphoid organs.   
 
 
MATERIAL AND METHODS 
 
Media and reagents 
The medium used in all cell cultures was RPMI 1640 supplemented with (2 mM) L-
glutamine and 25 mM HEPES buffer (Gibco BRL, Breda, The Netherlands), and with 1000 
U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf serum (Integro, Zaandam, The 
Netherlands).  
 
Antibodies 
We used the following mouse IgG monoclonal antibodies: FITC- or PE- conjugated 
CD3, CD4, CD11c, CD13, CD14, CD16, CD19, CD33, CD56, and CD71 (all from Becton 
Dickinson, San Jose, CA), PE- conjugated CD1a (CLB, Amsterdam, The Netherlands), 
PECy5-conjugated antibody against CD33, PE-conjugated antibody against CD83 (all from 
Immunotech, Marseille, France), FITC-conjugated antibody against CD40 (Monosan, Uden, 
The Netherlands), FITC-conjugated antibody against CD86 and PE-conjugated antibody 
against CDw123 (both from PharMingen, Hamburg, Germany), TC-conjugated antibody 
against CD38 (Monosan), FITC-conjugated antibody against IgD (SBA, Birmingham, USA), 
an APC-conjugated antibody against CD4 (Becton Dickinson), monoclonal antibody 9E10 
against the Myc tag (American Type Culture Collection)  and a monoclonal antibody against 
M13 that was biotinylated in house (Pharmacia Biotech Uppsala, Sweden). In this study also 
sheep anti-M13 polyclonal antibody (Pharmacia Biotech), PE-conjugated donkey anti-sheep 
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polyclonal antibody (Jackson ImmunoResearch, West Grove, PA), streptavidin-FITC (SBA), 
streptavidin-PE (Immunotech), streptavidin-PercP (Becton Dickinson), and rabbit anti-mouse 
Ig HRP conjugate (Dako, Glostrup, Denmark) were used. 
 
Phage antibody library 
The semi-synthetic phage antibody display library of human scFv antibody fragments 
was similar to that described in detail elsewhere 18;19. Briefly, germline VH genes were fused 
to semi-randomized synthetic heavy chain CDR3 regions, varying in length between 6 and 21 
amino acid residues. The resulting products were inserted into a phagemid vector, containing 
light chains of both kappa and lambda subclasses.  
 
Cell isolation procedures 
Peripheral blood was obtained from healthy donors. Heparin (50 U/ ml) or EDTA (0.47 
M; Venglect) was used to prevent clotting. Peripheral blood mononuclear cells (PBMCs) 
were isolated by Ficoll-Hypaque (Pharmacia Biotech) density gradient centrifugation. 
Granulocytes, visualized by flow cytometry, were gated based on typical forward and side 
scatter, after hypotonic lysis of peripheral blood. Human tonsils were cut into small pieces 
and digested with 1 mg/ml collagenase IV (Sigma Chemical Co., St.Louis, MO) and 0.1 
mg/ml deoxyribonuclease (Boehringer Mannheim) for one hour at 37°C. The single cell 
suspensions were washed twice. Single cell suspensions of adult bone marrow were obtained 
from healthy donors and mononuclear cells were obtained by Ficoll-Hypaque density 
gradient centrifugation, diluted 1:1 in medium. 
 
Selection of phage antibodies by cell sorting 
The selection of phage antibodies and propagation of the selected phage antibodies was 
done essentially as described 18. Briefly, 40 x 106 PBMCs were depleted of T cells by 
rosetting with sheep red blood cells as described 21. A 500 µl portion of the phage library, 
containing approximately 1013 antibody bearing phage particles per ml, was blocked for 15 
minutes in 250 µl of PBS/ 5% (w/v) milk powder. Subsequently, the T cell-depleted PBMCs 
were added to the blocked phages and the mixture was slowly rotated overnight at 4°C, the 
following day, the cells were washed twice with ice-cold PBS/1% (w/v) BSA. The pelleted 
cells were suspended in 20 µl PE-conjugated antibody CD33 and 20 µl FITC-conjugated 
antibody against CD14 to visualize different cell populations by flow cytometry. After 20 
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minutes incubation on ice, the cells were washed once with PBS/1% BSA and resuspended in 
4 ml of PBS/1% BSA. Cell sorting was performed on a FACStarPLUS fluorescence activated 
cell sorter (Becton Dickinson). For each cell population of interest 104 to 105 cells were 
sorted. Phages were eluted from the sorted cells, 1.5 times the volume of the cells of 76 mM 
citric acid (pH 2.5) was added followed by incubation for 5 minutes at room temperature. 
The mixture was neutralized with 0.5 times the volume of the mixture of 1 M Tris HCl (pH 
7.4). The eluted phages were used to infect Escherichia coli XL1-Blue (Stratagene, La Jolla, 
CA) and plated out on TYE medium 22 containing the appropriate antibiotics and glucose. 
Bacterial colonies were counted, scraped form the plates, and used as an inoculum for the 
next round of phage rescue. 
 
Preparation of MoPhabs and scFv fragments 
After three rounds of selection, MoPhabs were rescued from single ampicillin-resistant 
colonies of infected XL1-Blue cells22 and cultured in a final volume of 4 ml of 2TY 
containing the appropriate antibiotics and glucose. Helper phages were added to each culture 
and phages were harvested from the supernatant by precipitation using polyethylene 
glycol/NaCl, and resuspended in 400 µl of PBS/1%BSA, as described 18.  Binding to 
different cell populations was verified by immunofluorescence analysis. ScFv's were 
produced in the Escherichia coli non-suppressor strain SF110, which is deficient in the 
proteases DegP and OmpT. This results in the production of stable scFv fragments. Induction 
of protein synthesis and isolation scFv fragments from the periplasmic space was performed 
as described 18. Expression of the scFvs was analyzed by Western blotting 18. 
 
Immunofluorescence staining procedures 
For staining of cells, 100 µl of MoPhab was blocked by adding 50 µl of PBS/ 4% milk 
powder for 15 minutes at room temperature. 5 x 105 cells in 50 µl of PBS/ 1%BSA were 
added and incubated on ice for 1 hour. To detect cell-bound phages, the cells were incubated 
in 10 µl of a 1:400 dilution of sheep anti-M13 polyclonal antibody for 20 minutes on ice, 
washed, and incubated in 10 µl of a PE-conjugated donkey anti-sheep polyclonal antibody 
solution (20 :g/ml) for 20 min on ice. The cells were washed and incubated with conventional 
monoclonal antibodies of interest. After a single final wash, the cells were suspended in 400 
µl of PBS/ 1%BSA. Flow cytometric analyses were performed using a FACScan 
fluorescence-activated cell analyzer (Becton Dickinson).  
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Western blot analysis 
Samples were separated on 10% SDS-polyacrylamide gels followed by electroblotting to 
nitrocellulose. ScFv proteins were visualized by staining with undiluted hybridoma 
supernatant containing the myc-tag specific antibody 9E10, followed a HRP-conjugated 
rabbit anti-mouse Ig diluted in PBS/4% milk powder. After a final wash, blots were 
developed with diaminobenzidene.  
 
Screening and nucleotide sequence analysis of phage antibodies 
The diversity of the phages with binding activity was assessed by BstNI DNA 
fingerprint analysis of clones22. The nucleotide sequence of the selected clones was 
determined by automated sequencing to establish VH and VL gene identity and heavy and 
light chain CDR3 composition. 
 
Cell lines and transfectants 
T cell line Jurkat, pre-B cell lines Nalm-6 and Reh, mature B cell lines Raji and Daudi, 
plasmacytoid cell line U266, myeloid cell lines, HL60, U937, KG1-A, MonoMac and THP-1, 
megakaryocyte cell line DAMI, hepatoma cell line Hep-G2, human umbilical cord 
endothelial cells, Hodgkin's cell lines L428 and HDLM-2, erythroid precursor cell line K562, 
cervical carcinoma cell line HeLa, colon carcinoma cell line LS174T and lung carcinoma cell 
line GLC-8 were cultured in complete medium. Baby hamster kidney cells transfected with 
the GM-CSF receptor (GMR) α subunit, the GMR β subunit and the GMR α/β subunits were 
cultured in DMEM with 10% FCS and 1% pencillin/streptomycin, with supplement of 
respectively 200 µM methorexate, 4 µM G418 and, 200 µM methorexate and 4 µM G418 
together. Binding of MoPhbas to Jurkat transfected cell lines with immunoglobulin-like 
transcripts (ILT) 3, 4 and 5 respectively was kindly performed by Dr. Marco Colonna. The 
CD14 transfectant and the CD64 transfectants were a kind gift of drs R. Ulevitch and J. van 
de Winkel respectively. 
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RESULTS 
 
Experimental strategy 
 We have employed a semi-synthetic phage display library of human scFv fragments to isolate 
antibodies that bind to DC subpopulations present in human peripheral blood. PBMC were 
isolated and stained with a combination of FITC-labeled CD14 and PE-labeled CD33 antibodies. 
Previous studies have demonstrated that with this staining protocol, blood DCs can be subdivided 
into a mature CD14-CD33+ population and a precursor CD14-CD33dim population 6;7. In this 
scheme, monocytes can be identified as a distinct CD14+CD33+ cell population, whereas 
lymphoid cells such as B cell, T cells and NK cells are CD14-CD33-  (Fig. 1). 
 PBMCs were depleted of T cells and 3-9 x 107cells were incubated with the phage library. 
Subsequently, the cells with bound phages were incubated with PE-labeled CD33 and FITC-
labeled CD14. Approximately 6 x 104 cells mature DCs and 1.3 x 105 precursor DCs were 
sorted; the phages were eluted from the cell surface and propagated in bacteria for the next 
round of selection. After the first round of selection 1 x 105 colonies were obtained for the 
selection with mature DCs and 2.3 x 105 colonies for the selection with precursor DCs. 
 
 
 
 
 
 
 
 
 
Phages selected for binding to precursor DC 
 After three rounds of selection on CD14-CD33dim precursor DC a total number of 70 
bacterial clones was picked, MoPhabs were prepared and analysed in flow cytometry in 
double-staining with anti-CD33 for binding to PBMC. A total of 11 phages did not bind to 
any subpopulation in the PBMC fraction. The remaining 59 phages bound to subpopulations 
of CD33+ cells and 39 of these displayed additional binding to CD33- cells. Phages that dis-
played binding to CD33- PBMC were not considered for further study. The remaining 20 
MoPhabs were subjected to BstNI fingerprint and immunofluorescence staining analyses in 
Figure 1 Identification of precursor and mature blood DCs. 
PBMCs were stained with PE-labeled anti-CD33, followed by 
staining with FITC labeled anti-CD14. The dot-plot depicting 
CD33 versus CD14 fluorescence intensity is shown. Blood 
DCs can be subdivided into a mature CD14-CD33+ DC 
population (I) and a precursor CD14-CD33dim DC population 
(II). Rectangles represent sorted cell populations. Monocytes 
can be identified as a CD14+CD33+population, whereas 
lymphoid cells reside within the CD14-CD33- population. 
C
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combination with lineage-specific monoclonal antibodies. Based on the cell distribution 
patterns of the molecules identified by independent MoPhabs in this collection and the 
intensity of immunofluorescence staining, no MoPhabs from this selection were pursued for 
further analysis. 
  
Phages selected for binding to mature DC 
 A total of 90 MoPhabs derived from the selection on the CD14-CD33+ population was 
analysed by flow cytometry; 42 MoPhabs in this collection bound exclusively to CD33+ cells 
or displayed additional binding to small subpopulations of CD33- cells. After BstNI 
fingerprinting, 5 MoPhabs, named MatDC11, MatDC16, MatDC27, MatDC51 and MatDC64 
were propagated for further analysis. 
 
Reactivity of MoPhabs with cells in peripheral blood 
 The binding of MoPhabs to subpopulations of PBMC was assessed by triple staining 
experiments with FITC-labeled CD14 and CD16, PECy5-labeled CD33 monoclonal 
antibodies and PE-labeled MoPhabs. The CD16 antibody was included to separate the 
CD33dim cells in CD33dim/CD16+ monocytes and CD33dim/CD16- DCs23. For each 
experiment, 103 cells within the CD14+CD16-CD33+ monocyte gate, the CD14-CD16-CD33+ 
mature DC and the CD14-CD16-CD33dim precursor DC gates were analyzed. In addition, we 
performed double staining experiments with MoPhabs and fluorochrome-labeled lineage-
specific monoclonal antibodies including CD3 (T lymphocytes), CD19 (B lymphocytes) and 
CD56 (natural killer cells). Binding of MoPhabs to granulocytes was analyzed based on 
forward and side scatter profile. As a control, PBMC were stained with MoPhab Mono-14. 
This MoPhab was obtained by phage selections on the CD14+CD33+ monocyte population 
and recognizes the CD14 molecule, as determined by specific staining of CHO cells 
transfected with the human CD14 cDNA (results not shown). As a negative control in 
staining experiments, a MoPhab specific for thyroglobuline19 was used. The results are 
shown in figure 2 and summarized in table 1.  
 All five MoPhabs stained mature DC; with a bright staining for MatDC 11, MatDC 16 and 
MatDC 51. MatDC 11 bound to all CD14-CD33dim precursor DCs, while the other four 
MoPhabs appeared to recognize only a subpopulation of the precursor DCs. All five 
MoPhabs displayed binding to the CD14+CD16-CD33+ blood monocytes. No binding to 
blood CD3+ T cells or CD56+ NK cells was observed for any of the MoPhabs. MoPhabs 
MatDC 11 and MatDC16 bound to CD19+ B cells.  
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Reactivity of MoPhabs with tonsil mononuclear cells 
 Human tonsils contain DCs that can be identified as a CD3-CD4+  cell population that lacks 
lineage-specific markers. A further division of this population is obtained by staining with 
antibodies to IL-3Rα (CDw123). Germinal center DCs, which consist of 65% of the CD3-
CD4+ DCs, are only weakly stained with this antibody14, whereas the remaining CD3-CD4+ 
DCs highly express this marker9. Staining of tonsil cell with APC-labeled CD4, PE-labeled 
CDw123 and FITC-labeled CD3 in combination with PercP-labeled MoPhabs, was used to 
examine the reactivity of the MoPhabs with the different DC populations in tonsil (Fig. 3). 
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Figure 2 Binding of MoPhabs to different blood DC populations as assessed by three-color flow cytometric 
analysis. PBMCs were stained with individual MoPhabs, PECy5 labeled anti-CD33, and FITC labeled anti-CD14 
and anti-CD16. The histograms show fluorescence values of the MoPhabs binding to the gated cells depicted in the 
dot-plot. Transparent histograms show control stainings with a negative control MoPhab; grey histograms show 
staining with the different MoPhabs as indicated. 
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Figure 3 Binding of MoPhabs to DC subpopulations in tonsil as assessed by four-color flow cytometric 
analysis. Tonsil cells were stained with MoPhabs, APC-labeled anti-CD4, PE-labeled CDw123 and FITC 
labeled anti-CD3 antibodies. The histograms show fluorescence values of the MoPhabs binding to the gated 
cells depicted in the dot-plot. Transparent histograms show control stainings with a negative control MoPhab; 
grey histograms show staining with the different MoPhabs as indicated. 
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All MoPhabs stained the CDw123+ DC, whereas only MatDC 11, MatDC 16 and MatDC 51 
were positive on germinal center DCs. The CD3+CD4+  helper T cells and the CD3+CD4- 
cytotoxic T cells were not recognized by any of the MoPhabs. The CD3-CD4- population in 
tonsil consists predominantly of B lymphocytes that may be subdivided in four different 
subpopulations by staining with antibodies specific for IgD and CD3824. Triple-staining with 
these antibodies in combination with the MoPhabs, revealed that MatDC 11 and MatDC 16 
stained the IgD+CD38- naive B cells, the IgD-CD38+ germinal center B cells and the IgD-CD38++ 
plasma blasts. However, no staining of the IgD-CD38- memory B cells was observed. 
Table 1 Reactivity of MoPhabs with different cell populations 
 MatDC 11 MatDC 16 MatDC 27 MatDC 51 MatDC 64 
PBMC:      
Mature DC +++ ++ + ++/+++ + 
Precursor DC ++/+++  ++*  +/++*  ++*  ++* 
Monocytes ++ ++ ++ ++ ++ 
CD16+ Monocytes -/+ -/+ -/+ ++/+++ -/+ 
CD3+  T cells - - - - - 
CD19+ B cells + + - - - 
CD56+ NK cells - - - - - 
Granulocytes:  +#   +#  - + - 
Tonsil:      
CDw123dim DC ++ +/++ -(+) ++ -(+) 
CDw123+ DC ++ ++ + -/+ + 
CD3+CD4+ - - - - - 
CD3+CD4- - - - - - 
CD3-CD4- + + - - - 
Synovial Fluid:      
Mature DC + + - -/+ - 
Precursor DC  +*  +* - -(+) - 
Monocytes + + + + + 
CD33-CD14- cells - - - - - 
Adult BM:      
CD3+ cells - - - - - 
CD10+ cells + - - - - 
CD14+ cells + + + + + 
CD15+ cells + -/+ -  -/+ - 
CD19+ cells + - - - - 
CD34+ cells + -/+ - -/+ - 
Cells were stained as described in legends to Figs. 2-4 or with other antibodies as indicated. Mean fluorescence 
intensity (MFI) levels for the different populations are shown as -, indicating the highest MFI in the first decade 
on a four log scale which corresponds to negative control levels. The +, ++ and +++ indicate MFI in the 
second, third and fourth decades, respectively. A slash (/) indicates that the MFI is on the border between two 
decades. Parenthesis indicate that less than 5% of the population is positive. *Approximately 50% of the 
population is positive for this MoPhab. #10-15% of the granulocytes are positive for this MoPhab. 
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Reactivity of MoPhabs with hematopoietic progenitor cells 
 In adult bone marrow cells, MatDC 11 brightly and MatDC 16 and MatDC 51 weakly 
stained CD34+ hematopoietic progenitor cells. All five MoPhabs recognized CD14+ cells in 
bone marrow that were mostly monocytes from contaminating blood in the aspirates. 
MoPhabs MatDC11, MatDC 16 and MatDC 51 stained the CD15+CD14- myeloid progenitor 
cells. MatDC 11 also reacted with CD19+ B-lymphoid cells and CD10+ cells. CD10 is a 
marker expressed early during lymphoid development. None of the MoPhabs stained CD3+ T 
lymphocytes. 
 
Reactivity of MoPhabs with synovial fluid mononuclear cells of patients with rheumatoid arthritis  
 Synovial fluid (SF) from affected joints of patients with rheumatoid arthritis have been 
shown to contain increased numbers of DCs that may be involved in the prolongation and/or 
exacerbation of local immune-based inflammatory reactions25;26. DCs and monocytes in SF 
may be identified based on the same characteristics as DCs in peripheral blood. As in blood, 
all five MoPhabs stained monocytes present in SF (not shown).  MoPhabs MatDC 11, 
MatDC 16 and MatDC 51 stained the mature DCs in SF, whereas a subpopulation of the 
precursor DCs was positive for MatDC 11and MatDC 16. MatDC 27 and MatDC 64 did not 
stain mature DCs in SF and appear to stain a small fraction of  the precursor DCs (Fig. 4). 
 
 
 
 
 
 
 
 
 
Reactivity of MoPhabs with cell lines 
To identify MoPhabs that bound to known molecules, we developed the following 
strategy. Binding of the MoPhabs to a panel of 20 cell lines with known CD expression 
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Figure 4 Binding of MoPhabs to DC subpopulations in SF as assessed by three-color flow cytometry analysis. 
Synovial cells were stained as described in the legend to Fig. 2. The histograms show fluorescence values of the 
MoPhabs on gated cells in the rectangles depicted in the dot-plot. Transparent histograms show control stainings 
with a negative control MoPhab, grey histograms show stainings with the different MoPhabs as indicated. 
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patterns was determined 
(table 2). Subsequently, 
MoPhabs with expression 
patterns that resembled 
known CD antigens were 
tested for binding to cell lines 
transfected with the 
corresponding cDNA 
including transfectants for 
CD14, CD31, CD40, CD64, 
GM-CSF Rα, GM-CSF 
Rα/β and ILT 3, 4 and 5. 
From this analysis, we 
concluded that none of the 
MoPhabs bound to the panel 
of transfectants or appeared 
to match distribution patterns compatible with known CD antigens. In this analysis, it also 
became apparent that MatDC 27 and MatDC 64 do not recognize the same molecule. MatDC 
64 stains cell lines MonoMac and Jurkat, while MatDC 27 is negative on these cell lines. 
Conversely, MatDC 27 reacted with the U937 cell line while MatDC 64 did not. 
 
 
DISCUSSION 
In search for DC-specific antibodies, we have applied a recently developed method using 
a combination of a semi-synthetic phage antibody display library and fluorescence-activated 
cell sorting. We have previously shown that this approach can be used to obtain antibodies 
against rare populations of cells present in a heterogeneous mixture. DCs represent a rare and 
phenotypically and functionally heterogeneous population of cells with complex 
developmental relationships. DCs show the essential properties of antigen presenting cells: 
antigen uptake, processing and presentation. Monoclonal antibodies against subpopulations 
of DCs should provide valuable tools to gain insight in the developmental relationships and 
functional differences between DC subpopulations.  
We did not find MoPhabs directed against molecules uniquely expressed by DCs. All 5 
MoPhabs selected for further study also bound to blood monocytes and, in some cases, to 
MatDC 11 MatDC 16 MatDC 27 MatDC 51 MatDC 64
Cell lines:
Jurkat + + - - +/-
Nalm-6 nt - -  +* -
Reh + + - - -
Raji + + - - -
Daudi + + - - -
U266 nt - - - -
HL-60 + + - + -
U937 + + +/- - -
KG1a nt + - - -
MonoMac nt  +* - - +
THP-1 + + - + -
DAMI nt - - - -
Hep-G2 nt - - - -
HUVEC + +/- - - -
L428 + + - - -
HDLM-2 - - - - nt
K562 - - - - -
HeLa + + - - -
LS174T + + - - -
GLC-8 + + - - -
+/-, weak staining; nt, not tested; *, a subpopulation of cells is positive 
Table 2 Reactivity of MoPhabs with cell lines 
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other subpopulations of hematopoietic cells. Among the five MoPhabs, MatDC 27 and 
MatDC 64 displayed the most restricted distribution pattern. Both MoPhabs bound to all 
mature DCs and a subpopulation of precursor DCs in blood. In addition, both MoPhabs 
bound to the CD4+/CD3- DCs in tonsil that express high levels of the IL-3Rα, whereas few 
CD4+CD3-DCs in the tonsil expressing low levels of IL-3Rα were positive. Whether the 
tonsil CD4+CD3-IL-3Rαhigh DCs are of lymphoid or myeloid origin is still a matter of debate 
9;10
. Our observation that the tonsil CD4+CD3-IL-3Rαhigh DCs expressed a marker that is also 
present on all monocytes in blood, is suggestive of a myeloid origin. Both MatDC 27 and 
MatDC 64 did not appear to bind to bone marrow cells including the CD34+ and the 
CD15+CD14- cells representing early myeloid progenitors. Thus, expression of the molecules 
detected by MatDC 27 and MatDC 64 is restricted to the more mature stages of monocyte 
and DC development. Strikingly, although monocytes in SF from patients with rheumatoid 
arthritis stained with both MoPhabs, no staining of precursor or mature DCs was observed in 
SF. Apparently, precursor and mature DCs in SF, defined as CD33+CD14- and 
CD33dimCD14- respectively are phenotypically different from their peripheral blood 
counterparts. It is temping to speculate that this phenotypic difference is related to their entry 
into the inflamed tissue and/or related to the cytokine-rich environment of the SF.  
The epitope recognized by MoPhab MatDC 11, MatDC 16 and MatDC 51 displayed a 
broader distribution pattern on hematopoietic cells and cells of some other lineages. MoPhab 
MatDC 11 stained blood and tonsil DCs and B lymphocytes blood monocytes and a 
subpopulation of cells with forward scatter/side scatter properties of granulocytes. In bone 
marrow, the epitope recognized by MatDC 11 was found on both myeloid and B lymphoid 
progenitor cells. A common marker shared by myeloid cells and B lymphoid cells suggests a 
developmental relationship between these cell populations. It has recently been shown that 
normal murine pro-B cells can undergo a 'lineage-switch' to DCs in vitro by exposure to 
cytokines 27. In addition, although malignancies involving DCs are rare, some Hodgkin 
lymphoma's of B cell origin have distinct DC  features26. Indeed, MoPhab MatDC 11 bound 
to the Hodgkin cell line L428. DCs obtained during in vitro culture of pro-B cells 
progressively loose B cell markers such as CD19. In contrast, the molecule detected by 
MoPhab MatDC 11 appears to be shared by both lineages in vivo. The staining pattern of 
MatDC 16 on freshly-isolated cells closely resembled that of MatDC 11. Analysis of the 
hematopoietic progenitor cells revealed different staining patterns, suggesting that both 
Mophabs recognize different molecules.  
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In blood, MatDC 51 displayed binding to DC, monocytes, including the CD16+ 
monocytes, and all granulocytes. In bone marrow, this MoPhab bound to most CD34+ cells 
and to CD15+/CD14- myeloid progenitor cells. This indicates that the epitope recognized by 
this MoPhab is present on all myelomonocytic cells.  
 We demonstrate that flow cytometric selection of small populations of freshly isolated 
DCs that have bound phages from a phage display library of scFv antibody fragments yields 
MoPhabs that can be used as a tool to detect phenotypic differences between DCs present in 
various lymphoid organs and in SF from patients with rheumatoid arthritis. In addition to 
their application as a research tool, it may be envisaged that these scFv antibody fragments 
can be used in clinical applications. DCs are unique leukocyte populations, that control the 
primary immune response, and targeting of molecules to DCs in vivo is considered a 
potentially valuable vaccination strategy to evoke for example anti-tumor responses. Ample 
data from in vitro studies suggest that DCs loaded with tumor antigens or nucleic acids 
encoding tumor antigens are able to induce anti-tumor responses28-31. In vitro studies further 
show that antibodies against molecules expressed on the surface of DCs such as Fc receptors 
and MHC class I and II molecules can mediate targeted delivery of antigens that are correctly 
processed and presented to T Lymphocytes32;33;34. The scFv antibody fragments described 
here may be converted to complete human antibodies35 genetically fused to antigens or 
chemically coupled to nucleic acids for targeted delivery to subpopulations of DCs in 
immunotherapeutic applications.  
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ABSTRACT 
We have used a phage antibody display library in combination with multiparameter flow 
cytometry and cell sorting to isolate phage antibodies that bind to subpopulations of dendritic 
cells (DCs) in human tonsil. Two phage antibodies, TN55 and TN141, were further 
characterized. TN55 exclusively bound to the CD11c+ and CD11c- DC subpopulations in 
tonsil, whereas in peripheral blood binding to all myeloid populations was observed. TN141 
displayed a more DC-restricted reactivity pattern as it stained the CD11c+ and CD11c- DC 
subpopulations in tonsil, and predominantly the CD33high DC subpopulation in blood. An 
additional dim staining of TN141 on CD33dim DCs and monocytes was observed. These 
antibodies can be used for further analysis of subpopulations of human DCs as well as for 
targeted delivery of antigens to DCs for vaccination purposes. 
 
 
INTRODUCTION 
Dendritic cells (DCs) are professional antigen presenting cells that play a central role in 
initiating and modulating T-cell mediated immune responses 1. Located in tissues throughout 
the body, DCs act as sentinels to capture antigens. Following antigen uptake and processing, 
DCs migrate to the lymphoid tissues where initiation of the immune response takes place. 
DC lineage relationships and functional properties are based mainly on in vitro models of DC 
generation. In vivo, morphological, phenotypical and functional differences exist between 
DC subsets, depending on their anatomical localization 2. Whether these subsets represent 
distinct cell lineages or different maturation states is the subject of many current 
investigations 3-7. 
Within tonsil, three fresh DC subsets have been identified: plasmacytoid DCs, 
interdigitating DCs (IDCs), and germinal center DCs (GCDCs) 8-10. The major 
subpopulation, plasmacytoid DCs, is localized around the high endothelial venules and in T 
cell areas. They form the main source of type I interferon during inflammation 11. These 
plasmacytoid DCs have also been identified in blood 12, cord blood 13 and thymus 6 and are 
considered lymphoid related 14;15. The second subset consists of IDCs, which also populate 
the T cell areas of lymphoid tissues. These cells are characterized by high expression of 
MHC class II, CD40, CD80 and CD86 and have migrated from the periphery to lymph nodes 
where they interact with T cells 16. The third subset, the GCDCs, is localized to B cell areas 
and has limited antigen-capturing capacity but has stong antigen-presenting capacity 9. These 
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DCs are suggested to promote the T cell - B cell interaction with germinal centers and may 
regulate B cells. 
Since DCs are central to induction of an immune response, they have gained interest in the 
area of cancer vaccines 17;18. DC-based vaccine approaches rely on the generation of DCs ex 
vivo from precursor cells that are subsequently loaded with antigen and re-infused into 
patients to evoke an anti-tumor response. Alternatively, targeting antigens to directly DCs in 
vivo may induce anti-tumor responses. Antibodies to which antigens are chemically coupled 
or genetically fused antigen-antibody fusion proteins can be used as vehicles for targeted 
delivery of antigen, and may improve anti-tumor responses. As a prelude to these 
experiments, we set out to generate antibodies specific for subpopulations of human DCs. 
We have used a semi-synthetic phage display library and flow cytometry to generate 
phage antibodies specific for DCs in the tonsil. The three different subsets of DCs in tonsil 
express CD4, whereas they lack T cell marker CD3 and B cell marker CD19. Hence, tonsil 
DCs can be identified by flow cytometry based on these three markers. Tonsil mononuclear 
cells were incubated with the phage antibody library and subsequently stained with 
fluorochrome-labeled antibodies against CD3, CD19 and CD4. The CD4+CD3-CD19- DCs 
and attached phages were isolated by cell sorting, whereby the remainder of the mononuclear 
cells served as absorber population for phages recognizing more ubiquitously expressed 
molecules. After two rounds of selection, monoclonal phage antibodies (MoPhabs) were 
isolated and immunofluorescent analyses revealed their binding specificities. 
Three categories of MoPhabs were isolated, based on binding specificity of which one 
reacted uniquely with tonsil DCs. This category of MoPhabs consisted of two MoPhabs that 
stained both the CD11c+ and CD11c- DC subsets in tonsil, though more intense on CD11c+ 
DC. Staining of DC and monocyte subsets in peripheral blood revealed distinct differences 
between those MoPhabs. In conclusion, using phage antibody display, we identified putative 
novel markers on DCs in tonsil that can be used for identification and isolation of tonsil DC 
and may provide a tool in DC-based vaccines. 
 
 
 
 
 
 
 
PHAGE ANTIBODIES SELECTED ON TONSIL DCS 
 
55 
MATERIAL AND METHODS 
 
Media and reagents 
The medium used in all cell cultures was RPMI 1640 (Gibco BRL, Breda, The 
Netherlands), supplemented with, 25mM HEPES, 2mM L-glutamine, 5x10-5 M 2-
mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin 10% (vol/vol) heat-
inactivated fetal calf serum (Integro, Zaandam, The Netherlands), hereafter referred to as 
RMPI-S. 
 
Antibodies 
The following monoclonal and polyclonal antibodies were used for immunofluorescent 
analysis: phycoerythin (PE)-labeled CD1a (CLB, Amsterdam, The Netherlands), fluorescein 
isothiocyanate (FITC)-labeled CD3, PE-labeled CD4, allophycocyanin (APC)-labeled CD4, 
PE-labeled CD11c, FITC-labeled CD14, FITC-labeled CD16, FITC-labeled CD19, peridinin 
chlorophyll (PerCP)-labeled CD19 (all from Becton Dickinson, San Jose, CA), PerCP 
Cyanine 5.5 (PECy5)-labeled CD33, PE-labeled  CD83 (Immunotech, Marseille, France), 
and PE-labeled CD123 (PharMingen, San Diego, CA) antibodies. Sheep-anti-M13 polyclonal 
antibody (Pharmacia Biotech, Uppsala, Sweden) was biotinylated using Sulfo-NHS-biotin 
according to the manufactures protocol (Pierce, Rockford, IL). PE-labeled streptavidin 
(Immunotech) and PerCP-labeled streptavidin (Becton Dickinson) were used to detect the 
biotinylated sheep-anti-M13 antibody. 
 
Phage antibody library 
For the selection procedure, equimolar amounts of two semisynthetic phage display 
libraries of human single-chain Fv (scFv) antibody fragments were used. The first library is 
described in detail elsewhere 19. In brief, a collection of 49 different germ line heavy chain 
variable fragment (VH) genes fused to synthetic CDR3 regions were combined to seven 
different light chain variable fragments (VL) of both κ and λ subclasses and cloned in the 
pHEN1 vector containing a Myc-tag 19. This resulted in a repertoire of 3.6x108 different 
human scFvs displayed on filamentous phage particles. For the second library, 1x106 light 
chain variable fragments PCR-amplified from peripheral blood of healthy donors were fused 
to the semi-synthetic VH regions from aforementioned library, cloned in vector pPVT 
containing a VSV-tag, which resulted in a repertoire of 2x109 different clones (J. de Kruif 
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and M. Tijmensen, unpublished results). The pPVT vector is similar to pHEN1. It was 
constructed using standard molecular biology techniques, resulting in a phagemid containing 
the pUC19 backbone, the pelB leader sequence, an scFv cloning site, the VSV-tag and a 
truncated geneIII sequence. 
 
Cell isolation procedures 
Tonsils were obtained from children undergoing routine tonsillectomy. Tonsils were 
minced and digested for 1 hour at 37°C with collagenase IV (1mg/mL; Sigma, St Louis, MO) 
and deoxyribonuclease I (100ng/mL, Boehringer Mannheim, Mannheim, Germany). The 
tissue was subsequently filtered though an open-filter chamber (NPBI, Emmer-Copascuum, 
The Netherlands) and the collected cells were subjected to Ficoll-Hypaque (Pharmacia 
Biotech) density gradient centrifugation, to obtain tonsil mononuclear cells (MNCs). 
Peripheral blood was obtained from healthy volunteers. Peripheral blood mononuclear 
cells (PBMCs) were isolated by Ficoll-Hypaque (Pharmacia Biotech) density gradient 
centrifugation. Blood leukocytes were prepared by removal of erythrocytes from human 
peripheral blood by hypotonic shock. 
 
Selection of phage antibodies by cell sorting 
Phage selection on cells was performed as described elsewhere 20;21. In brief, 1013 phage 
particles were blocked for 15 minutes in PBS containing 5% low-fat milk powder. 108 tonsil 
MNCs were added to the blocked phages and the mixture was slowly rotated overnight at 
4°C. The following day, the cells were washed twice with ice-cold PBA (PBS containing 1% 
BSA and 0.05% sodium-azide), and subsequently stained for 30 minutes on ice with PE-
conjugated CD4 and FITC-conjugated CD3 and CD19 antibodies. The cells were washed 
with PBA and resuspended in RPMI-S; 104 cells CD4+CD3-CD19- cells were isolated by cell 
sorting on a FACStarPLUS (Becton Dickinson). Phages were eluted from the sorted cells by 
incubation for 5 minutes at room temperature with 1.5 volume of 76 mM critic acid, pH 2.5, 
and neutralized by addition of 0.5 volume of 1M Tris-HCl, pH 7.4. The eluted phages were 
rescued by infection of Escherichia coli XL1-Blue (Stratagene, La Jolla, CA), and 
propagated for a second round of selection, employing the same procedure. 
 
Preparation of MoPhabs and immunofluorescent analysis  
After the second round of selection, MoPhabs were prepared from individual ampicillin-
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resistant bacterial colonies 20 and analyzed for binding specificity in immunofluorescent 
analysis. For immunofluorescent analysis, MoPhabs were blocked for 15 minutes with PBS 
containing 4% milk powder. Cells were added and incubated for 1 hour on ice. Cell-bound 
phages were detected using biotinylated sheep anti-M13 polyclonal antibody for 20 minutes 
on ice, followed by either streptavidin-PE or streptavidin-PercP. Where indicated, cells were 
subsequently stained with appropriate FITC, PE, PercP, PECy5 or APC-labeled antibodies. 
Stained cells were analyzed on a FACSCalibur (Becton Dickinson).  
 
Screening and nucleotide sequence analysis of MoPhabs 
To establish VH and VL gene utilization and heavy chain CDR3 composition, the 
nucleotide sequences of selected MoPhabs were determined by automated sequencing using 
primers LINKSEQ and PHENSEQ 4. 
 
Generation of monocyte-derived DC 
DCs were generated from monocytes as previously described 22;23. Briefly, PBMCs were 
isolated from blood by Ficoll-Hypaque density centrifugation, and allowed to adhere for 2 
hours at 37°C. The adherent monocytes were cultured at 1x106 cells/ml in RPMI-S, in the 
presence of recombinant human (rh) interleukin (IL)-4 (500 U/ml; Strathmann, Hannover, 
Germany) and rh granulocyte-macrophage colony-stimulating factor (GM-CSF; 800 U/ml, 
Schering-Plough, Amstelveen, The Netherlands) for 5 days. Fresh cytokine-containing 
culture medium was added at day 3. After 5 days, the immature monocyte-derived DCs were 
harvested. To generate mature DC, a combination of 800U/mL of rhGM-CSF (Schering 
Plough), 1000 U/ml of rhIL-4 (Strathmann), 20 ng/ml of rh tumor necrosis factor (TNF) α 
(Intergen Company, Purchase, NY) 10 ng/ml of rhIL-1β (Strathmann), 1000 U/ml of rhIL-6 
(Roche Diagnostics, Almere, The Netherlands), 1 µg/ml of prostaglandin E2 (PGE2; Sigma, 
St. Louis, MO) were added to the immature DC for another 48 hours.  
 
Cell lines 
The following cell lines were used in this study: T cell lines CEM and Jurkat, B cell 
lines Raji and Daudi, myeloma cell lines RPMI8226 and Fravel, myelomonocytic cell line 
HL60, promonocytic cell line U937, monocytic cell line THP-1, erythroid/megakaryocytic 
precursor cell line K562. 
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RESULTS 
 
Experimental strategy 
To select MoPhabs specific for markers on DCs in human tonsil, a single cell suspension 
made from tonsil was incubated with a combination of two semi-synthetic phage antibody 
display libraries. Tonsil DCs were identified as CD4+CD3-CD19- cell population comprising 
about 0.8% of the tonsil MNCs (Fig. 1). The excess of non-selected cells in the mixture was 
hypothesized to absorb the MoPhabs that recognize molecules shared by selected and non-
selected cells 20;24. In the first round, 15x103 CD4+CD3-CD19- cells with attached phages 
were sorted. Rescue of the phages yielded 104 single colonies, which were propagated and 
subsequently used for a next round of selection. For the second round, 20x103 CD4+CD3-
CD19- cells were sorted, which resulted in 5000 single colonies. After two rounds of 
selection, single colonies were picked for production of individual MoPhabs.  
 
 
Figure 1 Identification of DCs in tonsil. Tonsil MNCs were 
stained with FITC-labeled CD3 and CD19, followed by PE-
labeled CD14. Tonsil DCs can be identified as a CD4+CD3-CD19- 
population. A rectangle represents the sorted cell population. 
 
 
Phages selected for binding to tonsil DC 
After the second round of selection, 168 individual colonies were picked to produce 
MoPhabs. Comparative flow cytometric screening of tonsil MNCs, established the reactivity 
of MoPhabs for DCs. As a negative control in staining experiments, a MoPhab specific for 
dinitrophenyl (DNP) was used 19. 8 % (14/168) of the MoPhabs were not reactive in flow 
cytometry and these MoPhabs were not pursued in further studies. Based on different 
staining patterns, the MoPhabs could be grouped in three categories. The majority of the 
MoPhabs reacted with all B cells in tonsil (category I). MoPhabs in category II stained DCs 
and in addition, a subpopulation of B cells in tonsil (Fig. 2). Two MoPhabs bound 
exclusively to DCs in tonsil (category III; Fig. 2). Subsequently, nucleotide sequence 
analysis was used to establish the VH and VL gene utilization and heavy chain CDR3 
composition of the different MoPhabs. This revealed that MoPhabs of category I were 
derived from the same clone based on CDR3 sequence, VH and VL identity. This MoPhab 
PHAGE ANTIBODIES SELECTED ON TONSIL DCS 
 
59 
was isolated previously,  recognizes the β-chain of CD22 20;25 and is expressed on all mature 
B cells. 
The MoPhabs in category II had different CDR3 sequences, though their staining 
patterns were similar. A similar staining pattern has been described by Van der Vuurst de 
Vries for MoPhab IV-7 24. MoPhab IV-7 is derived from selections on memory B cells in 
tonsil and binds to most memory B cells, a subpopulation of naïve B cells as well as all DC 
subsets in tonsil. The two MoPhabs in category III had different CDR3 regions and used 
different VH genes and were hence different MoPhabs. Since TN55 and TN141 both uniquely 
stained tonsil DCs, further studies concentrated on these two MoPhabs. All MoPhabs in 
categories I, II, and III contained a Myc-tag as demonstrated by dot-blot (data not shown), 
indicating that they derived from the phage antibody display library as described by De Kruif 
et al. 19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Staining pattern of MoPhabs of in tonsil. Triple immunofluorescent staining was performed with the 
MoPhabs in combination with FITC-labeled CD3, PercP-labeled CD19 and APC-labeled CD4 monoclonal 
antibodies. The histograms depict the staining patterns of the individual MoPhabs with DC (CD4+CD3-), T cell 
(CD3+) and B cell (CD19+) populations. The thin line represents staining with a control MoPhab specific for 
DNP, whereas the bold line represent staining with the MoPhab of category II (TN92) and III (TN55, TN141). 
DCs T cells B cells 
TN55 
TN92 
TN141 
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Staining patterns of TN55 and TN141 on DC subsets in tonsil and blood. 
Tonsil DCs can be separated based on staining of the IL-3Rα (CD123). Germinal center 
DCs as well as IDCs have a low expression of IL-3Rα, whereas plasmacytoid DC, have a 
high expression of the IL-3Rα 9;10;12. Reciproquely, CD11c stains the myeloid DCs, 
comprising GCDCs as well as IDCs, whereas it is negative on plasmacytoid DC. As shown 
in figure 3, staining patterns of TN55 and TN141 on CD11c- and CD11c+ DCs subsets are 
similar. Both MoPhabs stained all tonsil DCs though the staining was more intense on 
CD11c+ DCs. 
 
 
Figure 3 Staining patterns of MoPhabs 
TN55 and TN141 on different DC 
populations in tonsil. Tonsil MNCs were 
stained with individual MoPhabs, FITC-
labeled CD3, PE-labeled CD11c and APC-
labeled CD4 antibodies. The histograms 
show fluorescence values of the MoPhabs 
binding to the gated cells depicted in the 
dot plot: A, CD11c- DC; B, CD11c+ DC. 
The thin line represents staining with a 
control MoPhab specific for DNP, whereas 
the bold line represent staining with the 
MoPhab as indicated. 
 
 
 
 
 
 
In blood, two subsets of DCs can be identified by triple staining of markers CD14, CD16 
and CD33 (Fig. 3) 26. Accordingly, a more mature DC can be seen as a CD33brightCD14-
CD16- population, known as the CD11c- population, which can induce a potent immune 
response 27. The other DC subset can be seen as a CD33dimCD14-CD16- population, or 
CD11c- population. This population has recently been shown to represent the plasmacytoid 
DC 12. In addition to CD33brightCD14+ monocytes, a subpopulation of CD33dimCD16+ 
monocytes is observed 26;28-30. Binding specificity of different MoPhabs on DC subsets in 
TN55
TN141 
A B
A B
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blood was examined. Whereas TN55 and TN141 gave similar staining patterns on tonsil 
subpopulations, a clear difference was observed on DC subsets in peripheral blood.  
TN55 reacted with CD33bright and 
CD33dim DC subsets as well as CD14+ 
monocytes and CD16+ monocytes. TN55 did 
not stain lymphocytes in blood, while a 
bright staining on granulocytes was observed 
(Table 2).  
TN141 specifically stained CD33bright 
DC, whereas it was dim to negative on 
CD33dim DC. In addition, a dim staining of 
the CD14+ monocytes was observed. 
However, TN141 did not stain either 
lymphoid cells or granulocytes in peripheral 
blood. In conclusion, TN141 demonstrated a 
staining pattern restricted to DCs and CD14+ 
monocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Staining patterns of MoPhabs TN55, TN92, and TN141 to different DC and monocyte populations in 
blood. PBMCs were stained with individual MoPhabs, PECy5-labeled CD33, and FITC-labeled CD14 and 
CD16 antibodies. The histograms show fluorescence values of the MoPhabs binding to the gated cells depicted 
in the dot plot. A, CD33high DC; B, CD33dim DC; C, CD14+ monocytes; D, CD16+ monocytes. The thin line 
represents staining with a control MoPhab specific for DNP, whereas the bold line represent staining with the 
MoPhab as indicated.  
Table 2 Reactivity of MoPhab TN55 and TN141with 
different cell populations 
 TN55 TN141 
Tonsil   
CD11c+ DC +* + 
CD11c- DC ± - 
B cells - - 
T cells - - 
PBMC   
CD33bright DC ++ ++ 
CD33dim DC ++ ± 
Monocytes ++ + 
CD16+ Monocytes ++ - 
NK cells - - 
Lymphocytesa - - 
Granulocytesa ++ - 
Mo-derived DC   
Immature ± - 
Mature + - 
-, negative; ±, variable, +, positive; ++, strong 
positive; a, gated on forward and side scatter 
TN55 
TN141  
A B C D 
A 
B 
C 
D 
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Reactivity on cultured monocyte-derived immature and mature DC 
  Monocyte-derived immature and mature DC were generated to evaluate the staining 
patterns of the MoPhabs on ex vivo cultured DCs. Immature DCs characterized by expression 
of CD1a, were generated by culturing monocytes in the presence of GM-CSF and IL-4 for 5 
days 31. Subsequently, these immature DC were stimulated using a combination of cytokines 
and PGE2 23, resulting in mature DC that expressed high levels of CD83. TN55 stained both 
immature and mature DC, however TN141 was negative on both populations (Table 2). 
 
Reactivity of MoPhabs TN55 and TN141 on different cell lines 
  Binding to different cell lines with known CD 
expression patterns was assessed in order to identify 
whether MoPhabs bound to known molecules (Table 
3). From this analysis, we concluded that neither TN55 
nor TN141 staining patterns matched distribution 
pattern of known CD antigens.  Though staining of 
TN55 resembled expression pattterns of myeloid 
markers such as CD13, CD15 and CD33, these 
molecules are both expressed on U937. In contrast, 
staining of TN55 was lacking on these cell lines. 
 
 
 
 
DISCUSSION 
We employed a semi-synthetic phage display library in combination with 
multiparameter flow cytometry and cell sorting to select phage antibodies binding to tonsil 
DCs. We have previously used this method to identify phage antibodies that recognize 
putatively novel target antigens on DCs in human peripheral blood 21. This method is rapid 
and independent of immunogenicity of the target antigen, and results in the selection of 
antibodies directed against native cell-bound antigens. 
Tonsils from routine surgery provide the most readily accessible source of human 
lymphoid tissue. The tonsils play an important role in immunologic surveillance. As a route 
of pathogen entry, tonsils are considered a possible site of entry and/or replication of the 
HIV-1 virus 32. At least three DC subsets in tonsil have been described, the plasmacytoid 
Table 3 Reactivity of MoPhab TN55 and 
TN141 on different cell lines. 
  
TN55 TN141 
Jurkat - - 
CEM - + 
Raji - - 
Daudi - nt 
RPMI8226 + - 
Fravel - - 
HL60 + + 
U937 - - 
THP-1 + nt 
K562 - - 
*  -, negative; +, positive; nt, not tested 
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DCs, the IDCs and the GCDCs. These subsets have a distinct phenotype and anatomical 
localization and are hypothesized to have a specialized function. To date, no cell surface 
markers specific for tonsil DCs have been described, mainly due to the scarcity of these cells 
in vivo. In our strategy, isolation of DCs prior to the selections was not necessary. The 
presence of cells other than DCs in the selection procedure is even crucial for the absorption 
of phage antibodies directed against commonly expressed antigens. It should be noted that 
follicular dendritic cells present in the germinal center do not derive from a bone marrow 
precursor and belong to a separate lineage as compared above-mentioned DC subsets. They 
lack expression of CD4 and were not included in this study. 
In this study, a suspension of tonsil mononuclear cells was incubated with a combination 
of two semi-synthetic phage antibody display libraries. Tonsil DCs were identified as the 
CD4+CD3-CD19- cell population during cell sorting. After two rounds of selection, 168 
individual clones were tested for binding to CD4+CD3- DCs. More than 90% of these clones 
tested positive. Although our selection method was aimed at isolation of phage antibodies 
directed uniquely against DCs in tonsil, most of the isolated phage antibodies recognized 
antigens expressed by both DCs and B cells. This may not be very surprising, since both cell 
types are involved in antigen-presentation and are expected to share molecules associated 
with this function. In this context, it is noteworthy that we previously identified phage 
antibodies selected on blood DCs that also showed additional binding to B cells 21. 
MoPhabs were grouped in three categories based on staining patterns. Phage antibodies 
in the first category were derived from the same clone, which was previously identified to 
bind to CD22. It is known that CD22 is expressed on all mature B cells, however its 
expression on DCs in tonsil has never been reported. Detailed analysis of tonsil suspensions 
of different donors revealed that this phage antibody rarely stained DCs. Since the sorted cell 
fraction is 95 to 98% pure, we could not exclude the possibility that this phage antibody was 
isolated because of contamination of B cells in the sorted DC fraction. 
Phage antibodies from the second category actually contained all different antibodies 
based on nucleotide sequence analysis of VH regions, though their staining patterns were 
similar. Interestingly, a similar staining pattern is seen for a MoPhab called IV-7, which is 
selected on memory B cells 24. Notably, all MoPhabs with this staining pattern, including 
MoPhab IV-7, make use of a Vκ1 light chain in combination with a DP31 or DP32 VH 
segment. The significance of this restricted VH usage is not known.  
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The most interesting third category exclusively stained DCs in tonsil. This category 
contained only two phage antibodies, denoted TN55 and TN141. Further analysis revealed 
that MoPhabs TN55 and TN141 stained myeloid CD11c+ DC subsets, the IDCs and GCDCs, 
and the CD11c- subset, the plasmacytoid DCs, although their targets antigens were expressed 
higher on the myeloid DCs. To conclude, we successfully isolated two MoPhabs that 
recognized unique antigens present on DCs in tonsil. The isolation of two tonsil DC specific 
MoPhabs without prior isolation of this small population clearly underlies the strength of the 
absorption effect of phage antibodies to structures shared by cells other than DCs.  
TN55 uniquely bound to DCs in tonsil however further characterization binding to all 
myeloid cells, including granulocytes, in peripheral blood. In addition, binding to immature 
and mature monocytes derived DCs was demonstrated. From the staining pattern of TN55, 
we concluded that the target antigen is expressed on all myeloid cells. However, expression 
of the target antigen in an early stage of the myeloid lineage is not expected, since staining on 
the CD33+ cell line K652, also displaying erythroid and megakaryocytic markers, was not 
observed. Despite extensive efforts, we were unable to identify the target antigen of TN55. 
Presumably, TN55 did not bound to common myeloid markers such as CD13, CD15 and 
CD33, based on staining patterns on cell lines. 
TN141 showed a more restricted reactivity pattern in peripheral blood. Bright staining of 
the CD33high DCs was observed while staining of CD33dim DCs was almost lacking. In 
addition, TN141 bound to the CD14+ blood monocytes, whereas binding to in vitro generated 
monocyte-derived DCs was absent. In general, TN141 preferentially bound to fresh myeloid 
DCs. This staining pattern is distinct from that of MoPhabs MatDC 27 and MatDC64 derived 
from blood DC selections. While in blood a similar staining of these MoPhabs can be seen, in 
tonsil only binding to plasmacytoid DC was observed for MoPhabs MatDC27 and MatDC64. 
To identify the target antigen of MoPhab TN141, cDNA expression cloning using a 
commercially available Hela cDNA library transfected in 293T cells was carried out as 
described 33. Unfortunately, this approach was not successful. ScFv fragments derived from 
MoPhabs TN55 and TN141 did not perform in immunohistochemistry. Whether this is 
caused by a low affinity of the scFv fragments or the nature of the antigen remains to be 
resolved. 
In conclusion, we demonstrate that a subtractive approach to select antibodies specific 
for a small subpopulation of cells, yielded phage antibodies that bind exclusively to the cells 
of interest, tonsil DCs. Further characterization of these phage antibodies demonstrated a 
more broad reactivity pattern in peripheral blood. DCs represent a heterogeneous population 
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of cells, potentially derived from independent lineages. Therefore, it is likely that this 
selection method yields antibodies against antigens associated with the differentiation stage 
or anatomical localization of DCs, than antigens uniquely associated with DCs in general. In 
order to isolate more general DC-specific phage antibodies, one could envisage selection 
strategies whereby fresh DCs from different anatomical localizations, such as peripheral 
blood and tonsil, are used in alternating selection rounds. Another possibility is that DCs are 
not defined by unique antigens, but rather are distinguished from other cell types by 
expression of a unique combination of otherwise more commonly expressed cell surface 
antigens. 
The MoPhabs, isolated during this study, can be converted to complete human 
antibodies. An effective method for this was developed in our laboratory 34 and has 
previously been used to generate a functional and clinically applicable huMab against a 
tumor-associated antigen 35. As fully human antibodies, the MoPhabs described here could 
serve as tools for in vivo targeting to DCs in vaccination protocols. For example, chemical or 
genetic coupling of human DC-specific antibodies to tumor antigens may be explored to 
develop cancer vaccines. 
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ABSTRACT 
Interpretation of published data concerning the phenotype of dendritic cell (DC) subsets 
in different human tissues is hampered by the ambiguous definition of the DC population. In 
this report, we exploited multiparameter flow cytometry for detailed immunophenotypic 
analysis of cultured DCs and DCs obtained from blood, tonsil, spleen, thymus and skin. The 
panel of antibodies used for this study consisted of murine monoclonal antibodies, including 
the recently described BDCA-1-4 antibodies, and of four human monoclonal antibodies 
isolated from a phage display library. Using this set of antibodies in combination with flow 
cytometry allowed us to further define the heterogeneous DC population in humans. 
Furthermore, the analysis of the binding characteristics of the panel of human antibodies 
forms the basis of the selection of human antibodies for the targeted delivery of antigens to 
DCs in vivo, an important step towards the design of new vaccination strategies. 
 
 
INTRODUCTION 
Dendritic cells (DCs) are a heterogeneous population of cells, with extraordinary 
immunostimulatory capacity, including the ability to prime naive CD4+ T cells and CD8+ T 
cells towards T helper cells and CTLs, respectively 1. They are continuously produced from 
hematopoietic stem cells in the bone marrow and are widely distributed throughout the body 
as immature DCs 2. Following encounter with pathogens, DCs mature and migrate from 
peripheral tissues to the secondary lymphoid organs, where they initiate an immune response.  
The high antigen capture and presenting capacity that results in extremely efficient induction 
and maintenance of immune responses have led to increasing interest in the use of DCs as 
vaccines to induce anti-tumor immunity. DCs cultured ex vivo from precursor cells, loaded 
with tumor antigens in the form of peptides, whole antigens or tumor cell lysates are 
beginning to enter clinical trials with some encouraging results 3-7. However, several issues to 
ensure the optimal outcome of DC vaccines have to be evaluated further, among them the 
source of DCs in relationship tot the quality of the immune response. DCs used in clinical 
trials have been cultured and manipulated ex vivo, a tedious process that may alter the 
properties of DCs. An attractive alternative may be the targeting of antigens to DCs in vivo.  
Because of their exquisite specificity, monoclonal antibodies may be developed that, upon 
injection, act as targeting devices for the delivery of tumor antigens to DCs 8;9. Given their 
presumed role in polarization of the immune response, it may even be envisaged that 
CHAPTER 3 
 
72 
targeting of tumor antigens to different DC subsets may permit better control of the quality of 
the immune response.  
Different DC subsets have been described based on phenotype, function or anatomical 
localization. DCs can modulate of the development of T cell-mediated immune responses by 
influencing T helper (TH) cell differentiation into either TH type 1 (TH 1) or TH type 2 (TH 2) 
10
. It has been proposed that distinct DC subsets may have different specialized functions and 
can direct TH responses differently 11;12. However, there is increasing evidence that the type 
of response induced by a DC subset in TH cells depends also on the kinetics of activation, the 
microenvironment and nature of the pathogen that is encountered. Taken together, this 
implies considerable plasticity of DC functions within a subset 13-17. 
In a previous study, we have employed a semi-synthetic antibody phage display library, 
in combination with subtractive selection and flow cytometry to generate monoclonal phage 
antibodies against DCs in human blood 18 and tonsil (Lekkerkerker, A., De Weers, M., 
Logtenberg, T., Chapter 2B). Four of these phage antibodies, denoted MatDC16, MatDC27, 
MatDC64 and TN141, were found to preferentially bind to DCs and monocytes and chosen 
for further characterization. Here, we report the conversion of the phage antibodies to fully 
human monoclonal antibodies (huMabs) 19. Therapeutic monoclonal antibodies currently 
used in the clinic contain mouse protein sequences and have the potential to trigger for the 
patient unwanted immune reactions. These problems can be circumvented by the use of fully 
human antibodies 20;21 hence human antibodies (huMabs) are the most desirable antibody 
format for clinical application. The IgG4 isotype was chosen because: (a) it has low affinity 
for FcγRI, and does not bind other Fcγ receptors and (b) it does not activate complement 22. 
These characteristics make the IgG4 huMab an ideal vector for DC targeting strategies. 
In light of this application, a detailed phenotypical analysis of these IgG4 huMabs on in 
vivo DC subsets of different tissues is critical. Although the analysis of DC subsets in human 
tissues has been hampered by the availability of suitable reagents and unambiguous 
definitions, progress has recently been made. In human peripheral blood, in addition to 
CD14+ monocytes, two subsets of DC precursors were originally identified, based on the 
differential expression of CD11c and absence of lineage markers 23. The CD11c+ subset 
expresses myeloid-related surface molecules and is dependent on GM-CSF for growth and 
survival. In tissue culture, CD11c+ DCs spontaneously develop into mature DCs, even when 
cultured without any exogenous cytokines 24. The CD11c- subset expresses the IL-3 receptor 
(CD123) at high levels and has so-called plasmacytoid morphology 25;26. This population 
depends on IL-3 for its survival and differentiation into mature DCs with typical dendritic 
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morphology and potent T cell stimulatory function 11;27. Importantly, the plasmacytoid DCs 
are responsible for type I interferon (IFN) secretion in response to viral stimuli 28;29. It 
appears that CD11c+ DCs are of myeloid derivation, while the lineage commitment of 
plasmacytoid CD11c- DCs is less clear. 
In secondary lymphoid organs, such as tonsil and spleen, DCs interact with other cells of 
the immune system, resulting in the induction of an immune response. In tonsil, three DC 
subsets have been defined: first, the plasmacytoid DCs, located near high endothelial venules, 
correspond to the CD11c- population in blood. Second, germinal center DCs (GCDCs) are 
CD11c+ and are located in the germinal center, and presumably stimulate CD4+ T cells and 
play a role in germinal center B cell proliferation and differentiation 30;31. Third, the CD11c+ 
interdigitating DCs (IDCs) are found in the T cell areas of tonsils in close contact with T cells 
32
. Recently, CD11c+ DCs were identified in human spleen, at three distinct regions, the 
marginal zone, the T cell and B cell zones, the latter resembling tonsil GCDCs 33. 
The thymus is a primary lymphoid organ and of crucial importance in the development 
and maturation of T cells. Thymic DCs are implicated in elimination of self-reactive T cells. 
Human thymus contains two myeloid DC subsets, a CD11c+HLA-DRhigh subset that 
expresses markers of fully mature DCs such as CD40, CD83 and CD86, and a minor 
CD11c+HLA-DR+ population, resembling tonsil GCDCs 34;35. In addition, the CD11c- DCs 
corresponding in phenotype to plasmacytoid DCs described in tonsil and blood, are the most 
abundant population found in thymus. Recently, significant levels of pre-TCR α-chain 
transcripts in plasmacytoid DCs in thymus as well as tonsil have been demonstrated, 
indicating that they may have a lymphoid origin 36. 
Human skin, a non-lymphoid tissue, contains two distinct DC subsets: first, Langerhans 
cells (LCs) within the epidermis, characterized by the expression of CD1a and Birbeck 
granules 37;38. Secondly, interstitial DCs in the dermis, lack Birbeck granules, and are also 
found in other non-lymphoid tissues all over the body. 
The physiological differentiation pathways that yield the different DC subsets in vivo are 
not well known. In contrast, the origin and differentiation pathways of DCs in vitro have been 
extensively studied. In vitro, human hematopoietic CD34+ progenitors from bone marrow or 
cord blood differentiate into DCs when cultured with GM-CSF and TNFα via two 
independent pathways, resulting in cells with either a dermal or interstitial DC phenotype or 
with a LC phenotype 39;40. 
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Human peripheral blood monocytes cultured with GM-CSF and IL-4 generate immature 
DCs that can be driven into a mature state using different maturation mediators such as 
TNFα, LPS and CD40L 41-43. In addition, by in vitro crossing of an endothelial barrier in the 
ablumenal-to-lumenal direction, as occurs during entry into lymphatics, monocytes can 
differentiate into DCs 44. Nonetheless, there is still limited understanding of the relationships 
between in vitro generated DCs and DC subsets in vivo; hence the question concerning the 
developmental origin of the subsets in vivo remains under discussion 45. 
In the current study, we used a multi-parameter flow cytometry strategy to identify 
naturally occurring DC subsets and determine the phenotype of the distinct DC subsets found 
at different anatomical sites. Furthermore, in search of physiological counterparts of in vitro 
generated DCs, we compared the immunophenotype of freshly isolated DC subsets with DCs 
generated in well-defined culture systems. We provide extensive surface marker analyses 
using conventional monoclonal antibodies (Mab), including four recently described Mabs, 
BDCA-1 (CD1c), BDCA-2, BDCA-3, and BDCA-4, which identify three distinct blood DC 
subsets 46. We show differential staining patterns of the huMabs on DC subsets in vivo and in 
vitro. Conversion of DC-specific phage antibodies to IgG4 huMabs along with their reactivity 
profiles on naturally occurring DC subsets represent an important step towards their possible 
application in direct in vivo targeting in DC-based vaccination strategies. 
 
 
MATERIAL AND METHODS 
 
Culture medium 
Unless stated otherwise, medium consisting of RPMI 1640 (GIBCO, Grand Island, NY) 
supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (Integro, Zaandam, The 
Netherlands), 25 mM HEPES, 2 mM L-glutamine, 5x10-5 M 2-mercaptoethanol, 100 U/ml 
penicillin, and 100 µg/ml streptomycin (referred to as RPMI-S) was used for culturing cells. 
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Antibodies 
The sources of conjugated Mabs used 
for flow cytometry are listed in table 1. 
Alexa Fluor 633 streptavidin conjugate 
(Molecular Probes, Eugene, OR) or PE- 
streptavidin conjugate (Becton Dickinson, 
Erembodegem, Belgium) was used to 
detect biotinylated antibodies in flow 
cytometry.  Goat anti-human IgG 
unlabeled and HRP-labeled (SBA, 
Birmingham, AL) was used for ELISA, 
HRP-labeled goat anti-human IgG4 
antibody was used for immunoblotting 
(CLB, Amsterdam, the Netherlands). 
 
Construction and production of human 
IgG4 monoclonal antibodies 
The phage antibodies used in this 
study were previously described 18. To 
construct huMabs of the IgG4 istoype, the 
heavy and light chain variable regions 
encoding the phage antibodies of interest 
were excised and recloned into vectors for stable expression of complete IgG4/κ molecules in 
eukaryotic cell lines. The construction of the expression vectors and the production of 
huMabs has been described in detail elsewhere 19. Briefly, the heavy and light chain variable 
regions were cloned in a vector containing the T cell receptor α chain HAVT20 leader 
peptide sequence and a splice donor site. Next, the fragment containing the heavy or light 
chain variable region with attached leader sequence and splice donor site were subcloned in 
the pNUT-Cγ4 or pNUT-Cκ expression vectors. Using the appropriate restriction sites, the 
complete heavy or light chain was recloned in the pCDNA3.1 vector (Invitrogen, Carlsbad, 
CA). 
The different huMabs IgG4 were produced by stable transfection of human embryonic 
kidney (HEK) 293 cells. Cells were maintained in Iscove’s modified Dulbecco’s medium 
Table 1  Monoclonal antibodies used for flow cytometry. 
Antigen Clone Conjugate Source 
BDCA-2 AC144 PE M 
BDCA-3 AD5-14H12 PE, FITC M 
BDCA-4 AD5-17F6 PE M 
CD1a BL 6 PE I 
CD1c AD5-8E7 PE M 
CD3 SK7 PE BD 
CD4 SK3 PE BD 
CD11b D12 PE BD 
CD11c S-HCL-3 APC, PE BD 
CD13 L138 PE BD 
CD14 MfP9 FITC BD 
CD16 3G8 FITC BD 
CD19 SJ25C1 FITC BD 
CD20 L27 FITC BD 
CD25 2A3 PE BD 
CD40 Mab89 PE BC 
CD54 84H10 PE BC 
CD56 NCAM16.2 FITC BD 
CD64 M22 PE W 
CD80 L307.4 PE BD 
CD83 HB15a PE BC 
CD86 FUN-1 PE P 
CD123 7G3 PE P 
HEA HEA125 FITC M 
HLA-DR L243 PercP BD 
Lin 1*   FITC BD 
*Lineage Cocktail 1 (CD3, CD14, CD16, CD19, CD20, CD56). 
Antibodies were obtained from: BC, Beckman Coulter, 
Marseille, France; BD, Becton Dickinson, Erembodegem, 
Belgium; I, Immunotech, Marseille, France; P, BD Pharmingen, 
Erembodegem, Belgium; M, Miltenyi Biotec, Bergisch 
Gladbach, Germany; W, dr. J. van de Winkel, UMC Utrecht, 
The Netherlands. 
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(IMDM) containing 10% FCS, 2mM glutamine and 5x10-5 M 2-mercaptoethanol, 100 U/ml 
penicillin, and 100 µg/ml streptomycin (Gibco). Cells were transfected at a density of 70-
80% confluency using calcium chloride precipitated DNA of the heavy and light chain, for 5 
hours at 37 °C, followed by a 15% glycerol shock for 1 minute. Cells were washed and after 
48 hours and selection was initiated by adding 500 µg/ml of zeocin (Invitrogen). After 2 
weeks, colonies of resistant cells were picked and cultured in zeocin-containing medium. 
Production of recombinant huMabs IgG4 was determined in the supernatant by sandwich 
ELISA using standard procedures and an IgG standard (CLB) as control. Large quantities of 
huMabs were produced in ULTRA-CHO medium (BioWhittaker, Walkersville, MD) using 
triple-flasks (Invitrogen). HuMabs were purified by protein A sepharose column 
chromatography (Biorad Laboratories, Munchen, Germany). SDS-PAGE and subsequent 
Coomassie brilliant blue staining of gel demonstrated the integrity of purified huMabs.  The 
IgG4 isotype of the huMabs was confirmed by Western blot, stained with HRP-conjugated 
goat anti-human IgG4 antibodies, detected with the substrate diaminobenzidine containing 
0.01% H2O2. Concentration of purified huMabs was determined by spectrophotometry at a 
wavelength of 280 nm using the Biorad protein assay (Biorad Laboratories). For detection in 
flow cytometry, the huMabs were biotinylated using a Biotin Labeling Kit according to the 
manufacturers instructions (Roche Diagnostics, Mannheim, Germany). 
 
Flow cytometry 
Cells were blocked for 20 minutes on ice in phosphate- buffered saline containing 1% 
BSA and 0.05% sodium azide (PBA) containing 10% human pooled serum and subsequent 
incubated with the biotinylated huMabs for 30 minutes on ice. Next, visualization of the 
huMabs was obtained using Alexa Fluor 633 streptavidin conjugate, in combination with the 
directly fluorochrome-conjugated antibodies as indicated in the RESULTS section. Cells were 
washed twice between incubation steps in PBA. After a final wash, cells were fixed in PBA 
containing 1% paraformaldehyde, and analyzed using a FACSCalibur (Becton Dickinson). 
For each experiment compensation was set using unstained (“autofluorescent”), FITC-only, 
PE-only, PercP-only and APC-only samples to eliminate fluorchrome crossovers between 
FL1, FL2, FL3 and FL4 channels. 
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Preparation of single cell suspensions: 
Blood 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood obtained 
from healthy donors, by density centrifugation on Ficoll-Hypaque (Pharmacia, Uppsala, 
Sweden). Blood leukocytes were prepared by removal of erythrocytes from human peripheral 
blood by hypotonic shock. 
 
Spleen 
Spleen was obtained from organ transplant donors. Mononuclear cell suspensions were 
obtained by mechanical dissociation of spleen tissue, followed by digestion with type VII 
collagenase at 20 U/ml (Sigma) and deoxyribonuclease I (Dnase I; Boehringer Mannheim, 
Mannheim, Germany) at 20 U/ ml in medium supplemented with 2% FCS for 30 minutes at 
37°C. The tissue was subsequently filtered though an open-filter chamber (NPBI, Emmer-
Copascuum, The Netherlands) and the collected cells were subjected to Ficoll-Hypaque 
(Pharmacia Biotech) density gradient centrifugation, to obtain spleen mononuclear cells 
(MNCs). 
 
Thymus 
Normal human thymuses from 15-day to 7-year-old children undergoing corrective 
cardiovascular surgery were cut into small pieces and subsequently sieved trough a gauze, to 
obtain a single cell suspension. 
 
Tonsil 
Tonsils were obtained from children undergoing routine tonsillectomy. Tonsils were cut 
into small pieces and digested for 1 hour at 37°C with collagenase IV (1mg/ml; Sigma, St 
Louis, MO) and Dnase I (100ng/ml, Boehringer Mannheim, Mannheim, Germany). The 
tissue was subsequently sieved through an open-filter chamber (NPBI, Emmer-Copascuum, 
The Netherlands) and the collected cells were subjected to Ficoll-Hypaque (Pharmacia 
Biotech) density gradient centrifugation, to obtain tonsil mononuclear cells (MNCs). 
 
Epidermal cell suspension of the skin 
Full-thickness human skin specimens were obtained from healthy donors undergoing 
plastic surgery of the breast. These specimens were shaved into slices of 0.2-mm thickness by 
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using a dermatome. To enable separation of the epidermis from the dermis, the slices were 
incubated with 0.2% dispase II (Boehringer Mannheim, Mannheim, Germany) in phosphate-
buffered saline over night at 4 °C. The next day, slices were incubated for another 5 minutes 
at 37° C. The epidermis was collected in IMDM (Gibco) supplemented with 10% FCS and 5 
U/ml Dnase I and sieved through a gauze to yield a single cell suspension. 
 
Generation of monocyte-derived DCs 
DCs were generated from monocytes as previously described 41;47. Briefly, PBMCs were 
isolated from blood by Ficoll-Hypaque density centrifugation, and allowed to adhere for 2 
hours at 37 °C. The adherent monocytes were cultured at 1x106 cells/ml in RPMI-S, in the 
presence of recombinant human (rh) interleukin (IL)-4 (500 U/ml; Strathmann, Hannover, 
Germany) and rh granulocyte-macrophage colony-stimulating factor (GM-CSF; 800 U/ml, 
Schering-Plough, Amstelveen, The Netherlands) for 5 days. Fresh cytokine-containing 
culture medium was added at day 3. After 5 days, the immature monocyte-derived DCs were 
harvested. To generate mature DCs, a combination of 800 U/ml of rhGM-CSF (Schering 
Plough), 1000 U/ml of rhIL-4 (Strathmann), 20 ng/ml of rh tumor necrosis factor (TNF) α 
(Intergen Company, Purchase, NY) 10 ng/ml of rhIL-1β (Strathmann), 1000 U/ml of rhIL-6 
(Roche Diagnostics, Almere, The Netherlands), 1 µg/ml of prostaglandin E2 (PGE2; Sigma, 
St. Louis, MO) were added for another 48 hours to the immature DCs.  
 
Generation of CD34+-derived DCs 
Hematopoietic CD34+ progenitor-derived DCs were prepared as described previously 
39;40
. Briefly, mononuclear cells were isolated by Ficoll-Hypaque density centrifugation 
(Pharmacia) from adult bone marrow samples. CD34+ cells were enriched using the MACS 
CD34+ progenitor cells system according to manufacturers instructions (Miltenyi Biotec, 
Bergisch Gladbach, Germany). CD34+ cells were seeded at 2x105 cells per well in a six wells 
plate in 4 ml RPMI-S supplemented with rhGM-CSF (Scheringh Plough), 2.5 ng/ml 
(50U/ml) of rhTNFα (Intergen Company), 25 ng/ml of rh stem cell factor (SCF; Amgen, 
Thousand Oaks, CA) and 2.5% AB+ pooled human serum. At day 3 fresh RPMI-S 
supplemented with rhGM-CSF and rhTNFα was added to each well. Hematopoietic CD34+  
progenitor-derived DCs were collected at day 6 of culture for analysis. 
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RESULTS 
 
Conversion of phage antibodies to IgG4 huMabs 
Recently, we generated phage antibodies selected on human DC subpopulations in 
peripheral blood 18 and tonsil (Lekkerkerker, A., De Weers, M., Logtenberg, T., Chapter 2B) 
using a phage antibody display library. Four phage antibodies that bound to DCs and also 
monocytes, denoted MatDC16, MatDC27, MatDC64, and TN141 were chosen for further 
characterization. A phage antibody directed against the human epithelial marker EpCAM, 
UBS54 48, was used as a negative control. 
The phage antibodies were converted to complete human antibodies of the IgG4 isotype 
using previously described eukaryotic expressions vectors 19. The heavy and light chain 
variable regions coding the phage antibodies of interest, MatDC16, MatDC27, MatDC64, 
TN141 and UBS54, were recloned in vectors containing the genomic IgG4 heavy chain 
constant domain and the genomic kappa light chain constant domain, respectively. Stably 
transfected clones were made by co-transfection of the heavy and light chain constructs. The 
huMabs were purified from culture supernatants of the clones and integrity and purity of the 
huMabs was confirmed by Coomassie brilliant blue staining of a SDS-PAGE gel run under 
reducing and non-reducing conditions (Fig. 1). An immunoblot using goat antihuman IgG4 
antibodies confirmed the IgG4 isotype (data not shown). 
 
Figure 1 SDS-PAGE analysis of purified 
IgG4 preparations under (A) non-
reducing and (B) reducing conditions. 
Lane 1, IgG4 MatDC16; lane 2, IgG4 
MatDC27; lane 3, IgG4 MatDC64; lane 
4, IgG4 TN141; lane 5, IgG4 UBS54. 
The molecular weight markers are shown 
in kilodaltons on the left. 
 
Phenotypic identification of in vivo DC subsets in different tissues 
We examined the expression of target antigens of the huMabs on different DC subsets in 
vivo and in vitro. DC subsets from blood and different tissues of the body were identified 
using four-color flow cytometry analysis, using the following antibodies: APC-labeled 
CD11c, PercP-labeled HLA-DR, a FITC-labeled cocktail of lineage markers (Lin: CD3, 
CD14, CD16, CD19, CD20, CD56) versus a panel of PE-labeled monoclonal antibodies on 
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single cell suspensions. Typically, DCs are characterized by expression of HLA-DR and the 
absence of lineage markers (Fig. 2). Therefore, Lin-HLA-DR+ cells were gated (Fig. 2B) and 
analyzed for CD11c expression in combination with other makers to establish the DC 
phenotype (Fig. 2C).  
 
 
Figure 2 Identification of CD11c- and CD11c+ DC subsets in vivo in (I) peripheral blood, (II) tonsil, (III) spleen 
and (IV) thymus. Isolation of single cell suspensions was carried out as described in MATERIAL AND METHODS. 
To identify DCs (A) Lin- cells were gated, and subsequent (B) the HLA-DR+ cells within this gate were 
analyzed, resulting in (C) segregation of subsets based on CD11c expression. 
A B C 
I 
II 
III 
IV 
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CD34+ HSC 
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CD11c+ I 
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monocytes 
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DC 
CD11c+ II 
DC 
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imDC 
plasmacytoid
DC 
mDC 
LCs in the epidermal cell suspension were gated based on a high expression of HLA-DR 
(Fig. 5). Monocytes are a possible precursor pool of DCs 44, they were gated as CD14+ cells 
in a separate experiment and also subjected to detailed immunophenotyping (Table 2). A 
representative compilation of results of the different subsets is shown in table 2 and figure 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmacytoid DCs 
As shown figure 2, DC subsets in the examined tissue suspensions segregated based on 
CD11c expression. Based on the previously described subsets of DCs in blood, the CD11c+ 
cells corresponded to myeloid DCs and the CD11c- cells to plasmacytoid DCs 23;49. All DC 
subsets, including LCs, expressed HLA-DR, CD4, CD40 and CD54 (ICAM-1). The CD11c- 
DC subsets demonstrated a uniform expression of markers in different tissues. This CD11c- 
DC subset was CD123high, and expressed the recently described markers, BDCA-2 and 
BDCA-4 46. These two markers specifically recognize human CD11c-CD123high plasmacytoid 
DCs in blood, confirming the identity of this CD11c- subset. Myeloid associated markers, 
such as CD64, and CD11b were absent on CD11c- DCs. Although also a low expression 
CD11c was present in spleen, this CD11cdim subset expressed high levels of CD123, BDCA-2 
and BDCA-4, indicative of the plasmacytoid DC subset. 
Figure 3 Schematic 
representation of 
several DC subsets, 
possibly derived from 
separate pathways, 
found at different 
anatomical sites in 
vivo. Discriminating 
surface markers of the 
different DC subsets 
are indicated, based on 
data obtained in this 
study, see Table 2. 
Abbreviation: CD34+
HSC, hematopoietic 
stem cell. 
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In blood, BDCA-4 was uniquely expressed on plasmacytoid DCs, however in tonsil, 
spleen and thymus, expression was also observed on CD11c+ DCs. BDCA-2 was expressed 
only on the plasmacytoid DCs in the tissues. In contrast to a recent paper 50, a low expression 
of BDCA-2 on CD11c+ DCs in tonsil was observed. This might be caused by the relative 
sensitivity of flow cytometry for small subpopulations compared to either RT-PCR or 
immunohistochemistry. A heterogeneous expression of CD80 was observed for the CD11c- 
subset in blood, while the CD11c+ subset was negative; in addition both subsets expressed 
CD86. Differences in expression levels of co-stimulatory molecules CD80 and CD86 have 
been reported 26;49;51. A low expression of BDCA-3 was seen on the CD11c- subsets in tonsil 
and spleen while absent in blood and thymus. In thymus, also low levels of CD1a were 
observed on the CD11c- subset. 
 
Myeloid DCs 
A more diverse staining pattern was observed for the CD11c+ DCs at different 
anatomical sites. While high expression of CD123 is the hallmark of plasmacytoid DCs, low 
level expression was always also observed on CD11c+ subsets. In peripheral blood about 3-
4% of the HLA-DR+Lin- DCs (CD11c+ I) showed a differential expression of certain markers 
compared to the major CD11c+ DC subset (CD11c+ II). The CD11c+ I DC subset had a 
slightly lower expression of HLA-DR, CD11c, CD4, and CD86 and lacked expression of 
CD64, CD1c, CD11b. Noteworthy, the CD11c+ I DC subset expressed high levels of BDCA-
3 46. How this minor CD11c+ BDCA-3high DC subset relates to the CD11c+ II DC subset is 
not known. In addition, low levels of BDCA-3 were also observed on the CD1c+CD11c+ II 
subset in contrast to literature 46. 
Within the CD11c+ DC subset of tonsil, spleen and thymus, a small subset with a higher 
expression of HLA-DR was observed. This CD11c+ DC subset generally expressed higher 
levels of for CD40, CD80, CD83 and CD86, indicating that these cells are matured and 
activated, therefore this subset was denoted mDC (mature DC). Presumably in tissues, the 
other CD11c+ DCs comprised immature GCDC-like and splenic marginal zone DCs and were 
denoted imDC (immature DC). The mDC subset constituted presumably IDCs 30;32-34;52. The 
mDC subset had a somewhat higher expression of CD123. BDCA-3 expression on the mDC 
subset was lower compared to the imDC subset. Based on in situ identification of tonsil DC 
subsets, Summers et al. 53 propose that CD11c+ CD13- are GCDCs, whereas the 
CD11c+CD13+ as well as the HLA-DRhigh CD11c+ DC subsets are IDCs present in the T cell 
areas of the tonsil. Indeed the mDC subset expressed CD13, though our staining strategy did 
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not allow discriminating between different anatomical localizations of IDC subpopulations. 
 
A CD11chighHLADRhighLin+ subset in thymus 
The intriguing population of HLADRhighLin+ cells in thymus was more closely examined 
and a distinct CD11chigh subset was observed (Fig. 4). This CD11chighHLADRhighLin+ subset 
expressed DC-associated marker CD1a and in addition, CD4, CD40, CD54, CD80 and CD86, 
indicative of a DC phenotype. Notably, 
this subset showed a distinct, high 
expression of CD64 and CD11b. This 
population resembled the thymic 
CD11b+ DC subset expressing the 
myeloid markers M-CSFR, CD11c, 
CD14 and CD64 that was described 
recently 35. The Lin-cocktail we used, 
contained antibodies against CD14, 
which could explain why this CD11chigh 
DC subset was Lin+. 
 
Identification of Langerhans cells in the skin 
LCs, epidermis-resident DCs, were distinguished from other 
cell types in the skin by a high expression of HLA-DR (Fig. 5). 
These cells were also CD1ahigh, confirming their LC identity 
(Table 2). The LCs expressed CD11c and CD1chigh and had a low 
expression of CD11b and CD86. They lacked expression of 
CD64, CD80, BDCA-3, and BDCA-4, and only few cells 
expressed CD83. However, expression of CD123 and low levels 
of expression of BDCA-2 were found on the LCs. 
 
Staining patterns of the huMabs on in vivo DCs 
To determine whether the huMabs retained their specificities, PBMCs were stained with 
the biotinylated huMabs in combination with different lineage markers for B cell (CD19), T 
cells (CD3), NK (CD56) cells and monocytes (CD14) and compared with staining patterns 
obtained using phage antibodies as previously described 18. In peripheral blood, huMab 
MatDC16 stained in addition to DCs, monocytes and a subset of granulocytes, also a small 
Figure 5 Identification of LCs 
in the skin, by staining of an 
epidermal cell suspension with 
HLA-DR PercP. 
Figure 4 Identification of a CD11chigh subset within 
theHLA-DRhighLin+ cells. Cells were gated as (A) HLA-
DRhighLin+ cells and (B) CD11c staining revealed the 
presence of a CD11chigh subset. 
B A 
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subset of T cells (<5%), the latter staining was not observed with the phage antibody. In 
addition to DCs and monocytes, huMab MatDC27 showed a weak staining of T cells, the 
latter staining was not observed with the phage antibody. Reactivity of huMabs MatDC64 
and TN141 was restricted to DCs and monocytes as demonstrated for the phage antibodies. 
HuMab MatDC16 stained preferentially plasmacytoid DCs in different tissues (Table 3). 
In addition, in blood the CD11c+ II DC subset and monocytes were stained more intensely 
than the CD11c+ I DC subset. For tonsil and spleen, staining on the imDC and mDC subsets 
was comparable, while in thymus staining of the mDC subset was lacking. However, bright 
staining of the CD11chighHLADRhighLin+ subset was observed.  
HuMab MatDC27 followed the staining pattern of MatDC16 in human peripheral blood 
although in general the reactivity was less intense. Also for the secondary lymphoid tissues, 
MatDC27 staining patterns resembled that of MatDC16, albeit less strong on both 
plasmacytoid and myeloid DCs. Staining of thymic plasmacytoid DCs was present, though 
absent on the CD11c+ DC subsets. Similar to MatDC16, staining was also observed on the 
CD11chighHLADRhighLin+ subset in thymus. 
HuMab MatDC64 stained the different DC subsets and monocytes in blood. In tonsil and 
spleen staining of plasmacytoid DCs was observed, while staining of the CD11c+ DC subsets 
was lacking. In thymus, MatDC64 stained merely the CD11chighHLADRhighLin+ subset. 
Overall, while a more broad staining was observed in blood, MatDC64 in secondary 
lymphoid organs was restricted to the plasmacytoid DCs. In addition, MatDC64 reacted with 
the CD11chighHLADRhighLin+ subset in thymus. 
HuMab TN141 stained both the CD11c+ I and II DC subsets in peripheral blood. In 
addition, a dim staining on both monocytes and plasmacytoid DCs was observed. While a 
distinctive staining of the imDC subset in tonsil and spleen was observed, this staining was 
persistently lacking on the CD11c+ mDC subset. This staining pattern resembled that of 
BDCA-3, though intensity was much lower. Double staining of an antibody against BDCA-3 
and TN141 revealed that 
TN141 specifically stains 
the 0.03% of PBMCs that 
is BDCA-3high (Fig. 6). In 
tonsil and spleen, staining 
of TN141 on the 
plasmacytoid DCs was 
Figure 6 Double staining BDCA-3 and TN141 
on PBMCs. Shown is a two-color staining of 
PBMC with an FITC-conjugated antibody 
against BDCA-3 and a biotinylated TN141 
followed by Alexa Fluor 633 streptavidin 
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dim and of the CD11chighHLADRhighLin+ subset in thymus. None of the huMabs reacted with 
skin LCs. 
 
Generation of DCs in vitro 
To examine the phenotypic similarities and differences between fresh DCs and in vitro 
generated DCs, we cultured DCs using two well-defined systems. Culturing monocytes in the 
presence of GM-CSF and IL-4 generated CD83-CD1a+ immature Mo-derived DCs that were 
collected at day 5 of culture. Immature Mo-derived DCs were stimulated with a mix of 
cytokines consisting of IL-1β, IL-4, IL-6, GM-CSF, TNFα and PGE2, resulting in mature 
Mo-derived DCs that expressed high levels of CD83 and CD1a. Interestingly, CD64 was not 
observed on either immature or mature DCs. Cytokine receptors CD25 and CD123 were only 
expressed on mature DCs. 
In agreement with published data, BDCA-4 was also expressed at high levels on 
immature DCs and low levels on mature DCs, whereas BDCA-2 was absent on both 
populations (Table 3). Low levels of expression of BDCA-3 on both immature and mature 
Mo-derived DCs were detected 46. CD40, CD86 and CD11b expression was upregulated on 
mature DCs, and de novo expression of CD80 and CD83 was observed, confirming previous 
findings 41. 
Hematopoietic CD34+ progenitor cells differentiate in vitro along two unrelated DC 
pathways. The first pathway involves the generation of CD1a+CD14- cells with features of 
epidermal LCs. The second pathway includes a CD1a-CD14+ intermediate that can 
differentiate into interstitial DCs that lack LC markers. At day 6, two populations 
characterized by exclusive expression of CD1a and CD14 emerged independently, with 
similar percentages as previously reported, the major subpopulation being CD14+, the minor 
CD1a- 39. Both CD14+ and CD1a+  DC subsets expressed comparable levels of HLA-DR, 
CD4, CD11c, CD54, CD80 and CD86, whereas no CD83 was expressed. Only the CD14+ 
population expressed low levels of BDCA-3 and CD40. 
High levels of expression of BDCA-4 were observed on the CD14+ population while 
weakly expressed on the CD1a+ population. Although CD1c expression has previously been 
reported, we did not observe CD1c on either subpopulation. 
 
Staining patterns of the huMabs on in vitro DCs 
Previously, we showed that phage antibody MatDC16 was weakly expressed on the 
surface of bone marrow CD34+ progenitor cells 18. Up-regulation of the antigen was observed 
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Table 4 Immunophenotype of different DC subsets in vitro. 
  Mo-derived DC  CD34+-derived DC 
  immature mature  day 6 
Surface Antigen         CD14+ CD1a+ 
DC-associated 
 
     
  CD1a  ++ ++  - +++ 
  CD1c  + +  - - 
  CD83  - ++  - - 
  BDCA-2  - -  - - 
  BDCA-3  + +  ± - 
  BDCA-4  ++ +  ++ ± 
Myeloid 
 
     
  CD14  - -  ++ - 
  CD64  - -  nt nt 
Lymphoid 
 
     
  CD4  ± ±  ++ + 
Adhesion 
 
     
  CD11b  ++ ++  nt nt 
  CD11c  +++ ++  ++ ++ 
  CD54  ++ ++  ++ ++ 
Co-stimulation 
 
     
  CD40  ++ +++  ± - 
  CD80  ± ++  ± ± 
  CD86  ++ ++  + + 
Cytokine receptors     
  CD25  - ++  nt nt 
  CD123  - ±  + ± 
MHC 
 
     
  HLA-DR   ++ ++   ++ ++ 
The levels of staining on the various cell populations are indicated as follows: -, 
negative; ±, variable; each + corresponds to an increase in fluorescence intensity of one 
logarithm; nt, not tested 
 
 
during culture with a combination of SCF, GM-CSF and TNFα. On day 6, flow cytometric 
analysis demonstrated that MatDC16 stained the CD1a+ and CD14+ intermediates at 
comparable levels. MatDC16 stained immature Mo-derived DCs strongly but expression of 
the target antigen was down-regulated during maturation. MatDC27 stained immature Mo-
derived DCs weakly. Staining on both the CD1a+ intermediate and the CD14+ intermediate, 
was present, tough preferentially on the CD14+ intermediate. Staining of MatDC64 and 
TN141 on in vitro generated Mo-derived DCs or CD1a + and CD14 + intermediates was 
absent. 
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DISCUSSION 
In this report, we demonstrate that phage antibodies can be rapidly converted to whole 
human antibodies of the IgG4 isotype. The huMabs were correctly assembled and retained 
their specificities. We assessed the staining patterns of huMabs MatDC16, MatDC27, 
MatDC64 and TN141 by flow cytometry on different DC subsets found in the human tissues, 
using a multiparameter flow cytometry strategy to identify in vivo DCs without the need for 
extensive cell separation procedures. The identification relies on the absence of lineage 
markers and the presence of HLA-DR, as previously demonstrated 49;54. Expression of CD11c 
was employed to segregate DC subsets. Distinct CD11c- and CD11c+ DC subsets were 
identified reliably in different tissues in the body, enabling us to compare expression of DC 
discriminating markers on different subsets in vivo. 
While MatDC16 essentially bound to all in vivo DC subsets, in particular the 
plasmacytoid DCs had a high level of expression of the target antigen of MatDC16. 
MatDC27 bound preferentially to plasmacytoid DCs, though a weak staining was observed 
for myeloid subsets in tonsil and spleen. 
More restricted staining patterns were observed for the other huMabs. MatDC64 
uniquely reacted with plasmacytoid DCs in the secondary lymphoid organs, while in thymus 
only the CD11chighHLADRhighLin+ subset was positive. The high level of expression of 
CD11b and CD64 observed in this subset and the reactivity of MatDC64 on monocytes in 
peripheral blood, would argue in favor of a monocyte derivation of this subset. In summary, 
while a broad staining pattern on DC precursors was observed in blood, the staining pattern 
of MatDC64 was strictly confined to plasmacytoid DCs in secondary lymphoid organs. 
TN141 demonstrated a broad staining pattern in blood. In contrast, TN141 stained 
preferentially the myeloid DCs in tissues. Within the myeloid DC subset, expression of the 
target antigen of TN141 was restricted to the imDC subset, while expression was lacking on 
the mDC subset. Although the staining pattern of TN141 was reminiscent of expression of 
BDCA-3, we were not able to block binding of a antibody against BDCA-3 using huMab 
TN141 to CD11c+ DCs in peripheral blood (unpublished results). 
In thymus, negative selection of T cells takes place, a process that likely involves DCs. 
The different function of DCs in the thymus may account for the lack of staining of MatDC64 
on the CD11c- and CD11c+ DC subsets and absence of staining of the huMabs MatDC16 and 
MatDC27 on the mDC subset.  
LCs are thought to be immature because of their ability to efficiently take up and process 
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antigens and their low cell surface expression of co-stimulatory molecules 38. The low 
expression of CD40 and CD86 and the absence of CD80 confirmed this. LCs are considered 
myeloid DCs as they also express CD11c and CD1c. However, in addition to the expression 
of CD123, also a weak expression of BDCA-2, a plasmacytoid DC marker, was observed. 
Notably, staining of huMab UBS54, an antibody directed against the epithelial marker 
EpCAM, was observed (Table 2). This staining was confirmed using the conventional 
monoclonal antibody HEA against the human epithelial marker. Expression of the murine 
homologue of EpCAM has been demonstrated on mouse LCs 55, however this is the first 
report of EpCAM expression on human LCs. Staining of the other huMabs on LCs was not 
observed. We could not exclude that on LCs, the target antigens of the different huMabs were 
trypsin-sensitive, as trypsin was used in the cell separation procedure. 
We compared the phenotype of the in vivo DC subsets with DCs generated in vitro. 
Differential staining patterns of the huMabs on DC subsets in vitro were demonstrated. DCs 
derived from CD34+ hemopoietic progenitors in vitro have been shown to develop along two 
independent pathways giving rise to DCs with distinct phenotypes and functions. MatDC16 
stained both the CD14+ and CD1a+ intermediates while staining of MatDC27 on the CD14+ 
intermediate was higher than on the CD1a+ intermediate. This is unexpected in view of the 
absence of staining on CD1a+ LCs in vivo. MatDC64 and TN141 were negative on both the 
CD14+ and CD1a+ intermediates. Target antigens of MatDC64 and TN141 were 
downregulated during the differentiation of monocytes into immature Mo-derived DCs, 
around day 3 of culture. In this context, it is noteworthy that immature DCs obtained from 
reverse-transmigrated monocytes 44 were stained with phage antibodies MatDC16, MatDC27 
and MatDC64 (unpublished results). Staining of phage antibody TN141 on immature DCs 
was absent. Neither of the phage antibodies reacted with reverse-transmigrated mature DCs 
that had phagocytosed zymosan particles. Collectively,  ‘immature’ DCs from cultures of 
reverse-transmigrated monocytes differ from immature Mo-derived DCs generated in 
cultures of monocytes supplemented cytokines with respect to MatDC64 staining, suggesting 
substantial difference between different in vitro generated DC subsets. 
The finding that TN141 preferentially bound the small CD11c+ I DC subset but to none 
of the in vitro generated DCs indicates that no counterparts of these particular DCs found in 
vivo are present in any of the DC culture systems. In general, it appears that in vitro generated 
DCs may perhaps not have physiological counterparts and vice versa. This finding 
underscores the need to use in vivo DC subsets to determine the physiological generation and 
specific functions of DCs.  
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The fact that huMabs did not perform in immunohistochemistry, western blotting or 
immunoprecipitation studies using peripheral blood or positive cell lines, if available, 
hampered further characterization of the target antigens of these huMabs. Attempts to clone 
target antigens using cDNA expression libraries, including commercially available and a 
cDNA expression library made from monocytes and Mo-derived DCs (M. van Meijer, 
unpublished results) were unsuccessful.  
Using the four recently described antibodies against DCs, CD1c (BDCA-1), BDCA-2, 
BDCA-3, and BDCA-4 46, we demonstrate that the newly identified markers BDCA-2 and 
BDCA-4 form a reliable tool to identify plasmacytoid DCs in blood. In tissues, BDCA-2 
showed a more restricted staining pattern than BCDA-4. In this respect, BDCA-2, recently 
identified as a novel plasmacytoid DC-specific type II C-type lectin, proves a more valuable 
tool for identification of plasmacytoid DCs 50. In our hands, BDCA-3 expression was not 
restricted to the small CD11c+ I DC subset in blood, but was also observed on the CD1c+ 
CD11c+ II DC subset, although staining was less intense. 
In peripheral blood, part of the CD11c+ II DC subset expressed CD1a, confirming 
previous data by Ito et al. 51. Dzionek et al. 46 questions this observation by reasoning that the 
Mab used, B-B5, binds to CD1c. Dzionek et al. use anti-CD1a Mab BL-6 and do not observe 
CD1a expression on the CD11c+ DC subset. However, we repeatedly observed staining of 
CD11c+ cells using this same Mab BL-6, confirming the data of Ito et al.. 
The goal in DC-based cancer vaccination protocols is to elicit an effective immune 
response to the tumor by generation of large numbers of tumor-reactive effector T cells. 
CTLs can directly kill tumor cells 56, whereas TH cells are necessary to engage several 
effector mechanisms. Myeloid DCs can be induced to produce large amounts of IL-12 57 and 
cause TH1 differentiation. The TH1 response, characterized by IFNγ and IL-2 producing TH1 
cells, is correlated with an efficient CTL response 58. Therefore, targeting to myeloid DCs in 
vivo seems advantageous. Plasmacytoid DCs are said to preferentially promote a TH2 
response, however their action is still far from clear and data are contrasting in available 
studies 11;13;29;59. Considering the different features of plasmacytoid DCs compared to 
myeloid DCs, a potential beneficial role of the engagement of the plasmacytoid DCs in DC-
targeting strategies seems more intricate. 
Taken all this into consideration, we presume that MatDC27 is less attractive for 
targeting to DCs. HuMabs MatDC64 and TN141 had more with restricted staining patterns 
and may well be valuable tools for further investigation and delineation of DC subsets. 
TN141 might be valuable for targeting purposes as this huMab predominantly reacted with 
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myeloid DCs. MatDC16 may also prove valuable for in vivo targeting of DCs, on account of 
its broad reactivity, possibly engaging different DC subsets. Chemical or genetic coupling of 
tumor antigens to a huMab may provide a vector to target tumor antigen directly to DCs in 
vivo. To ensure an optimal outcome, adjuvants that provoke migration and maturation of DCs 
might be necessary. In this respect, CpG oligonucleotides are of special interest since they 
can activate DCs in vivo and polarize T cells toward TH1 60;61. Ongoing research will provide 
evidence concerning the efficacy of this approach. 
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ABSTRACT 
We have previously generated a panel of four human antibodies (huMabs) against human 
dendritic cells (DCs) and performed a detailed phenotypical analysis of the reactivity of these 
huMabs on different DC subpopulations. In the present study, we assessed the functional 
effects of binding of these huMabs to monocytes and DC in vitro. None of the huMabs 
affected the allostimulatory capacity of PBMCs in an allogeneic mixed leukocyte reaction. A 
single antibody, huMab MatDC64, exerted a suppressive effect on the cytokine-driven 
differentiation of monocytes into DCs. This phenomenon was associated with the production 
of interleukin 6 (IL-6), known to redirect differentiation of monocytes towards macrophages. 
These results suggest that IL-6 production observed after crosslinking of MatDC64 might 
contribute to the prevention of the generation of DCs. 
 
 
INTRODUCTION 
Dendritic cells (DCs) are professional antigen presenting cells (APC), which are efficient 
in the activation of naïve T cells and the induction of primary T cell-mediated immune 
responses 1. DCs reside in tissues throughout the body as immature cells that have high 
antigen capturing and processing capacities. Upon antigen uptake, DCs mature and 
concomitantly increase their antigen presenting functions. 
DCs can be generated in vitro from peripheral blood monocytes 2. Monocytes cultured in 
the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 
(IL) 4 acquire many morphologic, phenotypic and functional features of immature DCs. Loss 
of CD14 and the upregulation of costimulatory molecules, including CD80 and CD86 and the 
Langerhans cell marker CD1a characterize the transition of monocytes into DC. 
Alternatively, in response to macrophage colony-stimulating factor (M-CSF), monocytes can 
differentiate into CD14+ macrophages3;4. Collectively, cytokines act as regulating mediators 
of monocyte differentiation towards DCs or macrophages. 
Previous studies have suggested that binding of antibodies to monocytes may affect their 
capacity to differentiate into DCs in in vitro cultures. Binding of antibodies to inhibitory 
receptor LAIR-1 expressed on monocytes prevents the differentiation of monocytes into DCs 
by interfering with the GM-CSF receptor signaling pathway 5. Binding of antibodies to CD33 
expressed on monocytes inhibits the generation of DCs in cultures of monocytes 
supplemented with GM-CSF and IL-4 6. Both receptors are immune inhibitory receptors and 
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members of the immunoglobulin (Ig) superfamily. These inhibitory receptors can be 
identified by a consensus amino acid sequence, the immunoreceptor tyrosine-based inhibitory 
motif (ITIM), present in the cytoplasmic domain of these molecules. In addition, receptor 
engagement of FcεRI, containing a immunoreceptor tyrosine-based activation motif (ITAM), 
on monocytes from atopic donors has been shown to prevent their differentiation into DCs, 
mainly by production of the inhibitory cytokine IL-10 7. 
In a previous study, we have employed a semi-synthetic antibody phage display library, 
in combination with subtractive selection and flow cytometry to generate monoclonal phage 
antibodies specific for DCs in human blood 8. Three of these phage antibodies, denoted 
MatDC16, MatDC27 and MatDC64, were found to bind DCs and monocytes in peripheral 
blood. MatDC16 showed additional binding to B cells. Phage antibody TN141 selected from 
the phage library for binding to human tonsil DCs shows additional binding to blood DCs and 
monocytes (Lekkerkerker A., De Weers, M., Logtenberg, T., Chapter 2B). These four phage 
antibodies were converted to complete human monoclonal antibodies (huMabs) of the IgG4 
isotype, and a detailed phenotypical analysis of these huMabs on in vitro generated DCs and 
DC subsets found in vivo was carried out 9. It was shown that huMab MatDC16 stained 
immature Mo-derived DCs, while a dim staining was observed for MatDC27. Expression of 
target antigens of MatDC64 and TN141 was downregulated and lost around day three of 
culture of monocytes with GM-CSF and IL-4.  
In light of the possible application of these huMabs as a tool to target antigens to 
professional APCs, we analyzed whether engagement of the molecules recognized by these 
huMabs affects DC function or differentiation. In this study, we provide experimental 
evidence that crosslinking of MatDC64 inhibits the generation of DCs from monocytes, while 
it has no effect on the stimulatory capacity of PBMCs. HuMabs MatDC16, MatDC27 and 
TN141 showed no inhibitory nor activating properties. 
 
 
MATERIAL AND METHODS 
 
Culture medium 
Unless stated otherwise, medium consisting of RPMI 1640 (GIBCO, Grand Island, NY) 
supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (Integro, Zaandam, The 
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Netherlands), 25 mM HEPES, 2 mM L-glutamine, 5x10-5 M 2-mercaptoethanol, 100 U/ml 
penicillin, and 100 µg/ml streptomycin was used for culturing cells. 
 
Antibodies 
HuMabs used in this study were human IgG4 antibodies MatDC16, MatDC27, MatDC64 
and TN141 directed against human DCs as previously described 8;9 and human IgG4 UBS54 
directed against the epithelial cell marker Ep-CAM 10. Biotinylated huMabs were used for 
flow cytometry. To detect biotinylated huMabs, Alexa Fluor 633 streptavidin conjugate 
(Molecular Probes, Eugene, OR) was used. The following directly fluorochrome-conjugated 
antibodies were used for flow cytometry: PE-labeled CD1a (Immunotech, Marseille, France), 
FITC-labeled CD14 (Becton Dickinson, Erembodegem, Belgium), PECy5-labeled CD14 
(Immunotech), PE-labeled CD80 (Becton Dickinson), FITC-labeled CD86 (BD Pharmingen, 
Erembodegem, Belgium), PercP-labeled anti-HLA-DR (Becton Dickinson, San Jose, CA). 
 
Cell preparations 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood obtained 
from healthy donors, by density centrifugation on Ficoll-Hypaque (Pharmacia, Uppsala, 
Sweden). 
 
Flow cytometric analysis 
Cells were blocked for 20 minutes on ice in phosphate- buffered saline containing 1% 
BSA and 0.05% sodium azide (PBA) containing 10% human pooled serum. For staining with 
the huMabs, cells were incubated with biotinylated huMabs for 30 minutes on ice and 
subsequent with Alexa Fluor 633 streptavidin conjugate. Directly fluorochrome-conjugated 
antibodies were used as indicated in the RESULTS section. Cells were washed twice with PBA 
between incubation steps. After a final wash, cells were analyzed using a FACSCalibur 
(Becton Dickinson). 
 
Stimulation of monocytes in the presence of huMabs 
CD14+ monocytes were purified from PBMCs by magnetic cells sorting using CD14 
MicroBeads (Miltenyi, Bergisch Gladbach, Germany). CD14+ monocytes were blocked with 
10% goat serum in medium, for 30 minutes on ice. Next, the cells were incubated with the 
different huMabs (25 µg/ml) for 1 hour on ice. Subsequently, the cells (5x105 per well) were 
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cultured in a 24-wells plate in the presence of goat F(ab’)2 anti-human IgG (Southern 
Biotechnology Associates, Birmingham, AL), in medium supplemented with recombinant 
human (rh) GM-CSF (100 ng/ml, Schering-Plough, Amstelveen, The Netherlands) or GM-
CSF and IL-4 (50 U/ml; Strathmann, Hannover, Germany) at 37 °C. On day 2, the cells were 
analyzed by flow cytometry and supernatants were harvested and stored at –20 °C until 
cytokine levels were measured. 
 
Cytokine measurements 
Measurements of IL-6, IL-10 and IL-12p70, levels in the culture supernatants were 
performed by specific solid-phase sandwich ELISA as described previously 11. Measurements 
of IFNα were performed by ELISA using pairs of specific mAbs and recombinant cytokine 
standards obtained from Endogen (Woburn, MA). The limits of detection of these ELISAs 
were as follows: IL-6, 20 pg/ml, IL-10, 25 pg/ml, IL-12p70, 3 pg/ml; IFNα, 3 pg/ml. 
 
Allogeneic mixed leukocyte reaction 
Non-adherent cells from PBMCs, that were allowed to adhere for 1 hour at 37°C, were 
used for the isolation of allogeneic responder T cells, using Lympho-Kwik according to the 
manufacturer’s instructions (One Lambda, Canoga Park, CA). Density centrifugation of 
PBMCs on a 52% Percoll gradient (Pharmacia) was performed to enrich for monocytes and 
DCs and these freshly prepared PBMCs were gamma irradiated at 25Gy and washed. Graded 
doses (100-1000-10000) of PBMCs in 96-well round bottom culture plates were incubated 
with huMabs (20 µg/ml) in complete RPMI with 5% human serum for 30 minutes at room 
temperature. Allogeneic responder T cells (1x105) were added and the cells were cocultured 
for 4 days. On day 4, each well was pulsed with 1 µCi of 3H-thymidine (specific activity 5 
Ci/mmol; Amersham, Buckinghamshire, England) for 18 hrs, and thymidine incorporation 
was quantified on a betaplate counter (Wallac, Freiburg, Germany). Results are given as 
mean counts per minute ± SD of triplicate cultures. Blocking anti-HLA-DR mouse antibodies 
(Leinco Technologies, St. Louis, MO) and isotype control mouse IgG2a (Rockland, 
Gilbertsville, PA) were included. 
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RESULTS 
 
Crosslinking of  huMab MatDC64 suppresses cytokine-induced differentiation of monocytes into DC 
We analyzed whether binding and crosslinking of four previously described huMabs 
affect the differentiation of monocytes into DCs in cultures of monocytes stimulated with 
GM-CSF or with a combination of GM-CSF and IL-4. Expression of CD14 and CD1a were 
monitored during culture because GM-CSF rapidly down-regulates the expression of CD14 
on monocytes, while expression of CD1a is induced 2. First, blood monocytes were cultured 
with various concentrations of GM-CSF in combination with IL-4, to assess the number of 
CD1a+ cells that was generated. Six combinations, 50 ng/ml or 100 ng/ml GM-CSF in 
combination with either 50 ng/ml, 250 ng/ml or 500 ng/ml of IL-4 were tested and yielded 
the same number of CD1a+ cells on day 2 of the cultures (data not shown). A combination of 
100 ng/ml GM-CSF and 50 ng/ml IL-4 was used in subsequent experiments. 
Next, CD14+ monocytes were incubated with the huMabs in the presence or absence of 
F(ab’)2 goat anti-human IgGs to crosslink membrane-bound antibodies. After two days of 
culture, cells were analyzed for the expression of CD14 and CD1a by flow cytometry. In 
control cell cultures in the absence of antibodies, CD1a expression was induced upon 
stimulation with GM-CSF or GM-CSF and IL-4. Expression of CD1a was not altered in 
cultures supplemented with HuMabs MatDC16 and MatDC27 with or without F(ab’)2 anti-
human IgG. In contrast, upon crosslinking of MatDC64 bound to monocytes, a population 
that displayed low levels of CD1a was generated (Fig. 1). A reduction of 50-85% of the 
CD1a+ cells compared to the control was observed in the presence of GM-CSF. A less 
profound effect, 35-45% reduction of CD1a+ cells, was observed in the presence of GM-CSF 
and IL-4. 
In the presence of huMab TN141, a small decrease of 15-30% of the CD1a+ cell number 
was observed in the presence of GM-CSF. This effect was not detectable in cultures 
supplemented with GM-CSF and IL-4. Binding of HuMabs in the absence of the secondary 
crosslinker did not affect the differentiation of monocytes into CD1a+ DCs. Crosslinking of 
huMabs on purified monocytes and subsequent culture in the absence of exogenous stimuli 
for 48 hours did not affect the monocytes, as they remained CD14+. Monocytes rapidly lose 
expression of the CD14 during in vitro cytokine-stimulated differentiation into DC, and 
CD1a expression is induced. Expression of CD80, a marker not expressed by monocytes, is 
observed on day 5 of culture, whereas expression of HLA-DR and CD86, both present on 
monocytes, is augmented during differentiation of monocytes into DC 2. We did not detect 
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CD80 expressing cells at day 2 in cytokine-stimulated control cultures without antibodies or 
in the presence of MatDC16, MatDC27 and TN141. In contrast, the presence of MatDC64 
IgG4 antibodies induced a low but reproducible induction of CD80 expression. The 
expression of HLA-DR and CD86 on day 2 cytokine-stimulated monocytes was similar in 
presence or absence of huMabs. Staining of the cells with biotinylated MatDC64 at day 2 
demonstrated that the cells had lost the antigen for MatDC64 (data not shown), suggesting 
internalization of the target antigen. Comparable results were obtained after 72 hours of 
incubation with either GM-CSF or GM-CSF and IL-4. 
 
Figure 1 Phenotype of monocytes cultured in the presence of  (A) GM-CSF or (B) GM-CSF and IL-4. Dot plots 
show CD14 vs. CD1a expression of the monocytes at the start and after 48 hrs culture in the presence of 
huMabs, as indicated; only crosslinker was added in control cultures (ctrl).  
 
Crosslinking of huMab MatDC64 induces production of IL-6 
As cytokines have been shown to modulate the differentiation potential of monocytes, 
we measured the cytokine production of cytokine-stimulated monocytes in the presence of 
either huMab MatDC16, MatDC27, MatDC64 or TN141 (Fig. 2 and 3). Compared with the 
control culture in the absence of antibodies, the supernatants of cultures of MatDC64-
crosslinked cells showed an increased IL-6 production, while production levels of IL-10, 
bioactive IL12p70 and IFNα production were not altered. 
CD
1a
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Crosslinking of huMabs MatDC16, MatDC27 or TN141 did not result in increased 
production of the evaluated cytokines compared to the control. IL-6 is a pleiotropic cytokine 
that can inhibit the differentiation of hematopoietic CD34+ progenitor cells into DCs and 
promote their commitment toward the monocytic/macrophage lineage 12. Furthermore, IL-6 
produced by fibroblasts can skew differentiation of monocytes into macrophages at the 
expense of DCs 13. 
 
Figure 2 Monocytes were cultured in the presence of GM-CSF, crosslinked huMabs or crosslinker (neg). 
Supernatants were harvested after two days and secreted cytokines were measured by ELISA. A, IL-6; B, IL10; 
C, IL12p70; D, IFNα. 
 
It has been shown that IL-4 can reverse the inhibitory effect of IL-6 on the differentiation 
of DC from hematopoietic CD34+ progenitor cells 14. Presumably, this antagonistic effect of 
IL-4 accounted for the lower IL-6 production of monocytes crosslinked with huMab 
MatDC64 cultured in the presence of IL-4 and GM-CSF (Fig. 2) compared to GM-CSF (Fig. 
3). These findings indicate that, in addition to direct mechanisms, IL-6 produced by 
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monocytes after crosslinking of MatDC64 may contribute to the suppression of monocyte 
differentiation into DCs. 
Figure 3 Monocytes were cultured in the presence of GM-CSF and IL-4, crosslinked huMabs or crosslinker 
(neg). Supernatants were harvested after two days and secreted cytokines were measured by ELISA. A, IL-6; B, 
IL10; C, IL12p70; D, IFNα. 
 
Ligation of huMabs does not impair T cell stimulatory capacity in an allogeneic MLR 
We assessed whether triggering with the different huMabs affected the stimulatory 
capacity of blood monocytes and DCs. Although monocytes and B cells are capable of 
stimulating the allogeneic mixed leukocyte reaction (MLR), blood DCs are considerable 
more effective 15-17. Furthermore, a subset of CD2+ monocytes also act as potent inducers of 
the allogeneic MLR 18. Expression of MHC class II and accessory molecules by the 
stimulator cells is required for optimal stimulation of T cell proliferation. Accessory 
molecules, such as CD80/CD86 and adhesion molecules provide the necessary costimulatory 
signals. As the huMabs bound to DCs and monocytes, we decided to use PBMCs as a source 
of stimulator cells. The PBMCs were incubated with the huMabs and cocultured with 
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allogeneic T cells for 4 days. As a control, a blocking antibody against HLA-DR was 
included in the allogeneic MLR. HuMab UBS54, directed against the human epithelial 
marker Ep-Cam, was used as an IgG4 isotype control, to exclude the effect of engagement of 
Fc receptors. The anti-HLA-DR antibody efficiently blocked the capacity of the PBMCs to 
induce proliferation of allogeneic T cells (Fig. 4). Addition of the huMabs did not affect the 
stimulatory capacity of PBMCs in an allogeneic MLR. This suggests that the huMabs were 
not directed against epitopes involved in the stimulatory function of PBMCs. 
 
 
Figure 4 Ligation of huMabs on PBMC 
does not affect their stimulatory capacity 
in an allogeneic MLR. Allogeneic resting 
responder T cells were added to PBMCs 
with or without blocking huMabs. 
HuMab UBS54 was used as isotype 
control. Blocking mouse antibodies 
against HLA-DR together with a mouse 
IgG2a isotype control were included. 
The results are expressed as the mean 
percent of CPM from triplicate wells. 
 
 
DISCUSSION 
In this study, we assessed whether binding and crosslinking of a panel of huMabs to 
monocytes affected their capacity to differentiate into DCs in vitro. We demonstrate that 
crosslinking of monocyte-bound huMab MatDC64 suppresses the generation of CD1a+ DCs 
upon culture with GM-CSF or GM-CSF and IL-4 for 2 or 3 days. However, other phenotypic 
alterations such as induction of HLA-DR and CD86 were not affected while a marginal 
induction of CD80 expression was observed. Based on these observations, we hypothesize 
that binding and crosslinking of the MatDC64 target partially blocks the DC differentiation 
pathway at the level of the generation of CD1a+ DC. Crosslinking of huMabs MatDC16, 
MatDC27 and TN141 did not affect monocyte differentiation into DC. None of the antibodies 
interfered with the capacity of PBMCs to stimulate T cell proliferation, as determined in an 
allogeneic MLR, indicating that the target antigens are not involved in the primary immune 
response, dissimilar to e.g. the adhesion molecules CD11a, CD54 and CD58 16. 
10.00
100.00
1000.00
10000.00
100000.00
0 100 1000 10000
PBMC
(3H
)th
ym
id
in
e 
in
co
rp
or
a
tio
n
 (c
pm
) MatDC16
MatDC27
MatDC64
TN141
UBS54
aHLA-DR
mIgG2a
CHAPTER 4 
 
108 
Analysis of cytokine production revealed that in the cultures of monocytes crosslinked 
with huMab MatDC64 the production of IL-6 was approximately seven-fold, compared with 
the negative control. IL-6 is capable of inhibiting the differentiation of monocytes into DCs 
by promoting their differentiation towards macrophages 12;19. Chomarat and co-workers 13 
have shown that in the presence of IL-4 and GM-CSF, exposure of monocytes to IL-6 
increases M-CSF receptor expression and M-CSF receptor internalization in response to 
autocrine M-CSF. We postulate that binding and crosslinking of huMab MatDC64 directly or 
indirectly triggered IL-6 production by monocytes, redirecting monocyte differentiation into 
the macrophage pathway. 
We have so far not been able to identify the target antigen that is recognized by 
MatDC64, but in correlation with LAIR-1 and CD33, MatDC64 might bind to an inhibitory 
receptor. A large number of inhibitory receptors have recently been discovered, many of 
which are expressed by myeloid cells 20 Inhibition is as important as activation of the immune 
system for regulation of an immune response, and is controlled by a balance of inhibitory and 
activating signals. Different groups have report the presence on myeloid cells of ITIM-
bearing molecules like ILT-3 21, ILT-4 22 and ILT-5 23 belonging to a new group of Ig 
superfamily receptors named Ig-like transcripts (ILT) 24. Very recently it was shown that 
upregulation of ILT-3 and ILT-4 on monocytes and DCs, renders them tolerogenic, 
demonstrating their physiological significance 25. We previously showed that MatDC64 does 
not bind to stably transfected cells expressing ILT-3, ILT-4 or ILT-5 8. 
Another group of inhibitory receptors belongs to the family of sialic acid-binding Ig-like 
lectins (Siglecs) 26. Members of the Siglec family contain two conserved ITIM-like motifs in 
their cytoplasmic tails and recently six CD33-related human Siglecs have been described. 
Based on staining patterns, we could exclude binding of MatDC64 to CD33 (expressed on 
monocytes and monocyte-derived DC), Siglec-5, Siglec-9, Siglec-10 (all expressed on 
monocytes and B cells), and Siglec-7 (expressed on monocytes, monocyte-derived DC and 
NK cells). 
Similar to the inhibitory receptors CD33 and LAIR-1, the inhibitory activity of MatDC-
64 may be related to the presence of cytoplasmic ITIMs in the target molecule. Upon receptor 
engagement, ITIMs can undergo phosphorylation and recruit tyrosine-phosphatases SHP-1 
and/or SHP-2 26;27, which are major cytosolic mediators of inhibition. Consequently, future 
studies on MatDC64 should focus on testing whether these phosphatases are involved in the 
signaling pathway engaged by MatDC64 crosslinking. Alternatively, analogous to FcεRI 
crosslinking, MatDC64 may activate signaling of a stimulatory receptor. Intracellular calcium 
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mobilization serves as a parameter of an activation signal transduction mechanism. In 
conclusion, our data provide evidence that MatDC64 recognizes a cell surface molecule 
regulating DC differentiation, possibly mediated by signals that include IL-6. 
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ABSTRACT 
We have fused the human antibody MatDC16 specific for dendritic cells, monocytes and 
B cells to the MAGE-1 tumor antigen and analyzed the capacity of the fusion protein to 
induce T cell responses in in vitro systems. Targeting the antibody-tumor antigen fusion 
protein to dendritic cells resulted in the induction of strong T helper and CTL responses 
compared to minimal response obtained with stimulation of dendritic cells with the MAGE-1 
protein proper. Targeting to monocytes or B cells did not result in T cell stimulation. Another 
human antibody specific for a different molecule expressed by dendritic cells did not mediate 
the activation of T cells, suggesting that the uptake and presentation in class I and class II 
molecules, was receptor-dependent. These results suggest that targeted delivery of tumor 
antigens to dendritic cells via human antibodies may be used for the design of cancer 
vaccination strategies. 
 
INTRODUCTION 
The goal of cancer immunotherapy is the generation of an immune response against 
autologous tumors. Although there is abundant evidence for the presence of tumor antigens 
on a variety of tumors, they are seemingly unable to elicit an adequate anti-tumor immune 
response. Tumor antigens should be presented to the patients’ immune system in such a way 
as to enhance both the cellular and humoral immune response. The efficient capture and 
presentation of antigens by dendritic cells (DCs) render these professional antigen presenting 
cells (APCs) central to the induction of an immune response, and appear efficient mediators 
for eliciting anti-tumor immunity 1-5. 
Various strategies to deliver tumor antigens to DCs have been reported. These include 
the loading of DCs with soluble tumor antigens, tumor-derived RNA, defined peptides of 
known sequences, undefined acid-eluted peptides from the MHC class I molecules of tumor 
cells, tumor cell lysates, retroviral and adenoviral vectors encoding tumor antigens, fusion of 
DCs with tumor cells or the transfection of DCs with plasmid DNA encoding tumor antigens 
6;7
. The most commonly used, clinically approved approach is based on loading empty MHC 
class I molecules with exogenous peptides. 
The efficacy of current tumor vaccines could be improved by optimizing delivery of full-
length native or recombinant protein as tumor antigen to DCs, which can ‘decide’ which 
epitopes will be presented to effector cells of the immune system. The antigen-processing and 
presenting machinery would direct responses to important and immune dominant epitopes 
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including both MHC class I and class II restricted epitopes, thereby exploiting the exceptional 
ability of DCs to induce CD4+ T-helper (TH) cells as well as CD8+ cytotoxic T cells (CTLs). 
Antigens taken up via receptor-mediated internalization are processed in the endosomal 
pathway, and presented as exogenous antigen by MHC class II to activate TH cells. Moreover, 
DCs are capable of presenting internalized exogenous antigens on MHC class I for activation 
of CTLs, a pathway called crosspresentation or crosspriming 8. Peptide presentation by MHC 
class I as well as class II molecules is essential, in view of the critical contribution of TH cells 
in the induction and maintenance of effective immunity against cancer 9. 
Antibody-mediated targeting of tumor antigens provides an exciting approach for direct 
antigen delivery to DCs in vivo. Targeted vaccine strategies employing a variety of cell 
surface molecules have been described, including MHC class II, and FcγRI 10-13. We describe 
a strategy that involves the construction of a eukaryotic expression vector encoding a fully 
human monoclonal antibody (huMab) that binds to DCs that is genetically fused to a tumor 
antigen at the C-terminus. Fully human antibodies are, by their very nature, minimally if at all 
immunogenic and therefore preferable for clinical application. Previously, we isolated 
monoclonal phage antibodies against human in vivo DCs 14. In addition, the phage antibodies 
recognized a precursor pool of DCs, the monocytes. Two of these phage antibodies were 
chosen for recloning in the aforementioned expression vector, which resulted in conversion 
of the phage antibodies to complete human antibodies fused to a tumor antigen. 
Melanoma-associated antigen A-1 (referred to as MAGE-1), a well-characterized tumor 
antigen already employed in clinical trials 15-17, was chosen for this study. In the past years, 
melanoma-specific CTL clones have served as tools to identify genes that code for a tumor 
antigen 18. The MAGE gene family includes at least 17 related genes, namely MAGE-A1 to 
A12, MAGE-B1 to B4, and MAGE-C1. The MAGE genes are expressed by tumors of 
various histological types, but they are silent in normal cells, with the exception of male 
germ-line cells that do not carry MHC class I molecules and are therefore unable to present 
antigens to CTLs. Hence, antigens encoded by MAGE-A, -B, -C genes should be strictly 
tumor specific. Because the MAGE antigens are shared by many tumors and on account of 
their strict tumor specificity, they are of particular interest for cancer immunotherapy. The 
MAGE-1 gene was isolated as it encoded an antigen presented on HLA-A1 molecules to 
autologous CTLs of a melanoma patient 19. 
The results of the current study demonstrated that the intracellular tumor antigen, 
MAGE-1, could be genetically fused to a fully human monoclonal antibody, and efficiently 
produced as a fusion protein that targets to DCs in vitro. This antigen delivery strategy led to 
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antigen processing and subsequent presentation of MHC class I and II -peptide complexes by 
DCs, as it was demonstrated that MAGE-1-specific TH cells and CTL responses were induced 
by the targeted DCs. It can be envisaged that this approach offers new possibilities for tumor 
antigen delivery into DCs in vivo in an adjuvant-free manner, inducing efficiently both arms 
of the adaptive immune system. The approach described in this report may lead to more 
potent vaccines and immunotherapies. 
 
 
MATERIAL AND METHODS  
 
Cell lines, media, and reagents 
Human recombinant interleukin (IL)-2 was purchased from Eurocetus (Amsterdam, The 
Netherlands), granulocyte-macrophage colony-stimulating factor (GM-CSF) was purchased 
from Novartis Pharma (Brussels, Belgium). Human recombinant IL-4 was produced in the 
Ludwig Institute for Cancer Research, Brussels, Belgium. The HLA-A*0101 MAGE-A1 and 
HLA-DR*1301 MAGE-A1 specific T cell clones, derived from melanoma patients 20;21, and 
the melanoma cell line MZ-2Mel MAGE-1+ were cultured in Iscove’s modified Dulbecco 
medium (IMDM) (Life Technologies,Gaithersburg, MD) supplemented with 10% fetal calf 
serum and 0.24 mM L-asparagine, 0.55 mM L-arginine, 1.5 mM L-glutamine (AAG), 100 
U/ml penicillin and 100 µg/ml streptomycin.  
 
Vector construction 
A eukaryotic expression vector pcDNA3.1+/zeo containing the genomic region that 
encodes the constant domain of the heavy chain of the IgG4 (Cγ4) 22, was fused in frame to 
the full-length cDNA of the MAGE-1 gene (acc nr P43355) and a poly-A tail. The heavy 
chain variable (VH) regions from phage antibodies MatDC16, MatDC27, and Mono14 14 were 
excised from the pHEN vector using restriction sites NcoI and XhoI and subcloned into the 
pLEADER vector 22 containing sequences coding for eukaryotic leader peptide HAVT20, and 
a splice donor site. Using restriction sites BamHI and NotI, a fragment containing the VH 
region and flanking leader and splice donor sequences, was cloned into the pcDNA3.1 Cγ4-
MAGE-1 vector. Transfection of this vector in combination with an expression vector 
containing the appropriate light chain would lead to a fusion protein comprising a complete 
human IgG4 with a MAGE-1 protein fused to the C-terminus of the heavy chain. The 
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eukaryotic expression vector pcDNA3.1 Cγ4-MAGE-1 vector also encoded for zeocin, a 
selective marker used for the generation of stable transfectants.  
 
Northern blot analysis 
Transient tranfections of constructs pCDNA3.1-Cγ4-MAGE-1 including a VH fragment 
of MatDC16, pCDNA3.1-Cγ4 including a VH fragment of MatDC16, and pCDNA3.1-
MAGE-1 in the human embryonic kidney (HEK) cell line 293T were carried out using 
Lipofectamin according to the manufacturers instructions. After two days at 37 °C, the cells 
were harvested and washed twice with phosphate buffer. Total RNA was prepared using 
RNAzol B according to the manufacturers instructions (TelTest, Friendwoods, TE), followed 
by phenol-chloroform extractions and 2-propanol precipitation. 10 µg of total RNA was used 
for Northern analysis on 1% agarose containing 6% formaldehyde. RNA, transferred to 
hybond N+ membrane (Amersham Pharmacia, Uppsala, Sweden), was hybridized with a 
MAGE-1 specific probe labeled using RadPrime DNA labeling system according to the 
manufacturers protocol (Life technologies). 
 
Production of fusion proteins 
Stably transfected cell lines for the production of fusion proteins, were established by co-
transfection of pCDNA3.1-Cγ4-MAGE-1 including a VH fragment of the phage antibody of 
interest, with the corresponding light chain construct, in HEK293 cells. 1.5x 105 HEK293 
cells were seeded per well in a 6-wells plate (Costar, Corning, NY). The next day, 
transfections were carried out at a cell density of 70-80% confluence using calcium chloride 
precipitated DNA for 5 hours at 37 ºC, followed by a 15% glycerol shock for 1 minute. Five 
µg of pCDNA3.1-Cγ4-MAGE-1 and 5 µg of the appropriate light chain construct were used. 
Cells were washed and after 48 hours 500 µg/ml zeocin (Invitrogen, Carlsbad, CA) was 
added as selective drug to obtain stable transfectants. When drug resistant colonies were large 
enough, 48 individual clones were picked and expanded, and tested in sandwich ELISA for 
production of fusion protein. Next, a fusion protein-producing clone was used for large-scale 
production in triple flasks (Invitrogen) using ULTRA-CHO medium (BioWhittaker, 
Walkersville, MD). Culture supernatant was harvested after 4 days, and fresh ULTRA-CHO 
medium was added to the triple flasks. After 4 days the culture supernatants were again 
harvested. Fusion protein was purified from the pooled culture supernatants by protein A 
chromatography. Concentration of purified proteins was determined by spectrophotometry at 
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a wavelength of 280 nm using the Biorad protein assay (Biorad Laboratories, Munchen, 
Germany). 
 
ELISA 
Supernatants from 48 stable clones per construct were screened for production of fusion 
protein by a sandwich ELISA. Briefly, microtiter plates (NUNC, Roskilde, Denmark) coated 
with anti-MAGE-1 antibodies (Ab-4; NeoMarkers, Fremont, CA) were incubated with 
culture supernatants of stable clones at room temperature for 2 hrs. After washing the plates 
with 0.05% Tween20/PBS, binding of IgG4-MAGE-1 fusion protein was detected by 
horseradish peroxidase (HRP) conjugated antibody against human IgG (Southern 
Biotechnology Associate, Birmingham, AL). As a substrate tetramethylbenzidine was used to 
detect bound conjugate. An ELISA-plate reader (Molecular Devices, Sunnyvale, CA) was 
used to measure absorbency at 450 nm. 
 
Flow cytometric analysis 
Cells were blocked for 20 minutes on ice in phosphate buffer containing 1% BSA and 
0.05% sodium azide (PBA) supplemented with 10% human pooled serum. Next, the cells 
were incubated with the fusion proteins for 60 minutes on ice. Subsequently, the cells were 
incubated with a mouse anti-MAGE-1 antibody (Ab-4; Neomarkers) for 30 minutes. This 
step was followed by incubation with phycoerythrin (PE) conjugated goat anti-mouse 
antibodies (Southern Biotechnology Associate). Cells were washed twice between incubation 
steps in PBA. After a final wash, cells were resuspended in PBA, and analyzed using a 
FACSCalibur (Becton Dickinson, San Jose, CA). 
 
Western blot analysis 
The purified proteins were separated by SDS-PAGE and electroblotted onto 
nictrocellulose membrane (Millipore, Bedford, MA). Proteins were detected with either 
mouse anti-MAGE-1 antibodies (Ab-4; Neomarkers), followed by HRP conjugated rabbit 
anti-mouse IgG antibodies (Pierce, Rockford, IL) or by HRP conjugated mouse anti-human 
IgG antibodies (SBA). Immunublotted proteins were visualized by chemiluminescence using 
enhanced chemiluminescence detection reagents (ECL; Amersham Pharmacia). A total 
protein cell lysate of human cells expressing MAGE-1 was used as a positive control 
(Neomarkers). 
 
CHAPTER 5 
 
118 
Preparation of DC 
Blood cells were collected as buffy-coat preparations from HLA-A*0101 and HLA-
DR*1301 positive donors. DCs were prepared as described 23. In brief, PBMCs isolated by 
Lymphoprep (Nycomed, Oslo, Norway) were allowed to adhere for 2 hrs at 37 °C days in 
RPMI 1640 medium (Life Technologies) supplemented with AAG, antibiotics and 10% FCS 
(hereafter referred to as complete RPMI medium). Non-adherent cells were discarded and 
adherent cells were cultured in the presence of IL-4 (100 U/ml) and GM-CSF (100 ng/ml) in 
complete RPMI medium. Cultures were fed on days 2 and 4 by removing 1/3 of the volume 
and adding fresh complete RPMI medium with IL-4 (100 U/ml) and GM-CSF (100 ng/ml). 
On the day 5, the nonadherent cell population was used as a source of enriched immature 
DCs. 
 
Induction of MAGE-1 specific T cell responses 
Cultures were set up in 96-well round bottom plates (Nunc). 105 DCs per well were 
blocked in RPMI 1640 medium (Life Technologies) supplemented with AAG and 20% 
human serum for 30 minutes on ice. Next, the DCs were incubated with fusion proteins 
(10nM or 100nM) in RPMI medium supplemented with AAG and 10% human serum for 
either 24 hrs. Subsequently, the cells were washed and cocultures of 15 x 103 DC with 5 x 103 
T cells and 25 U/ml IL-2 (Eurocetus, Amsterdam, the Netherlands) were set up in triplicate. 
Twentyfour hours later, supernatants were collected and assayed for interferon (IFN) γ, using 
the human IFNγ ELISA kit (BioSource, Camarillo, CA). Data are presented as picograms of 
IFNγ released /5 x 103/ ml/ 24 hrs (mean ± SD of triplicate cultures). 
 
 
RESULTS 
 
Construction of a vector for the production of a human IgG4-MAGE-1 fusion protein 
To evaluate the feasibility of antibody-mediated targeted delivery of tumor antigen to 
DCs, a fusion protein was constructed using the constant region of the heavy chain of the 
human IgG4 gene and the entire coding region of the MAGE-1 molecule (Fig. 1). The IgG4 
isotype was selected for this approach since it has low affinity for FcγRI and does not bind 
other Fcγ receptors. In addition, it does not activate complement, presumably preventing 
complement-mediated lysis of targeted DCs 24. Melanoma tumor antigen MAGE-1 was 
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chosen since it is essentially tumor-specific and expressed in a variety of tumors other than 
melanoma. 
cDNA encoding MAGE-1 was fused in-frame at the 3’ terminus of the germline Cγ4 
gene, cloned in a eukaryotic expression vector. Upon co-transfection of a construct 
containing the appropriate immunoglobulin light chain 22, a complete human antibody with 
the MAGE-1 protein fused to the C-terminus was produced (Fig.1). Different constructs were 
generated; each construct contains a different VH, resulting in different antibody specificity. 
MatDC16, derived from phage display selections on human peripheral blood DCs, binds to 
blood DCs and immature monocyte-derived DCs 14;25. In addition, binding to monocytes and 
weak binding to B cells was observed. MatDC27 also binds to blood DCs and weakly to 
immature monocyte-derived DCs. Mono14 recognizes the CD14 molecule expressed on 
monocytes 14. 
 
 
 
 
 
Figure 1 Schematic representation of the recombinant vector for production of IgG4-MAGE-1 fusion proteins. The 
IgG4-MAGE-1 construct was cloned into eukaryotic expression vector pcDNA3.1+. LEADER, the HAVT20 
leader sequence; VH, the variable domain of the heavy chain; d, the donor splice site; Cγ4, the constant domain of 
the heavy chain of the IgG4 isotype; MAGE-1, cDNA encoding the MAGE-1 protein; A , poly-A signal. 
 
 
Integrity of the constructs was confirmed by 
Northern blot analysis using total RNA derived from 
transient transfections of the constructs in the Human 
Embryonic Kidney cell line (HEK) 293T (Fig. 2). 
Probing RNA from cells harboring the MAGE-1 fusion 
construct yielded a specific band of the correct size (lane 
3), while a specific band appears in lane 4 accounting 
for the non-fused MAGE-1 transcript. RNA from mock 
transfected HEK cells (lane 1) and RNA from cells 
containing the non-fused IgG4 MatDC16 (lane 2) were 
negative.  
 
LEADER VH Cγ4 MAGE-1 A 
Figure 2 Northern blot analysis: 1) 
mock; 2) MatDC16Cγ4; 3) 
MatDC16Cγ4-MAGE-1; 4) MAGE-1, 
probed with a MAGE-1 specific probe. 
d 
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Characterization of the recombinant fusion protein 
To produce whole immunoglobulin fused to MAGE-1, stably transfected cell lines were 
established by co-transfection of Cγ4-MAGE-1 including a VH domain, with a light chain 
construct, in the HEK cell line. Supernatants from stable clones were screened for production 
of fusion protein by a sandwich ELISA, using anti-MAGE-1 antibodies as a coating and anti-
human IgG antibodies to detect the captured fusion proteins. The best producing clone was 
used for large-scale production. Recombinant fusion protein was purified from pooled 
supernatants using a protein A column. 
The purified fusion proteins were further characterized by SDS-PAGE and 
immunoblotting. Under non-reducing conditions the fusion proteins migrated at an estimated 
molecular mass of ~230 kDa, indicating that the IgG4-MAGE-1 was expressed as a complete 
protein (data not shown). The molecular weight of the fusion protein was deduced from the 
known molecular weight of the IgG4 (146 kDa) and two times the MAGE-1 protein (40-45 
kDa), as it is linked to each heavy chain. An additional band was observed at ~160 kDa, at 
the same height as an IgG4 control without MAGE-1. Under reducing conditions, Western 
blot analysis revealed a band of 100 kDa detected with the anti-MAGE antibody (Fig. 3), as 
well as with anti-human IgG antibodies, representing the heavy chain-MAGE-1 component 
of the fusion protein. A cell lysate containing MAGE-1 protein showed a band at ~43 kDa 
representing the MAGE-1 protein. Furthermore, an additional band appeared at ~50 kDa, 
representing heavy chain without MAGE, indicating that not all fusion protein that was 
produced contained MAGE-1. 
 
 
 
 
Antibody specificity of the different IgG4 MAGE-1 fusion proteins was retained, as 
determined by flow cytometry (Fig. 4). Surface binding of the fusion protein to monocytes 
was detected by flow cytometry using a mouse anti-MAGE-1 antibody followed by PE 
conjugated goat anti-mouse Ig antibodies. A positive signal in this assay depends on the 
binding of intact IgG4 MAGE-1 fusion protein. 
80 
61 
49 
36 
111 
1        2        3       4 Figure 3 Western blot analysis of purified fusion proteins under 
reducing conditions, stained with a mouse anti-MAGE-1 followed by 
an HRP conjugated anti-mouse IgG antibodies, visualized by ECL. 
Lane 1) IgG4 MatDC16 MAGE-1; 2) IgG4 MatDC27 MAGE-1; 3)
IgG4Mono14 MAGE-1; 4) cell lysate containing MAGE-1. The 
molecular weight markers are shown in kilodaltons on the right 
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Figure 4 Flow cytometric 
analysis of fusion 
proteins using monocytes, 
identified by scatter 
characteristics. Unfilled 
histogram: indicated IgG4 
MAGE-1 fusion protein, 
followed by mouse anti-
MAGE-1 antibody and PE conjugated goat-anti-mouse antibodies; filled histogram: secondary mouse anti-
MAGE-1 antibody followed by PE conjugated goat-anti-mouse antibodies. 
 
 
MHC class I and II presentation of MAGE-1 peptides by immature DCs targeted with fusion protein 
We determined whether the IgG4 MAGE-1 fusion proteins could be used for targeted 
delivery of the tumor antigen to immature DCs. Experiments were carried out with IgG4 
MatDC16MAGE-1 and IgG4 MatDC27MAGE-1. As negative controls MatDC16 without 
MAGE-1 and non-fused protein MAGE-1 were used and in addition, IgG4 Mono14MAGE-1, 
a fusion protein that recognizes CD14 expressed by monocytes 14. 
Immature monocyte-derived DCs from HLA.A1/DR1301+ donors were incubated with 
the fusion proteins (10 nM or 100 nM) or control protein MAGE-1 (200nM) and cultured for 
24 hrs. The molecular weight of the fusion protein (230 kDa), and the molecular weight of 
the IgG4 (146 kDa) and the MAGE-1 protein (43 kDa) were used for molar conversions of 
the proteins, using the concentration as determined by spectrophotometry. It must be taken 
into account that fusion protein preparations contained non-fused antibodies as well. 
 Subsequently, the DCs were replated and cocultured with either the anti-MAGE-1 HLA-
DR13 TH cell clone or the anti-MAGE-1 HLA-A1 CTL clone. Activation was assessed as 
IFNγ release in 24 hr supernatants. As a positive control, the stimulatory capacity of the DCs 
was assessed by exogenous peptide pulsing of the DCs with either an HLA-A1/MAGE-1 
specific peptide, EADPTGHSY, in case of the CTL clone or an HLA-DR13/MAGE-1 
specific peptide, LLKYRAEPVTKAE, in case of the TH clone. The activation ability of the T 
cell clones was assessed by coculturing with the above-mentioned peptides in combination 
with the melanoma cell line MZ-2. 
As shown in Figure 5, 100 nM IgGMatDC16MAGE-1 targeted to immature DCs was 
enough to stimulate a response from the CTL, resulting in a significant amount of IFNγ 
production. The non-stimulated CTL clone did not secrete detectable amounts of IFNγ (<30 
MatDC16 MAGE-1 MatDC27 MAGE-1 Mono14 MAGE-1 
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pg/ml/24 h). No stimulatory activity can be seen for the negative control proteins 
IgG4MatDC16, IgG4Mono14MAGE-1 and MAGE-1. This excludes the possibilities that the 
response is a consequence of targeting via FcγRI 26 or by macropinocytosis. In addition, upon 
incubation with IgG4 MatDC27MAGE-1, no IFNγ was produced suggesting that the uptake, 
and subsequent processing and presentation were receptor-dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Tumor antigen presentation by immature DC incubated with fusion proteins. Immature DCs (105) 
derived from an HLA-A1+/HLA-DR1301+ donor were incubated with (fusion) proteins (10nM or 100nM) as 
indicated. After 24 hrs incubation, cocultures of DCs (15x103) with (A) CTL anti-MAGE-1.A1 or (B) TH anti-
MAGE-1.DR1301 (5x103) were set up. Activation was assessed as IFNγ release at 24 hrs. Data are presented as 
picograms of IFNγ released/5x103/ml/24 hrs (mean ± SD of triplicate cultures). 
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Upon addition of the MAGE-1 protein to immature DCs, IFNγ was also produced by the 
TH clone. This is most likely the result of macropinocytosis by the DCs, ensuing in MHC 
class II presentation. Targeted delivery of MAGE-1 resulted in a two-fold up regulation of 
the IFN-γ production by the TH clone. The stimulatory effect observed with the IgG4 
Mono14MAGE-1 might be caused by residual expression of CD14 on the immature DCs 
23;27
. Collectively, these data demonstrate a very efficient induction of MAGE-1-specific 
responses, using an IgG4 MAGE-1 fusion protein targeted to DCs. 
Monocytes (Fig. 6) and B cells (Fig. 7) were also tested for their ability to stimulate T 
cell clones upon incubation with the fusion proteins. In these cultures no detectable IFNγ was 
produced, except in cultures with IgG4 Mono14 MAGE-1. This resulted in MHC class II 
presentation since TH anti-MAGE-A1.DR1301 was activated. We conclude that the uptake, 
processing and presentation by DCs was very efficient compared to other populations of 
APCs. 
 
Figure 6 Tumor antigen 
presentation by 
monocytes incubated 
with fusion proteins. 
Monocytes (105) derived 
from an HLA-A1+/HLA-
DR1301+ donor were 
incubated with (fusion) 
proteins (100nM) as 
indicated. After 24 hrs 
incubation, cocultures of 
monocytes (15000) with 
(A) CTL anti-MAGE-
1.A1 or (B) TH anti-
MAGE-1.DR1301 (5000) 
were set up. Activation 
was assessed as IFNγ 
release at 24 hrs. Data are 
presented as picograms of 
IFNγ released/ 5x103/ 
ml/24 hrs (mean ± SD of 
triplicate cultures). 
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Figure 7 Tumor antigen 
presentation by B cells 
incubated with fusion proteins. 
B cells (105) derived from an 
HLA-A1+/HLA-DR1301+ 
donor were incubated with 
(fusion) proteins (100nM) as 
indicated. After 24 hrs 
incubation, cocultures of B 
cells (15000) with (A) CTL 
anti-MAGE-1.A1 or (B) TH 
anti-MAGE-1.DR1301 (5000) 
were set up. Activation was 
assessed as IFNγ release at 24 
hrs. Data are presented as 
picograms of IFNγ 
released/5x103/ml/24 hrs 
(mean ± SD of triplicate 
cultures). 
 
 
 
DISCUSSION 
We have evaluated the capacity of the DC-specific human antibody MatDC16 fused to 
the tumor antigen MAGE-1 to stimulate tumor antigen-specific T cells in an in vitro system. 
The results showed that immature monocyte-derived DCs targeted by the antibody-MAGE-1 
fusion protein presented the tumor antigen, in all probability on MHC class II molecules via 
the endosomal pathway as well as on MHC class I molecules via the crosspresentation 
pathway. 
Presentation of antigen by targeted DCs led to the induction of IFNγ secretion by 
MAGE-1 specific TH and CTL clones. Efficient presentation was dependent on the antibody 
moiety because stimulation of DCs with the MAGE-1 protein did not result in CTL activation 
and only a marginal TH activation. Our results confirmed previous findings that exogenous 
pulsing of DC with intact tumor proteins (not fused to an antibody) is very inefficient 28. 
MAGE-1 fused to a control human antibody not binding to human DC, did not induce TH or 
CTL activity, excluding the involvement of Fc-receptor-mediated uptake of the 
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MatDC16MAGE-1 fusion protein. MAGE-1 protein fused to another antibody, MatDC27 
that binds to DCs, did not induce T cell responses, suggesting a receptor-dependent 
mechanism of fusion protein uptake and presentation. Targeting of the MatDC16MAGE-1 
fusion protein to B cells did not lead to detectable activation of TH and CTL clones, whereas 
targeting to monocytes induced a small but detectable TH but no CTL response. These results 
confirm the unique capacity of DCs to present exogenous antigens for both induction of TH 
and CTL responses. 
The migratory function and strong antigen presenting capacities make DCs the cells of 
choice for transport of tumor antigens into secondary lymphoid organs and induction of anti-
tumor immunity. Antigen-specific tumor immunotherapy can only be successful when high 
affinity tumor antigen-specific T cells are generated by appropriate immunization. Inducing 
both TH and CTL activity is considered to be an important aspect of a successful vaccination 
approach. Generation in vivo of MHC class I-restricted CTL by crosspriming has been shown 
to be dependent on TH cells 29-32. The cross talk between the TH and the APC and the 
spectrum of cytokines produced by the TH cells will both contribute to the outcome of cellular 
immune response 9. As a consequence, both CTL and helper epitopes need to be recognized 
on the same APCs 33.  
In the current study, the antibody-tumor antigen fusion proteins were targeted to 
immature monocyte-derived DCs. The use of immature DCs as a target for delivery of tumor 
antigens is expected to result in an efficient uptake and processing of the tumor antigen 34. 
However, in light of the strong the immunostimulatory capacity of mature DCs, induction of 
maturation of an immature DC upon uptake of the tumor antigen appears to be a desirable if 
not essential element of a successful vaccination approach. Indeed, it has previously been 
shown that immature DCs are able to silence an immune response 35;36. In vivo maturation 
signals can be provided by TH cells, which induce maturation of DCs through CD40 ligation 
further defining an essential role of TH cells for initiating a CTL response 29-31. In that light, 
our finding that targeted delivery of a tumor antigen to immature DC via the MatDC16 
antibody activates both TH and CTL responses is of pivotal importance. 
Previous studies have shown that an antibody-mediated FcγRI-targeted fusion protein, 
containing a TH cell epitope of tetanus toxoid, resulted in efficient presentation, and could 
potentially be used for delivery of peptides to APCs in vivo 12. A drawback of this format is 
imposed by the presentation of a single TH epitope and the lack of data in this study showing 
activation of CTL responses via the FcγRI receptor. FcγRI-PSA, a fusion protein targeting the 
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prostate tumor antigen also targeting to FcγRI, resulted in presentation of MHC class I-
peptide complexes, however the delivery of antigen into the MHC class II pathway was not 
studied 26.  
MAGE-1 is a defined tumor antigen expressed by subgroups of patients with 
metastasized melanoma, esophageal squamous cell carcinoma, head and neck squamous cell 
carcinoma, non-small cell lung carcinoma, and bladder carcinoma. Using a defined tumor 
antigen instead of intact tumor cells, tumor cell lysates or nucleic acids derived from tumor 
cells, has the advantage that the antigen is well-defined, preventing the induction of 
undesirable autoimmune responses against ‘self’ proteins in the undefined preparations 1. The 
use of the full-length protein instead of MAGE-derived peptides poses a further advantage 
because the whole protein contains both TH and CTL epitopes and allows the use of the 
antibody-MAGE-1 fusion protein for patients with different HLA haplotypes. Furthermore, 
other characteristics of peptides such as their very short half-life in vivo and the rapid turn 
over of peptide-loaded MHC class I molecules, render them a less optimal format. The half-
life of a fusion protein consisting of a human antibody and a tumor antigen is unknown. 
Experiments with antibodies fused to cytokines have shown that the fusion protein acquires a 
long half-life, resembling that of the antibody moiety 37. 
The antibody-mediated targeting approach we developed has several advantages. 
Different antibodies interacting with DCs can be simply tested, since the vector, as described 
in this report, allows rapid exchange of the immunoglobulin variable fragments. With these 
cassettes and the availability of a panel of DC-binding antibodies, the question whether 
targeting tumor antigen to different molecules on a DC or to different DC subsets may alter 
the type of response elicited can be evaluated. This would permit rapid evaluation of different 
antibodies for development of the most effective vaccine for induction of therapeutic anti-
tumor immunity 5;38. 
Recently developed DC-based vaccination strategies with ex vivo generated DCs loaded 
with tumor-derived materials are patient-specific and tedious for large-scale application. This 
drawback can be alleviated by procedure for efficient in vivo targeting of DCs, facilitating the 
broad application of this approach for the treatment of cancer patients 4;5. Further 
investigation will demonstrate whether the fusion protein presented in this study targeted to 
blood DCs and monocytes can elicit a potent anti-tumor response in vivo. Studies on the 
effect of MatDC16MAGE-1 receptor-mediated uptake on maturation/activation state of the 
DC will elucidate whether additional signals are necessary to ensure maturation and 
migration of the targeted DCs to secondary lymphoid organs in vivo. We previously 
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demonstrated that IgG4MatDC16 did not inhibit differentiation of monocytes into DC nor 
inhibit the stimulatory capacity of PBMCs in an allogeneic MLR (Lekkerkerker, A., Chapter 
4). Although numerous questions concerning in vivo DCs targeting still need to be answered 
e.g. the optimal route, dose and frequency of vaccination and the type of DC subset that 
should be targeted, these data give a first indication that this targeted vaccine can induce anti-
tumor immunity in vitro and can potentially be used in vivo in cancer vaccination protocols. 
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ABSTRACT 
We have constructed a panel of lipid-tagged scFv (LT-scFv) antibody fragments specific 
for dendritic cells and monocytes and inserted them in the membrane of the tumor cell line 
Jurkat. Tumor cells displaying LT-scFv were brought in contact in vitro with blood 
mononuclear cells and the uptake of tumor cells by monocytes and dendritic cells was 
monitored. The results showed that monocytes had taken up tumor cells loaded with an LT-
scFv specific for the CD14 molecule but not tumor cells loaded with LT-scFv with other 
specificities. Blood dendritic cells were not capable of taking up LT-scFv-modified Jurkat 
cells. Induction of apoptosis of tumor cells did not affect the capacity of LT-scFv to mediate 
uptake of tumor cells by antigen presenting cells (APC). Phagocytosis of LT-scFv modified 
tumor cells did not appear to induce the maturation of monocytes into DCs. We conclude that 
some APC populations are capable of phagocytosing LT-scFv-loaded tumor cells and that 
this process is receptor-dependent.  
 
INTRODUCTION 
In cellular immunotherapy for the treatment of cancer, tumor cells are administered to 
induce an antitumor immune response in the patient. Immunity produced by cellular vaccines 
depends largely on the efficiency of antigen-presenting cells (APC) that process and present 
antigens to effector cells of the immune system. A variety of cell types including monocytes, 
macrophages and dendritic cells (DC) may function as APCs. Peripheral blood monocytes 
migrate into tissues and develop into macrophages, whereas they are also regarded as a 
precursor pool of DCs1-3. DCs are the most potent APCs with the ability to initiate primary 
immune responses4 and are increasingly being explored for use in cellular vaccines5-7. 
Several strategies to deliver antigens to DC have been used in clinical trials7. The most 
frequently used approach is based on loading of MHC class molecules of ex vivo generated 
DCs with exogenous peptides derived from known tumor antigens. In the majority of human 
cancers, where tumor antigens are unknown, DCs pulsed with various tumor-derived 
preparations are employed as cancer vaccines. DCs can capture apoptotic tumor cells and 
elicit recall MHC class I restricted CD8+ cytotoxic T cells (CTL) responses against tumor 
antigens 8-10 providing an alternative strategy for tumor antigen delivery. Another promising 
approach involves the immunization of patients with hybrids of DCs fused to the tumor cell. 
This approach has been used for patients with renal cell carcinoma, demonstrating significant 
clinical responses in a number of patients11. The approaches for antigen delivery that involve 
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whole tumor cells as source of antigens, allow DCs to process and present multiple antigens 
to both inducing CD4+ T cells and CTLs, leading to a diverse immune response. 
Previously, in our lab a procedure was developed that allows rapid and efficient insertion 
of lipid-tagged (LT) proteins into the membrane of prokaryotic and eukaryotic cells 12. LT-
single chain (sc) Fv antibody fragments, specific for molecules expressed by APC, such as 
CD14, CD32 and CD64, attached to the membranes of tumor cells mediated efficient 
phagocytosis of the tumor cells. It can be envisaged that targeting irradiated tumor cells to 
APC by membrane-bound LT-scFv provides an alternative strategy for delivering tumor 
antigens to APC in cellular immunotherapy. 
In the present study, we expanded on these data by exploring whether insertion of other 
APC-specific scFv antibody fragments would induce phagocytosis. Specifically, four scFv 
antibody fragments, MatDC16, MatDC27, MatDC64 and TN141, previously generated by 
phage antibody display in combination with flow cytometry on human blood or tonsil DCs, 
with an APC-restricted reactivity pattern were converted to LT-scFvs. Unexpectedly, 
insertion of these LT-scFvs in the cell membrane of Jurkat cells did not result in phagocytosis 
by either human peripheral blood monocytes or DCs. We concluded that phagocytosis of 
cells with APC-specific membrane-anchored LT-scFvs requires engagement of specific 
receptors. Apparently, mere recognition of the lipid-modified cells did not suffice to trigger 
engulfment of the lipid-modified cells. 
Previous experiments demonstrated that the insertion of anti-CD14 LT-scFvs into the 
membrane of cells mediated phagocytosis of these cells by monocytes. CD14 is expressed as 
membrane–anchored molecule on the surface of monocytes, macrophages, and granulocytes. 
Since CD14 does not have a membrane spanning domain it cannot transmit a signal into the 
cell 13. Engagement of CD14 by ligands like bacterial lipopolysaccharide (LPS) results in a 
pro-inflammatory response. Toll like receptor (TLR) 2 and TLR4 function as co-receptors 
mediating cellular activation in response to LPS14;15. CD14 has also been implicated in 
recognition of apoptotic cells, which leads to phagocytosis without activation16;17. 
The unique properties of DCs make them the APC of preference for use in cancer 
vaccines. Along these lines, we examined whether phagocytosis of lipid-modified cells 
altered the monocytes phenotype into DC, as LPS, and other microbial products as well as 
apoptotic cells are implicated in activation of DCs 1;18;19. However, phagocytosis did not 
appear to induce the maturation of monocytes into DCs. In conclusion, some APC 
populations were capable of phagocytosing LT-scFv-loaded tumor cells and this process 
appeared receptor-dependent. 
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MATERIAL AND METHODS 
 
Medium 
The medium used in all cell cultures was RPMI 1640 (Gibco BRL, Breda, The 
Netherlands), supplemented with, 25mM HEPES, 2mM L-glutamine, 5x10-5 M 2-
mercaptoethanol, 100 U/mL penicillin, and 100 µg/mL streptomycin 10% (vol/vol) heat-
inactivated fetal calf serum (Integro, Zaandam, The Netherlands). 
 
ScFv fragments and conversion into LT-scFv 
ScFv fragments used in this study were previously described 20. The anti-CD14 scFv 
Mono14 was selected on monocytes and scFvs MatDC16, MatDC27 and MatDC64 were 
selected on CD33high blood DCs using flow cytometry 21. ScFv TN141 was selected on 
tonsillar DCs (Lekkerkerker A., De Weers M., Logtenberg T., Chapter 2B). DNA encoding a 
scFv fragment was cloned into vector pLP2, as previously described 12. 
 
Production and purification of LT-scFv 
The resulting pLP2-scFv constructs were expressed in the E. coli strain SF110 F’. 
Bacteria were collected and the LT-scFv antibody fragments were purified as described. 
SDS-PAGE and Coomassie brilliant blue staining of the gels was carried out to examine 
production and purification.  
 
Incorporation of LT-scFvs into cell membranes 
Incorporation of LT-scFv into Jurkat or Ramos tumor cell lines was carried out as 
described 12. Membrane-anchored LT-scFv antibody fragments were detected using 
monoclonal antibody 9E10 (ECACC, Salisbury, United Kingdom), specific for the myc-tag 
fused to the LT-scFv. A phycoerythrin (PE)-conjugated polyclonal goat antibody directed 
against mouse IgG (DAKO, Carpinteria, CA) was used to detect cell-bound 9E10 antibody 
against myc. Cells were analyzed by flow cytometry using a FACS Calibur (Becton 
Dickinson, San Jose, CA).   
 
Phagocytosis of cells displaying a membrane-anchored LTscFv fragment 
Jurkat or Ramos cells were labeled with the lipophilic dye PKH-26 (Sigma), according to 
the manufacturer recommendations. The LT-scFv antibody fragments MatDC16, MatDC27, 
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MatDC64, TN141 and anti-CD14 or a control LT-scFv specific for denitrophenol, were 
incorporated into the cell membrane. Peripheral blood was obtained from healthy volunteers. 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque (Pharmacia 
Biotech, Uppsala, Sweden) density gradient centrifugation. For some experiments, 
enrichment of monocytes in the PBMC suspension was obtained by density gradient 
centrifugation on a 50% Percoll gradient (Pharmacia Biotech), resulting in 60% CD14+ 
monocytes in the Percoll-enriched cell suspension. Approximately 1 x 105 modified Jurkat or 
Ramos cells were added to 1 x 106 PBMCs or 1.7 x 105 Percoll-enriched cell suspension in a 
total volume of 200 µl RPMI-S. This resulted in a Jurkat or Ramos: monocyte ratio of about 
1:1. Apoptotic Ramos cells were used in some experiments. Apoptosis was induced by over 
night incubation of the Ramos cells with 50 µgr/ml campthotecin, dissolved in DMSO, as 
observed after staining with prodium iodide and annexinV. The cells were stained with an 
fluorescein isthiocyanate (FITC)-conjugated antibody against CD14 (Becton Dickinson) with 
or without an FITC-conjugated antibody against CD16 (Becton Dickinson) and a peridinin 
chlorophyll protein Cyanine 5 (PECy5)-conjugated antibody against CD33 (Immunotech, 
Marseille, France) and resuspended in PBS containing 1% BSA. Phagocytosis was analyzed 
by flow cytometry using a FACS Calibur (Becton Dickinson). 
  
Phenotyping of monocytes 
For phenotypic analysis, monocytes were stained after incubation with PECy5-
conjugated antibody against CD14 (Immunotech) in combination with either an fluorescein 
(FITC)-conjugated antibody against CD83 (Immunotech) or FITC-conjugated antibody 
against HLA-DR (Becton Dickinson) and the cells resuspended in PBS containing 1% BSA. 
The cells were analyzed by flow cytometry using a FACS Calibur. 
 
 
RESULTS AND DISCUSSION  
 
Phagocytosis of LT-scFv modified cells is receptor-specific 
ScFv antibody fragments MatDC16, MatDC27, MatDC64 and TN141 were previously 
selected from a phage library of human scFv antibody fragments and were found to 
preferentially bind to human DCs and monocytes 21 (Lekkerkerker A., De Weers, M., 
Logtenberg T., Chapter 2B). To determine whether these APC-specific scFv antibody 
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fragments coupled to tumor cells are capable of mediating phagocytosis by different 
populations of blood APC, the scFv antibody fragments were converted to lipid-tagged scFv, 
purified and incubated with Jurkat cells to anchor the lipid-modified proteins to the plasma 
membrane.  
The LT-scFv modified Jurkat cells were labeled with the red lipophilic dye PKH-26 and 
incubated with unseparated PBMC containing both DCs and monocytes. Using a FITC-
labeled antibody against CD14, monocytes could be identified as CD14+ cells. Insertion of 
anti-CD14 LT-scFvs into the membranes of the Jurkat cells mediated phagocytosis by the 
monocytes, as visualized by the presence of red fluorescent monocytes. Insertion of a control 
LT-scFv specific for the hapten DNP, LT-scFv MatDC16, LT-scFv MatDC27, LT-scFv 
MatDC64 or LT-scFv TN141 did not lead to phagocytosis by monocytes (Fig. 1). 
To visualize blood DC subsets, cells were stained with a PECy5-labeled antibody against 
CD33, a FITC-labeled antibody against CD14, and a FITC-labeled antibody against CD16, 
revealing a CD14-CD16- CD33high mature DC population and a CD14-CD16-CD33dim 
precursor DC population 22. Phagocytosis of the lipid-modified cells with either a control LT-
scFv specific for the hapten DNP, LT-scFv MatDC16, LT-scFv MatDC27, LT-scFv 
MatDC64 or LT-scFv TN141 by the mature or precursor DCs did not occur given that no red 
fluorescent DCs were observed (data not shown). 
These results confirm that membrane-anchored LT-scFv act as artificial receptors that 
may be capable of mediating phagocytosis of tumor cells by monocytes. This process appears 
to be dependent on the nature of the receptor molecule on the monocyte to which the tumor 
cells are targeted. CD14, CD32 and CD64 mediate the uptake of LT-scFv decorated tumor 
cells 12 whereas no phagocytosis was observed with tumor cells carrying LT-scFv MatDC16, 
MatDC27, MatDC64 or TN141. These results suggest that bridging tumor cells and 
monocytes through insertion of LT-scFv in the membrane is not sufficient for the induction 
of tumor cell phagocytosis. CD32 and CD64 are Fc receptors are involved in the uptake of 
antigen-antibody complexes and antibody-coated bacteria, hence phagocytosis mediated by 
these receptors could be anticipated 23. Anti-CD14 LT-scFv mediated phagocytosis was less 
predictable, since CD14 cannot signal by itself. The role of CD14 as a macrophage receptor 
mediating phagocytosis of apoptotic cells has been demonstrated, however associated 
transmembrane proteins that mediate CD14 signaling which leads to phagocytosis of 
apoptotic cells have not been defined.  
Gating on the CD14-CD16- CD33high mature DC population and the CD14-CD16-
CD33dim precursor DC population demonstrated that none of the membrane-anchored LT-
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scFvs mediated phagocytosis of Jurkat cells by these blood APC populations. These 
experiments show that blood DCs and monocytes differ in their capacity to phagocytose LT-
scFv decorated tumor cells.  
 
Figure 1 
Phagocytosis of LT-
scFV modified 
Jurkat cells by 
monocytes. PBMCs 
were mixed with 
Jurkat cells 
containing both a red 
fluorescent dye 
(PKH-26) and LT-
scFv fragments. The 
cells were allowed to 
interact for 90 min at 
37 °C, stained with 
FITC-labeled 
antibody against CD14 analyzed by flow cytometry. a, Jurkat cells displaying a control anti-DNP LT-scFV; b, Jurkat 
cells displaying anti-CD14 LT-scFv; c, Jurkat cells displaying LT-scFv MatDC16; d, Jurkat cells displaying LT-scFv 
MatDC27; e, Jurkat cells displaying LT-scFv MatDC64; f, Jurkat cells displaying LT-scFv TN141. 
 
Induction of apoptosis of LT-scFv modified cells does not support phagocytosis 
Recognition and processing of apoptotic cells in the human body is mediated by 
receptors that capture the apoptotic cells. A growing number of receptors are implicated in 
this clearance process, such as phosphatidylserine (PS) receptors and CD14 16;24. DCs appear 
to phagocytose apoptotic cells via αvβ5 and CD36 rather than via CD14 25. As a multiplicity 
of cell-surface changes take place during apoptosis, we reasoned that properties of the 
apoptotic-cell surface might support the recognition and phagocytosis of the LT-scFv-
modified tumor cells. Viable Ramos cells, a B lymphocytic cell line, with incorporated LT-
scFvs against CD14 and CD64 have previously been shown to be phagocytosed similar to 
Jurkat cells 12 (own observation). To induce apoptosis, Ramos cells were incubated with 
camptothecin and stained with annexin V and propidium iodide to determine the percentage 
of apoptotic cells that ranged from 25% to 40%. Incorporation of the red fluorescent dye 
PKH26 as well as the LT-scFv fragments was not affected by the induction of apoptosis (Fig. 
2).  
c 
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As shown in figure 3, phagocytosis of apoptotic Ramos cells with membrane-anchored 
LT-scFvs MatDC16, MatDC27, MatDC64, TN141 was not augmented compared to control 
LT-scFv specific for the hapten DNP. These data indicate that apopotosis of the cells that had 
membrane-anchored LT-scFvs MatDC16, MatDC27, MatDC64 or TN141 could not support 
phagocytosis by monocytes. 
 
Figure 3 
Phagocytosis of LT-
scFv modified 
apoptotic RAMOS 
cells by monocytes. 
PBMCs were mixed 
with apoptotic 
RAMOS cells 
containing both a 
red fluorescent dye 
(PKH-26) and LT-
scFv fragments. 
The cells were 
allowed to interact for 90 min at 37 °C, stained with FITC-labeled antibody against CD14 analyzed by flow 
cytometry. Transparent histograms show fluorescence value of red apoptotic RAMOS cells displaying a control anti-
DNP LT-scFv in the gated CD14+ monocytes. Filled histograms show apoptotic RAMOS cells displaying a, anti-
CD14 LT-scFv; b, LT-scFv MatDC16; c, LT-scFv MatDC27; d, LT-scFv MatDC64; e, LT-scFv TN141. 
LT-scFv DNP LT-scFv CD14 LT-scFv MatDC16 
LT-scFv MatDC27 LT-scFv MatDC64 LT-scFv TN141 
Figure 2 Incorporation of 
different LT-scFv into 
cell membrane of 
apoptotic Ramos cells 
labeled with a red 
fluoresenct dye (PKH26). 
Cells were stained using 
the antibody against myc 
tag and analyzed by flow 
cytometry. Filled 
histograms, cells 
incubated with buffer; 
Unfilled histograms, cells 
incubated with LT-scFv 
as indicated. 
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Phagocytosis of LT-scFv modified tumor cells does not induce DC maturation of monocytes 
To assess whether uptake of LT-scFv-modified tumor cells induced differentiation of 
monocytes into DCs, the induction of CD83, an early marker of DC activation/differentiation 
was monitored by flow cytometry. Human blood DCs induce expression of CD83 by 
overnight culture in media alone, and it was shown the CD83+ cells are first detected after ~6 
hours in culture 26;27. These CD83+ cells express high levels of HLA-DR.  
Expression of CD83 and HLA-DR was monitored after 90 minutes, 3 hours and 18 hours 
of incubation of lipid-modified Jurkat cells and monocytes. After 90 minutes an induction of 
CD83 was observed on the CD14+ monocytes, however this staining also observed in the 
absence of lipid-modifed Jurkat cells (Fig. 4). Similar CD83 expression was also observed if 
the serum used during experimenting was substituted for 1% bovine serum albumin. 
Expression of CD83 did not alter after 3 or 18 hours incubation, compared to 90 minutes 
incubation. 
A similar pattern was observed for HLA-DR expression, since it was upregulated on the 
CD14+ monocytes irrespective of the LT-scFv inserted in the Jurkat cells. This suggests that 
phagocytosis of Jurkat cells displaying anti-CD14 LT-scFvs did not induce an activated DC 
phenotype. Future experiments will concentrate on functional properties of monocytes upon 
phagocytosis, such as the capability to efficiently process and present antigens, as this is most 
important for use of this antigen delivery approach in immunotherapy.  
 
 
Figure 4 Staining of CD83 on CD14+ monocytes before 
(filled histograms) and after (unfilled histograms) 90 minutes 
incubation on 37°C a, monocytes in the absence of lipid-
modified Jurkat cells; b, monocytes in the presence of lipid-
modified Jurkat cells displaying anti-CD14 LT-scFv.  
 
 
We conclude that the uptake of LT-scFv-modifdied tumor cells by monocytes is 
dependent on the specificity of the scFv fragment inserted in the membrane of the tumor 
cells. ScFv specific for CD14, CD32 and CD64 mediate uptake whereas a panel of four scFvs 
binding to unknown targets on monocytes and DCs do not. We have not identified antibody 
fragments that mediate the uptake of LT-scFv modified tumor cells by blood DC. 
Phagocytosis of LT-scFv- modified tumor cells does not appear to signal monocytes to 
differentiate into DCs. Appropriate signals that would induce monocyte differentiation into 
a b 
CD83 
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DC could be provided by incorporation of additional LT-scFv in the tumor cell membrane, 
e.g. scFv directed against CD40 28.  
Insertion of LT-scFv in tumor cell membranes provides a simple and rapid procedure for 
the modification of properties of tumor cells. It does not require gene transduction and culture 
of tumor cells, a method currently used to modify tumor cells prior to application in vaccine 
approaches. Further research is required to determine the optimal (combination of) scFv for 
the induction of an anti-tumor immune response.    
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The dendritic cell (DC) was named after its distinctive cell shape and also 
metaphorically the DC honors its name by extending its protrusions throughout the immune 
system. As reviewed in Chapter 1, DCs are key players in the immune system as they bridge 
the innate and adaptive immune system and are able to initiate a primary immune response. 
In addition, DCs might have roles in central and peripheral tolerance, but are also implicated 
in autoimmune diseases, as presentation of ‘self’ antigens is likely to play an important role 
in the initiation of autoimmunity. 
The unique features of DCs lead to the hypothesis that, just like other cells in the 
immune system such as B, T and NK cells, unique cell surface molecules would exist for this 
cell type. Indeed, as DC research progresses and new techniques for the detection of markers 
have become available, several novel DC molecules have been discovered, paralleled by the 
discovery of different DC subsets based on anatomical localization and function 1-6. The 
novel DC molecules are linked with the functional and/or anatomical features of DCs, rather 
than DC lineage. Although routes of DC differentiation are still a black box, the possibility of 
a DC lineage independent from the lymphoid or myeloid lineages remains and is supported 
by the recent description of a DC common progenitor 7. 
The importance of DCs in generating an immune response has stimulated the exploration 
of these cells in cancer vaccines. Indeed, pilot DC-based vaccination studies have induced 
anticancer responses including some clinical responses 8-10. In conclusion, understanding the 
complexity of the DC system is fundamental, enabling the construction of better cancer 
vaccines that are effective in eliciting a protective anti-tumor immune response. 
The subject of the research described in this thesis is the identification of human 
antibodies that bind to human DCs, the use of such antibodies for further examination of DC 
subsets and the evaluation of their potential as targeting vehicles for the delivery of tumor 
antigens to DC for use in DC-based cancer vaccination strategies. 
 
Phage antibody technology 
The research described in this thesis exploited the versatility of phage antibody display 
technology (Fig. 1). First, isolating intact cells of interest with attached phage antibodies 
using flow cytometry combined with an excess of non-selected cells, that serve to absorb 
irrelevant phage antibodies, allows the selection of phage antibodies against cell surface 
markers in their native form 11. In addition, selections can be performed on very small cell 
populations such as DCs, representing less that one percent of total mononuclear cells in 
blood and tonsil. Furthermore, the difficulty in obtaining antibodies to self-antigens that are 
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conserved between mouse and humans using standard hybridoma technology can be 
overcome by the use of phage display technology. The observation that MatDC16, one of the 
phage antibodies isolated and characterized in this thesis, also binds to HLA-DR+Lin- DCs in 
peripheral blood of macaques, as well as to splenic DCs in rat and mouse (data not shown) 
underlines this concept. It is evident that this property forms a major advantage for utilization 
of this antibody in in vivo models. 
 
Figure 1 Schematic drawing of the engineering 
technology employed in the research described 
in this thesis. (a) Phage antibody comprised 
antigen binding antibody fragments (light gray) 
fused to the phage minor coat protein, 
expressed at the tip of the phage particle (dark 
gray). (b) The phage antibody was converted to 
a complete human antibody, containing 
constant domains (white), using a eukaryotic 
expression vector. (c) A fusion protein 
containing a human antibody linked to a tumor antigen was obtained by genetic fusion of coding sequences of a 
tumor antigen (black) to the constant domain of the IgG4 heavy chain. (d) Lipid-tagged antibody fragments were 
obtained by genetic fusion of the bacterial lipoprotein (line) to the antigen binding antibody fragment. 
 
For immunotherapy in humans, the efficacy of mouse antibodies is hampered by the 
induction of human anti-mouse antibody responses 12. This limitation can be overcome by the 
use of human antibodies. The engineering potential of phage display technology provides a 
direct route from antibody fragment to human antibodies. A eukaryotic expression vector 
system, that allows conversion of monoclonal phage antibodies to fully human monoclonal 
antibodies 13, was used to convert four phage antibodies to human antibodies (huMabs) of the 
IgG4 isotype (Chapter 3). In addition, the phage display engineering technology enabled the 
biosynthetic lipid tagging of phage antibodies into functional lipid-tagged antibody fragments 
that could be inserted in cell membranes 14 (Chapter 6). 
 
Generation of phage antibodies against DCs 
A large semi-synthetic phage antibody display library 15 was employed in combination 
with cell sorting to generate phage antibodies binding to cell surface molecules expressed on 
DCs. Selections were performed on DCs subsets found in human peripheral blood and tonsil 
(Chapter 2A and 2B). These selections yielded four phage antibodies that were chosen for 
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further characterization based on their restricted staining patterns. In summary, phage 
antibody MatDC16 bound to DCs, monocytes and weakly to B cells and a small subset of 
granulocytes in peripheral blood, whereas a unique reactivity on DCs in tonsil was observed. 
Phage antibodies MatDC27 and MatDC64 reacted with DCs and monocytes in blood and in 
tonsil only with DCs. Based on differential staining patterns on cell lines, we could exclude 
that MatDC27 and MatDC64 bound the same antigen. Phage antibody TN141, which was 
derived from the selections on tonsil DCs, stained uniquely DCs in tonsil, whereas in 
peripheral blood, DCs as well as monocytes were stained. 
 
Analysis of phage antibodies 
In light of the potential application of our huMabs as targeting vehicles for the delivery 
of tumor antigens directly to DCs in vivo, a detailed analysis of binding characteristics of the 
huMabs on naturally occurring DC subsets is essential. In due course, targeting to a specific 
DC subset may provide control of the quality of the immune response. 
The four phage antibodies used in this study, MatDC16, MatDC27, MatDC64 and 
TN141 reacted with DCs as well as monocytes in peripheral blood. Monocytes and myeloid 
related DCs, such as the mature CD33high DCs used for selections, may arise from a common 
myeloid progenitor 16. During the past years, it has become clear that monocytes can be 
regarded as immediate DC precursors. Monocytes are induced into DCs in vitro using the 
appropriate cytokines, while a subset of monocytes can differentiate into DCs after reverse 
transendothelial migration 17. The latter in vitro system provides a more physiological 
context in which monocyte differentiation into DC can be studied. It is noteworthy that 
recent attempts to generate antibodies specific for blood DCs yielded four new antibodies of 
which two uniquely bound to plasmacytoid CD11c- DCs in blood 4. However, such 
antibodies are still lacking for myeloid DCs, since the two other antibodies recognized 
myeloid CD11c+ DCs plus either B cells (BDCA-1/CD1c) or monocytes (BDCA-3). We 
reason that the myeloid CD11c+ DCs are a heterogeneous population in a flexible 
differentiation potential, closely related to other APCs. The plasmacytoid CD11c- DCs are 
much more mature, as they already exert their function in blood as IPCs 18;19. 
Different DC subsets have been described based on tissue location, maturation stage or 
lineage. Originally, two DC subsets were identified in peripheral blood by the lack of lineage 
markers and expression of high levels of HLA-DR, and could be distinguished based on their 
ability or inability to express CD11c. In Chapter 3, these immunophenotypic properties were 
used along with analysis of discriminating cell surface markers to characterize these subsets. 
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This multiparameter flow cytometry could also be applied to single cell suspensions of 
different tissues, revealing CD11c+ and CD11c- DC subsets. This enabled evaluation of the 
immunophenotype of DC subsets at distinct anatomical locations. A closer look at the DC 
subsets revealed two phenotypes within the CD11c+ subset, an immature phenotype and a 
maturer phenotype with higher expression of MHC class II and costimulatory molecules. The 
recently described marker BDCA-3 was preferentially expressed on the more immature 
CD11c+ DC in tissues. The staining pattern of huMab TN141 resembled that of BDCA-3, 
albeit at lower intensity. HuMab MatDC64 stained both DCs and monocytes in peripheral 
blood, however in secondary lymphoid organs staining was restricted to the plasmacytoid 
DCs.  
The origin of DCs is still controversial, since in vitro lymphoid as well as myeloid 
precursors can differentiate into distinct DC subsets dependent on the cytokine 
environment16. It remains unclear how these differentiation pathways and the DCs that are 
generated parallel the in vivo situation. The fact that selected phage antibodies on fresh DCs 
did not react with DCs in vitro (this thesis) strengthens our idea that in vitro generated DCs 
may not have physiological counterparts. Additionally, MatDC64 staining was absent on 
monocyte-derived immature DCs, while immature DCs that had retraversed endothelium in 
vitro were positive, highlighting the differences between different DC culture systems. While 
MatDC16 was selected on myeloid DCs, this antibody stained plasmacytoid DCs brightly. 
This could argue for a resemblance of the myeloid and plasmacytoid DC subsets. However, 
the expression of markers might not be decisive evidence of DC relationships. 
Furthermore, in view of the targeting device of our huMabs, we analyzed whether 
engagement of the molecules recognized by the huMabs exerted functional effects. We were 
not able to identify the target antigens of our four huMabs, in spite of extensive efforts that 
included cDNA expression cloning using a baculovirus-based cDNA library 20 as well as 
eukaryotic cDNA expression libraries, and immunoprecipitation studies (data not shown). 
Therefore, the functional role of the target antigens remained unknown. The observation that 
expression of the target antigens of some huMabs that bound to monocytes, was 
downregulated during in vitro differentiation of monocytes into DCs, lead us to analyze the 
effect of crosslinking of huMabs on DC differentiation in vitro (Chapter 4). HuMab 
MatDC64 suppressed the differentiation of monocytes into CD1a+ DCs, which could indicate 
that MatDC64 engaged an inhibitory receptor. A large number of inhibitory receptors have 
been discovered in the past few years, many of which are expressed by myeloid cells of the 
innate immune system 21. The prevention of generation of CD1a+ DCs was accompanied 
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with the upregulated production of IL-6. This cytokine is able to redirect the differentiation 
of monocytes towards macrophages at the expense of DCs. As an alternative, this might point 
to the engagement of a presently unknown stimulatory receptor by MatDC64, eventually 
leading to the production of IL-6.  
It is evident that future studies should focus on identification of the target antigens of 
these huMabs. What could be the nature of the target antigens recognized by the four 
huMabs? Many C-type lectins have been identified recently, some of them specific for DCs 
such as BDCA-2 22 and the DC-specific adhesion receptor DC-SIGN 5. Blocking the cells 
with mannan can inhibit specific antibody binding to C-type lectins. Preliminary data 
demonstrated that mannan could not inhibit the binding of MatDC16 or MatDC27 to cell line 
U937 (data not shown), suggesting that these huMabs did not recognize C-type lectins. 
Furthermore, staining using the four huMabs performed on transient or stable transfectants 
expressing ILT-3, ILT-4, ILT5, GM-CSF receptor, CD40, CD64 23, OX40L and TREM-2, 
excluded the possibility that they bound to any of these molecules (unpublished data). In 
conclusion, further studies are required and currently undertaken to identify the target 
antigens of our four huMabs. 
 
Use in vaccination 
In a first step toward in vivo targeting of DCs in cancer immunotherapy, huMabs were 
employed as vector to target tumor antigens to DCs (Chapter 5). A eukaryotic expression 
vector was constructed encoding a complete huMab, genetically fused to the tumor antigen 
MAGE-1. Incubation of immature monocyte-derived DCs with the IgG4MatDC16MAGE-1 
fusion protein resulted in presentation of MAGE-1 epitopes on MHC class I and II, as 
demonstrated by the activation of specific T helper and CTL clones. This uptake and 
subsequent processing and presentation appeared receptor-dependent, as 
IgG4MatDC27MAGE-1 and IgG4Mono14MAGE-1 could not induce CTL activation. In 
conclusion, fusion protein IgG4MatDC16MAGE-1 was able to target to DCs, resulting in 
stimulation of MAGE-1 specific T cells, providing a tumor antigen delivery vehicle that 
potentially can be targeted directly to DCs in vivo. In this respect MatDC16 might act as an 
‘intelligent missile’ 24. Ideally, an ‘intelligent missile’, containing a tumor antigen, should 
target to the desired DC subset, ensure efficient uptake and presentation by the DCs, and also 
DC activation. It will be exciting to further explore whether huMab MatDC16 can live up to 
the task. 
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Delivery of a broad spectrum of tumor antigens in DC-based cancer vaccination can be 
achieved when whole tumor cells are used for antigen delivery. Moreover, prior 
identification of tumor antigens is not necessary. In particular, lipid-tagged antibody 
fragments incorporated in the membrane of tumor cells can mediate phagocytosis by APCs, 
providing an alternatively strategy for tumor antigen delivery. Lipid-tagged antibody 
fragments MatDC16, MatDC27, MatDC64 or TN141 anchored in the membrane of tumor 
cells could not induce uptake by monocytes while an anti-CD14 lipid-tagged antibody 
fragment was able to induce phagocytosis, indicating that this process was receptor-
dependent (Chapter 6). Future research is required to determine the efficacy of this simple 
and rapid procedure, for the induction of anti-tumor immunity. 
 
Future perspectives 
To further investigate the potential of the IgG4MatDC16 MAGE-1 fusion protein for 
induction of anti-tumor immunity, the use of animal models is imperative. Mice carrying a 
tumor expressing a human tumor antigen may provide an acceptable experimental model in 
which knowledge about vaccine strategies can be obtained prior to initiating clinical trials. 
Such a tumor model can for example be generated by injection of murine melanoma cells 
genetically engineered to express the human MAGE-1 molecule into mice 25. Of great 
importance will be evaluation of the efficacy of this approach in elimination of pre-existing 
tumors. However it must be taken into account that the introduction of a xenogeneic protein 
into mice, such as the human MAGE-1, may induce a broad T cell response since no 
tolerance exists against this antigen. It may prove more difficult to induce anti-tumor 
immunity against naturally occurring, autologous antigens. Therefore, results obtained from 
animal models have to be interpreted with caution since successful strategies in mice may not 
be applicable in human. 
Future studies in progress will elucidate the potential of in vivo targeting to DCs using 
huMab MatDC16 fused to a tumor antigen in cancer vaccination. It is tempting to speculate 
on the applicability of huMab MatDC16, not only in cancer vaccination but also in the 
treatment of other life-threatening diseases. For example, the infection of rhesus macaques 
with simian immunodeficiency virus (SIV) provides a useful animal model for experimental 
in vivo studies on HIV 26. Since huMab MatDC16 binds to rhesus macaque DCs, this HuMab 
can be explored in an experimental HIV-1 vaccine. An appropriate experimental animal 
model can provide information on the efficacy, limitations, and safety of vaccination 
strategies before initiating clinical trials. 
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In conclusion, phage display antibody technology was successfully used to isolate four 
novel huMabs directed against DCs. These huMabs were used to further delineate DCs. In 
addition, a first step was made to evaluate the potential of modified forms of these huMabs as 
targeting vehicles for the delivery of tumor antigens. Targeting the antibody-tumor antigen 
fusion protein to DCs resulted in the induction of strong T helper and CTL responses. Future 
research on these huMabs in in vitro and in vivo models could open new and exciting 
avenues for cancer vaccination. 
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Dendritische cellen (DC’s) worden gezien als de waakhonden van het immuunsysteem. 
Wanneer DC’s een binnendringer zoals een micro-organisme waarnemen, dan wordt deze 
opgenomen en in kleine stukjes eiwit ofwel peptiden afgebroken. De peptiden worden naar het 
oppervlak van de cel getransporteerd en gepresenteerd aan andere cellen van het 
immuunsysteem, zoals T-lymfocyten. De presentatie van peptiden, antigeen-presentatie 
genoemd, vormt een belangrijke stap in de activatie van het immuunsysteem die uiteindelijk leidt 
tot de eliminatie van de binnendringer. 
DC’s bevinden zich in onrijpe vorm in alle weefsels van het lichaam. Na opname van de 
indringer rijpen ze uit en migreren naar lymfoïde weefsels, waar presentatie door de uitgerijpte 
DC’s aan de andere cellen van het immuunsysteem plaats vindt. DC’s worden professionele 
antigeen-presenterende cellen genoemd en zijn als enige in staat naïve cellen van het 
immuunsysteem te activeren. Naast de initiatie van een immuunrespons kunnen DC’s ook 
tolerantie induceren. Samenvattend kan gezegd worden dat DC’s meerdere functies vervullen. 
Afhankelijk van het weefsel waar men DC’s aantreft of het activatiestadium waarin ze zich 
bevinden, vertonen ze een ander fenotype, ofwel ze vormen een aparte subset. DC’s vormen een 
heterogene populatie en de relatie tussen de verschillende DC subsets is niet exact bekend. Een 
overzicht is gegeven in hoofdstuk 1.  
Antilichamen zijn in staat zeer specifiek te binden aan een bepaald molecuul. Hierdoor 
kunnen antilichamen die specifiek binden aan celoppervlakte moleculen van DC subsets meer 
inzicht geven in de heterogene DC populatie. Daarnaast kunnen antilichamen ook voor 
therapeutische doeleinden gebruikt worden. Aangezien DC’s een centrale rol spelen bij de 
initiatie van een immuunrespons, zijn ze in de belangstelling gekomen bij het ontwikkelen van 
nieuwe vaccinatie strategieën ter behandeling van kanker, met als doel het immuunsysteem aan 
te zetten tot bestrijding van een tumor. Reeds uitgevoerde patiënten-studies demonstreren dat in 
het laboratorium of in vitro gekweekte DC’s kunnen worden beladen met tumorantigenen; 
wanneer deze cellen worden terug toegediend aan de patiënt, kunnen ze een immuunrespons 
opwekken. Deze methode is echter tijdrovend en arbeidsintensief en maakt gebruik van 
gekweekte cellen die mogelijk niet dezelfde eigenschappen hebben als DC’s die in vivo 
voorkomen. Een andere mogelijkheid zou kunnen zijn om in het lichaam een tumoreiwit naar de 
DC’s te brengen met behulp van een DC-specifiek antilichaam als een doelgerichte drager. 
Voor het genereren van zulke antilichamen gericht tegen DC’s is gebruik gemaakt van een 
faag-antilichaam collectie die een groot aantal verschillende antilichaam fragmenten bevat. 
Hoofdstuk 2 beschrijft het selecteren van faag-antilichamen die gericht zijn tegen DC subsets, die 
men aantreft in bloed en keelamandelen, een bron van lymfoïd weefsel, door middel van sorteren 
met behulp van een flow cytometer. Er werden vier interessante antilichaam fragmenten 
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gevonden, MatDC16, MatDC27, MatDC64 en TN141, die bonden aan DC’s en ook aan 
monocyten, een voorloper-populatie van DC’s. 
In hoofdstuk 3 is een inventarisatie beschreven van de fenotypes van natuurlijk 
voorkomende DC subsets in verscheidende weefsels. Deze fenotypes zijn onderzocht met behulp 
van de flow cytometer in combinatie met een groot aantal conventionele antilichamen en de vier 
geïdentificeerde antilichaam fragmenten. Met het oog op therapeutisch gebruik, is de specificiteit 
van de antilichaam fragmenten van belang aangezien aparte DC subsets mogelijk een 
verschillende immuunrespons kunnen opwekken. De overeenkomsten en verschillen tussen in 
vitro gekweekte DC’s en de natuurlijk voorkomende DC subsets werden eveneens bestudeerd. 
De vier antilichaam fragmenten zijn eerst omgezet naar intacte en functionele humane 
antilichamen. In therapie hebben humane antilichamen de voorkeur aangezien deze als ‘eigen’ 
worden gezien in de mens en dus geen ongewenste afweerreactie opwekken. 
In hoofdstuk 4 is beschreven hoe binding van het humane antilichaam MatDC64 op 
monocyten ervoor zorgde dat deze niet meer konden uitgroeien naar DC’s. Deze cellen werden 
gekenmerkt door een verhoogde produktie van het cytokine IL-6, die mogelijk de oorzaak was 
van het waargenomen fenomeen. 
In een eerste stap naar het gericht brengen van tumorantigenen naar DC’s met behulp van 
een humaan antilichaam als drager, is er een fusie-eiwit gemaakt bestaande uit een humaan 
antilichaam met daaraan gekoppeld een geheel tumoreiwit. In hoofdstuk 5 is te zien dat incubatie 
van dit fusie-eiwit met gekweekte onrijpe DC’s ervoor zorgde dat deze DC’s anti-tumor 
specifieke T-lymfocyten activeerden. Dit impliceerde dat het fusie-eiwit gericht de DC’s 
bereikte, aangezien een tumoreiwit zonder antilichaam dit effect niet gaf. Dit proces was 
eveneens afhankelijk van het antilichaam fragment dat werd gebruikt, aangezien enkel een fusie-
eiwit met antilichaam fragment MatDC16 dit effect liet zien. Opname door DC’s gevolgd door 
presentatie van tumorantigenen resulteerde in aktivatie van twee typen T-lymfocyten, die beide 
essentieel zijn voor een goede anti-tumor immuunrespons. Op lange termijn kan deze vaccinatie 
strategie mogelijk ingezet worden ter bestrijding van kanker. 
Hoofdstuk 6 beschrijft het onderzoek aan antilichaam fragmenten met daaraan een 
vetstaartje gekoppeld voor mogelijk gebruik in anti-tumor vaccinatie. Deze lipide-gelabelde 
antilichaam fragmenten kunnen worden geïncorporeerd in de celmembraan van tumorcellen, 
waarbij vervolgens de opname van deze tumorcellen door antigeen presenterende cellen een 
alternatieve methode voor het gericht afleveren van tumoreiwitten kan vormen. Monocyten, 
eveneens antigeen presenterende cellen, waren in staat deze ‘gelabelde’ tumorcellen op te nemen. 
Dit gebeurde echter alleen wanneer het antilichaam fragment was gericht tegen CD14, een 
bekende receptor aanwezig op het celoppervlak van monocyten, en niet met een van de andere 
antilichaam fragmenten. Dit impliceert dat de opname door monocyten van ‘gelabelde’ 
tumorcellen receptor afhankelijk is. Aan het eind van dit proefschrift, in hoofdstuk 7, worden de 
belangrijkste resultaten van het beschreven onderzoek samengevat en bediscussieërd.
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HET DUURT ALTIJD LANGER DAN JE DENKT, 
OOK ALS JE DENKT 
HET ZAL WEL LANGER DUREN DAN IK DENK 
DAN DUURT HET TOCH NOG LANGER 
DAN JE DENKT 
 
 
HET IS ALTIJD VEEL DUURDER DAN JE DENKT, 
OOK ALS JE DENKT, 
HET ZAL WEL DUURDER WORDEN DAN IK DENK 
DAN WORDT HET TOCH NOG DUURDER 
DAN JE DENKT. 
 
 
HET KOST MEER MOEITE DAN JE DENKT 
OOK ALS JE DENKT 
HET ZAL WEL MEER MOEITE KOSTEN DAN IK DENK 
DAN KOST HET TOCH MEER MOEITE 
DAN JE DENKT. 
 
 
HET DUURT VEEL KORTER DAN JE DENKT 
OOK ALS JE DENKT 
HET ZAL WEL KORTER DUREN DAN IK DENK 
DAN DUURT HET TOCH 
NOG KORTER DAN JE DENKT. 
 
 
JUDITH HERZBERG 
 
  
 
 
 
